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Since the introduction of paclitaxel in 1992, the overall survival for women diagnosed with 
ovarian cancer has remained relatively stagnant.  This unsatisfactory outcome is in part 
attributed to the presence of subpopulations of tumor cells with stem cell-like properties, which 
are resistance to front-line therapies.  Efforts to identify unappreciated drugs to combat these 
resistant cell populations typically have used traditional two-dimensional (2D) cell culture 
models which do not always reflect the tumor heterogeneity seen in clinical samples including 
reduced cell proliferation, hypoxia, and cancer stem-like cells.  The lack of congruency between 
in vitro screening models and the patient’s outcome has limited the number of successful anti-
cancer drugs that demonstrate clinical benefit.  In order to identify drugs that are more likely to 
benefit patients, a drug screening model that better represents clinical disease was required.  
Towards this goal, I developed and characterized a three-dimensional (3D) cell culture model in 
which ovarian cancer cells were grown as multicellular tumor spheroids (MCTS) and directly 
compared drug activity in 2D and 3D models. 
Compared to a panel of ovarian cancer cell lines grown in 2D, MCTS formation induced 
many different phenotypes associated with clinical drug resistance including reduced cell 
proliferation, cellular hypoxia, and stem-like gene expression and function.  Cells grown as 
MCTS better mimicked the response to chemotherapy seen in the clinic as compared to 2D.  
Specifically, paclitaxel treatment of MCTS revealed significant increases in expression of stem 
cell-related genes, e.g., CD133, CD44, OCT4, SOX2, and NANOG.  Correspondingly, 
significant reduction in cell proliferation with accompanying resistance to paclitaxel was 
observed in MCTS compared to 2D cultures, providing an in vitro model that reflects certain 
aspects of clinical progression and drug resistance.  Interestingly, the drug resistance and stem-
like properties observed in MCTS were maintained in cells grown under 2D conditions when 




These changes provided an in vitro model that better reflects clinical disease that can be 
exploited for drug screening. 
To exploit these differences, the MCTS model was used to compare the activity of 304 
repurposed drugs, most that are FDA approved for indication other than cancer, in four 
established ovarian cancer cell lines grown in 2D and 3D.  I identified a number of compounds 
with selective activity in MCTS that can target subpopulations of resistant cells with stem-cell 
like properties.  In a primary drug screen between 2D and 3D cultures designed to directly 
compare response to 10 µM of the 304 clinically approved drugs revealed fifteen compounds 
with preferential activity against cells grown as MCTS as measured by CellTiter-Glo.  Drug hits 
were classified to have 3D specific activity based on >75% viability reduction in MCTS but <50% 
viability reduction in 2D cultures.  Secondary screening using a range 0 to 25 µM drug identified 
licofelone and glafenine to have the most robust and selective activity in MCTS across a 
genetically diverse panel of ovarian cancer cell lines.  Both are anti-inflammatory drugs that had 
not previously been considered for the treatment of cancer.  Since an increasing number of 
drugs are removed from the market because of unacceptable toxicity, subsequent experiments 
focused on licofelone.  Licofelone has demonstrated a better safety profile as compared to 
glafenine, i.e., reported increased risk of anaphylaxis and kidney failure.  Importantly, treatment 
of MCTS using IC50 concentration of licofelone significantly reduced expression of stem cell 
markers by up to 90%, as measured using qRT-PCR and immunofluorescent (IF) 
immunohistochemistry in cells grown as MCTS.  Consequently, Ki67 positive cells were 
increased from vehicle treatments (30%) in response to licofelone (57%) treatment in MCTS.  
Combination treatment in MCTS showed significant synergy (Combination Index <1) for 
sequential additions of licofelone followed by paclitaxel, or vice-versa.  Likewise, licofelone 
addition reversed stemness (gene expression, colony forming and spheroid forming assays) in 





 By performing drug screens using a MCTS model, I identified two previously 
unappreciated candidate anti-cancer drugs that had preferential activity on ovarian cancer cells 
with stem cell-like properties.  When used in combination with paclitaxel, licofelone showed 





To my graduate thesis advisor and mentor Dr. Andrew (Andy) Godwin, thank you for all of your 
support and guidance throughout my graduate career.  The insight you provided has made me a 
better and more complete scientist.  The high standards for which you demand research be 
performed has pushed me to constantly better myself and my work.  It has been an honor to 
learn from you and work for you in the laboratory.  The vast knowledge based you have 
bestowed upon me, and everyone you have taught, is appreciated and has driven me to better 
my project in every way.  Applying what you have taught me will be valuable and better my 
career, no matter where it takes me.  It has been my pleasure to work for you and to meet your 
challenges over the past years. 
 To my committee members: Dr. Fariba Behbod, Dr. Soumen Paul, Dr. Benyi Li, Dr. Adam 
Krieg, thank you for all of your wonderful insight.  You have not only helped shaped my project, 
you have helped shaped me as a scientist and as a person.  I have appreciated every 
recommendation and challenge you have provided me.  The extent of guidance and broad 
knowledge base has supported me in more ways that I could have ever expected.  Dr. Behbod’s 
knowledge of cancer stem cells and functional assays was instrumental into guiding my project.  
Dr. Paul contributed vast knowledge of stem cells and how to identify and detect them as well 
as measure stem cell function.  Dr. Li has been an incredible resource for clinical knowledge 
and drug development.  Dr. Krieg’s expertise in cellular hypoxia was instrumental into several 
methods and the development of my project.  To Dr. David Albertini, a member of my 
comprehensive exam committee member, thank you for the insight into the development stages 
of my project.  Without any of your guidance and breadth of knowledge, I would be less of a 
scientist than I am today without any of your support and knowledge. 
 To all of the members of the Godwin Laboratory that I have worked with throughout my 




always providing insightful discussion.  Specifically, to my other mentor, Dr. Harsh Pathak, 
thank you for your guidance and unwavering patience when I inevitably needed help to solve 
problems, run new protocols, or bounce new ideas off of you.  You have taught me an incredible 
amount and were critical in both developing and executing my project.  To our administrative 
assistant, Susan Ard, thank you for always being there for the lab and keeping us functioning 
day-to-day.  We could not do any of this without your constant support.  To specific members of 
the Godwin laboratory, Drs. Stephen Hyter, Rebecca Water, Jennifer Crow and Ziyan Pessetto, 
thank you for the guidance in my project.  Whether it be Stephen’s assistance with animal 
models and hypoxia, Rebecca constantly being there to talk to and discuss ideas, Jennifer for 
being a fellow graduate student and laying the foundation and support before me, and Ziyan’s 
knowledge of drug screening and development; all of your support has helped me with this 
project and with progressing through my career.  There are many other members of the Godwin 
Laboratory that have contributed my project and graduate career to specifically thank, but all of 
you have made my time during graduate school both more enjoyable and insightful. 
 To other supporting members at the University of Kansas Medical Center from core 
facilities, faculty members, staff, the Cancer Center, the Department of Pathology, and other 
graduate students; thank you for making KUMC a wonderful and supportive place to attend 
graduate school.  Specific members that have supported my project include the Genomics 
Sequencing Facility (and Clark Bloomer) and the Department of Biostatistics (and Dr. Devin 
Koestler and graduate student Stefan Graw). 
 Also, thank you to all of my different funding sources that have made this project, any 
research I have participated in, and my graduate education possible.  Firstly, thank you to The 
University of Kansas Self Graduate Fellowship (and the late Self Family Madison “Al” and Lila) 
not only for full graduate funding for four years but for the extensive training and development 




traditional research in areas such as communication, entrepreneurship, leadership, public 
policy, business development, and many other areas.  This program, and the interaction with 
the Self Fellowship staff other astute Self Fellows, has made me a better, more rounded 
scientist and person.  I would also like to thank other funding mechanisms that supported this 
research including the University of Kansas Cancer Center, the Kansas Bioscience Authority, 
the NIH (RO1 CA140323), and the OVERRUN Ovarian Cancer Foundation. 
 Finally, to my family (my mother Gayla Hirst, my father Jim Hirst, and my sister Lisa Hirst) 
words cannot describe how thankful I am for all of your support throughout my academic career.  
I would not have been able to do any of this without you.  Whether it be from simple words of 
encouragement, financial assistance, and to you helping me recover and stay in graduate 
school following two major surgeries you have been there for me whenever I needed it most.  
You have been my inspiration and my biggest supporters.  I will be forever grateful for 
everything you have helped me achieve.  You have always shown support and interest in my 






Table of Contents 
Chapter 1: Introduction ........................................................................................................... 1 
Ovarian Cancer Epidemiology ............................................................................................. 2 
Ovarian Cancer Symptoms, Diagnosis, and Staging ......................................................... 3 
Identification and Characteristics of Ovarian Cancer Subtypes ....................................... 5 
Ovarian Cancer Dissemination ...........................................................................................12 
Ovarian Cancer Risk Factors ..............................................................................................13 
Ovarian Cancer Therapy .....................................................................................................18 
Development of Paclitaxel for the Treatment of Ovarian Cancer .....................................23 
Drug resistance in Ovarian Cancer ....................................................................................26 
Failures of drug development in ovarian cancer...............................................................32 
Chapter 2: Exploiting Three-Dimensional Cell Culture to Better Replicate Clinical Drug 
Resistance in Ovarian Cancer Cell Lines ..............................................................................44 
Introduction .........................................................................................................................45 
3D Culture History ............................................................................................................................... 45 
3D Culture Methods ............................................................................................................................ 46 
MCTS as a Model for Resistant Disease .............................................................................................. 46 
Using 3D Culture to Enhance Drug Development ............................................................................... 48 
Methods ...............................................................................................................................50 
Cell Culture .......................................................................................................................................... 50 
Spheroid Formation ............................................................................................................................ 50 
In Vivo Tumorigenicity ........................................................................................................................ 51 
Secondary Spheroid Assays ................................................................................................................. 51 
Cell Cycle Analysis ............................................................................................................................... 52 
Immunofluorescence .......................................................................................................................... 52 
Western Blot Analysis ......................................................................................................................... 53 
RT-PCR and RNASeq Analysis .............................................................................................................. 54 
Colony Forming Assay ......................................................................................................................... 55 
Results .................................................................................................................................56 
Formation of Multicellular Tumor Spheroids in Established Ovarian Cancer Cell Lines Using Agarose 




MCTS Formation Induced Multiple Cellular Changes Associated with Solid Tumors and Drug 
Resistance ........................................................................................................................................... 57 
MCTS Displayed Intermediate Gene Expression Between 2D Cultures and Tumor Xenografts ......... 59 
Properties Specific to Tumorigenic Cell Lines ..................................................................................... 59 
Reduced Sensitivity of Ovarian MCTS to Paclitaxel Compared to 2D Cultures................................... 60 
Paclitaxel Treatment Reduced Proliferation and Increased Stemness ............................................... 61 
Paclitaxel Resistance and Stem-Like Phenotype was Maintained in 2D Cultures of MCTS Derived 
Cells ..................................................................................................................................................... 61 
Discussion ...........................................................................................................................77 
Conclusion ...........................................................................................................................79 
Chapter 3: 3D Culture Drug Screening Identified Unappreciated Anti-inflammatory Drug 
Candidates that Reverse Stemness and Synergize with Paclitaxel ....................................81 
Introduction .........................................................................................................................82 
Cancer Stem Cells ................................................................................................................................ 82 
Stemness in Ovarian Cancer ............................................................................................................... 86 
Cancer Stem Cells and Drug Resistance .............................................................................................. 88 
Targeting Cancer Stem Cells ............................................................................................................... 89 
Using 3D Cell Culture to Target Stem-like Cells .................................................................................. 90 
Methods ...............................................................................................................................91 
Transcriptome Sequencing and IPA Pathway Analysis ....................................................................... 91 
Drug Screening .................................................................................................................................... 91 
Cell Viability Assays ............................................................................................................................. 92 
Drug Combination Assays ................................................................................................................... 92 
Results .................................................................................................................................94 
Cell Viability in Response to Drug Treatment in Ovarian MCTS ......................................................... 94 
MCTS Drug Screening Identified Unappreciated Drug Candidates ..................................................... 95 
The Top 3D Specific Drugs, Licofelone and Glafenine, Reduced Stemness in Ovarian MCTS ............ 97 
Pretreatment of Ovarian MCTS with Licofelone Synergistically Enhanced Paclitaxel Activity ........... 99 
Pretreatment of Ovarian MCTS with Paclitaxel Synergistically Enhanced Licofelone Activity ......... 100 
Licofelone Combination Enhanced Apoptosis and Reduced Stemness Induced by Paclitaxel ......... 101 
Discussion ......................................................................................................................... 121 
Conclusion ......................................................................................................................... 125 
Chapter 4:  Summary, Discussion, and Future Directions ................................................. 127 




Discussion and Future Directions .................................................................................... 129 
Perspective ........................................................................................................................ 134 






List of Tables 
Table 1: FIGO Stages of Ovarian Cancer ................................................................................... 4 
Table 2: Subtypes of Ovarian Cancer .......................................................................................11 
Table 3: Clinical Trials for the Treatment of Ovarian Cancer .....................................................36 
Table 4: Qualitative Comparison of 3D Culture Methods. ..........................................................65 






List of Figures 
Figure 1: Risk Factors for the Development of Ovarian Cancer .................................................18 
Figure 2: Disease Recurrence and Drug Resistance in Clinical Ovarian Cancer .......................22 
Figure 3: Structure and Chiral Centers of Taxol. .......................................................................26 
Figure 4:  Mechanisms of Chemotherapy Resistance in Ovarian Cancer ..................................32 
Figure 5: Drug Development History for Ovarian Cancer ..........................................................35 
Figure 6: Laboratory Models of Cancer .....................................................................................48 
Figure 7: 3D Culture for the Formation of Ovarian Cancer Spheroids .......................................51 
Figure 8: Properties to Develop 3D Culture Models to Form Ovarian MCTS .............................64 
Figure 9: Formation of MCTS Across Ovarian Cancer Cell Lines. .............................................66 
Figure 10: MCTS Formation Reduced Cell Proliferation in Ovarian Cancer Cell Lines. .............67 
Figure 11: Cellular Hypoxia in Ovarian Cancer Cell Lines was Increased in MCTS. ..................68 
Figure 12: Increased Stemness in Ovarian MCTS Compared to 2D Cultures............................69 
Figure 13: MCTS Displayed Intermediate Gene Expression Between 2D Cultures and Tumor 
Xenografts. ...............................................................................................................................70 
Figure 14: In Vivo Tumorigenic Assay of HIO Cell Lines. ..........................................................71 
Figure 15: HIO Cell Spheroids Demonstrated Low Levels of a Hypoxia Marker and High Levels 
of a Cell Proliferation Marker Compared to Ovarian MCTS. ......................................................72 
Figure 16: Paclitaxel Resistance in MCTS Compared to 2D Cultures. ......................................73 
Figure 17: Paclitaxel Reduced Proliferation and Increased Stemness in MCTS. .......................74 
Figure 18: MCTS Derived Cells Maintained Paclitaxel Resistance in 2D Cultures. ....................75 
Figure 19: Stem Cell Gene Expression was maintained in 2D Cultures in Cells Derived from 
MCTS. ......................................................................................................................................76 
Figure 20: Drug Resistant Phenotypes of MCTS. ......................................................................80 
Figure 21: Models of Cancer Stem Cell Progression. ................................................................86 
Figure 22: Cancer Stem Cells Repopulate the Tumor Following Chemotherapy. ......................90 
Figure 23: CellTiter-Glo Measured Cell Viability and Drug Response in MCTS. ...................... 103 
Figure 24: Pathway Analysis of Transcriptome Sequences Identified Inflammation and 
Metabolism Upregulated in MCTS. .......................................................................................... 104 
Figure 25: 3D Cell Culture Screening Identified Drug Hits Unappreciated by 2D Cultures. ...... 105 
Figure 26: 3D Drug Screening in Non-tumorigenic Cell Lines did not Identify 3D Specific Hits.
 ............................................................................................................................................... 107 
Figure 27: Secondary Screening Validated 3D Specific Hits Across Multiple Cell Lines. ......... 108 
Figure 28: Dosage Response Validation of 2D Only Hit and 2D and 3D Hit. ........................... 109 
Figure 29: Dosage Response Showed 3D Specific Activity of Both Licofelone and Glafenine. 110 
Figure 30: The 3D Specific Drugs Licofelone and Glafenine Reduced Stem-like Gene 
Expression in Ovarian MCTS. ................................................................................................. 111 
Figure 31: Glafenine and Licofelone Treatment Increased Cell Proliferation in Ovarian MCTS.
 ............................................................................................................................................... 112 
Figure 32: Licofelone Showed Enhanced Activity in Paclitaxel Resistant Cells........................ 113 
Figure 33: Licofelone had More Activity Against Ovarian Cancer Cell-Derived MCTS than the 




Figure 34: Pretreatment of Ovarian Cancer Cell-Derived MCTS with Licofelone Synergistically 
Enhanced Paclitaxel Activity. .................................................................................................. 115 
Figure 35:  Pretreatment of Ovarian Cancer Cell-Derived MCTS with Paclitaxel Synergistically 
Enhanced Licofelone Activity .................................................................................................. 116 
Figure 36: Licofelone Blocked the Induction of Stem-like Gene Expression by Paclitaxel. ...... 117 
Figure 37: Combination of Licofelone and Paclitaxel Increased Apoptosis in Ovarian Cancer 
Cell-Derived MCTS. ................................................................................................................ 118 
Figure 38: Licofelone Decreased Stem-like Function of Paclitaxel Treated MCTS. ................. 119 
Figure 39: Licofelone Reduced the Secondary Spheroids Forming Ability of Paclitaxel Treated 
MCTS. .................................................................................................................................... 120 










Ovarian Cancer Epidemiology 
Ovarian cancer is the 9th leading cause of cancer and the 5th most common cause of cancer 
death in American women (Siegel, Naishadham et al. 2013), with an estimated 21,000 new 
cases and 15,000 deaths in 2015 (Howlader, Noone et al. 2015).  The disease primarily effects 
perimenopausal and postmenopausal women in the sixth decade of life, with a mean incidence 
of 63 years of age and over 88% of all cases occur in women 45 years of age and older.  
Overall, both the incidence and 5-year survival of ovarian cancer have decreased since the 
1970s (Howlader, Noone et al. 2015) though the rate of these declines has fallen behind many 
other cancers.  For example, the overall 5-year survival for 2005 to 2011 in the United States 
was 45.6 %, which was lower than both breast (over 90%) and cervical cancer (almost 70%). 
 Ovarian cancer is more common in developed parts of the world, specifically both North 
America and Europe (WHO 2014, Ferlay, Soerjomataram et al. 2015) and the incidence rate is 
higher in Caucasian women (12.5%) compared to other races (Singh, Ryerson et al. 2014, ACS 
2015, Howlader, Noone et al. 2015).  While women of African American descent are more 
susceptible to die of ovarian cancer than Causcasian women (Chan, Zhang et al. 2008), a 
recent report of women in Cook County, IL show the relationship may be in fact tied to socio-
economic status and disease diagnosis (Brewer, Peterson et al. 2015).  Socio-economic factors 
also drive treatment decisions such as surgery that can effect survival rates between races in 
stage-adjusted studies (Terplan, Smith et al. 2009).  Genetic links between incidence and race 
are not well known but there are higher rates of mutations of BRCA2 mutations in Ashkenazi 
Jewish women (Berman, Costalas et al. 1996).  Some studies suggest lower BRCA mutations 
among in  eastern Asia (Khoo, Chan et al. 2002, Kim, Nam et al. 2005) and higher rates than 
western women in Turkey and Pakistan(Liede, Malik et al. 2002, Yazici, Glendon et al. 2002).  
Deep sequencing techniques suggest the rates might not be as low as previously predicted 




Ovarian Cancer Symptoms, Diagnosis, and Staging 
Ovarian cancer is often termed a “silent killer” due to the vague nature of symptoms present in 
early stage disease.  The primary symptoms of ovarian cancer at the time of diagnosis are loss 
of appetite, early satiety, pelvic or abdominal pain and swelling, urinary frequency and 
sometimes vaginal bleeding.  However, these symptoms are often being ignored or 
misdiagnosed as other maladies, such as gastrointestinal issues or menopause, by both 
patients and primary physicians.  Unfortunately, many of these symptoms develop after the 
disease has already spread to distal organs.  Therefore, there is an urgent need for increased 
screening and improved early detection methods to circumvent the reliance on symptomatic 
presentation for initial diagnosis. 
 However, screening and detection methods for ovarian cancer have been controversial.  
Women with a family history of ovarian cancer (especially 1° relatives) and/or germline 
mutations in BRCA1 or BRCA2 can undergo preventative surgeries such as tubal ligations and 
more commonly bilateral salpingo-oophorectormy.  However, in women without a family history 
of ovarian cancer or germline mutations in BRCA and other less penetrant gene mutations, the 
early detection of ovarian cancer is problematic for both sensitive and accurate methods as well 
as improving the overall survival of women with ovarian cancer.  The two primary forms of 
screening for ovarian cancer are transvaginal sonography (TVS) and serum CA-125 testing; 
however, diagnosis is only confirmed by biopsy during cytoreductive surgery.  CA-125 screening 
is used to detect ovarian cancer in asymptomatic women by testing for elevated serum levels of 
the antigen above the, where normal levels of the protein are 0-35 units/ml in normal patients 
(Jacobs, Skates et al. 1999).  However, the rate of false positives for both procedures is 
problematic leading to unnecessary confirmation surgeries in some patients.  Overall, it has 
been shown that yearly CA-125 and TVS screenings have no significant change in survival 




improvements in methodology using a multimodal screening protocol improved the positive 
predictive value (Menon, Gentry-Maharaj et al. 2009) and survival by 8% from years 0-7 and by 
28% from years 7 to 14 (Jacobs, Menon et al. 2016).  In addition, levels of CA-125 have a 
positive predictive value for response to chemotherapy in terms of decreased progression free 
survival (PFS) and overall survival (OS) (Tian, Markman et al. 2009). 
 Ovarian cancers are diagnosed and staged after cytoreductive surgery that removes any 
visible mass within the peritoneal cavity.  The International Federation of Gynecology and 
Obstetrics (FIGO) have established guidelines for the staging of ovarian cancer summarized in 
Table 1. 
Table 1: FIGO Stages of Ovarian Cancer 
FIGO Staging of Ovarian Cancer 
Stage Disease Localization 5-year survival 
I Ovaries only ~90% 
IA One ovary, capsule intact, no tumor on surface, negative washing 
 
IB Tumor involves both ovaries 
IC Tumor limited to 1 or both ovaries 
1C1 Surgical spill 
1C2 Capsule rupture before surgery or surface tumor 
1C3 Malignant cells in the ascites or peritoneal washing 
II Pelvic extension or primary peritoneal cancer 45-60% 
II2A Extension/ metastases to the uterus and/or fallopian tubes 
 IIB Extension to other pelvic or intraperitoneal tissues 
III One or Both ovaries, cytological or histological confirmed spread to the peritoneum outside of the pelvis or lymph nodes 30-40% 
IIIA Positive retroperitoneal lymph nodes and /or microscopic metastasis beyond the pelvis nodes 
 
IIIA1 Positive nodes only: (i) Metastasis < 10mm, (ii) Metastasis >10mm 
IIIA2 Microscopic, extrapelvic (above the brim) peritoneal involvement ± positive retroperitoneal lymph nodes 
IIIB Metastases less than 2 cm and negative nodes 




IV Distant Metastases including plural effusion and parenchymal liver metastases <20% 
IVA Pleural effusion with positive cytology 
 
IVB Hepatic and/or splenic parenchymal metastasis, metastasis to extra abdominal organs (including inguinal lymph nodes and lymph nodes outside of the abdominal cavity) 
 
Identification and Characteristics of Ovarian Cancer Subtypes 
Ovarian cancer is a generic term used to classify cancers involving the ovaries though they can 
arise from many different cell types within the Müllerian compartment.  The embryologic origin of 
the Müllerian system is critical to understanding the theories surrounding the origin of ovarian, 
peritoneal, and tubal cancers.  Ovarian surface epithelium (OSE) is derived from the coelomic 
epithelium in early development.  The coelomic epithelium is derived from the mesoderm, and 
consists of the epithelial lining of the intraembryonic body cavity or coelom, and overlies the 
intraembryonic body cavity (which will become the peritoneum), including the area that will 
develop into the gonadal structures.  During fetal development, near the area that will form the 
gonadal structures, the coelomic epithelium invaginates to give rise to the Müllerian ducts, 
which will ultimately differentiate to become the fallopian tubes, uterus, cervix, and upper 
vagina).  Therefore, while the reproductive organs and peritoneum originate from distinct 
pathways, the Müllerian epithelia, OSE, and peritoneal (coelomic) epithelium have a close 
developmental relationship. 
 Traditionally, epithelial ovarian, tubal, and peritoneal cancers have been viewed as 
separate entities with disparate origins, pathogenesis, clinical features, and outcomes.  
Additionally, previous classification systems for ovarian cancer have proposed two primary 
histologic groups, type I and type II cancers that encompass the standard histologic subtypes.  
The type I and type II classification is generally used to broadly classify ovarian neoplasms for 
research purposes based on their unique clinical and molecular genetic features.  The 




serous and low-grade endometrioid cancers, as well as mucinous, clear cell, and transitional 
cell carcinomas.  Tumors in this category typically develop from atypical proliferative borderline 
tumors, benign cystic lesions, or endometriosis.  Transitional cell tumors and mucinous tumors 
do not typically have Mullerian features, but may develop from cortical inclusion cysts and 
Walthard cell nests.  However, there is an uncommon subtype of mucinous tumors which does 
demonstrate Müllerian (endocervical) characteristics.  Generally, type I tumors are more 
indolent, present at an earlier stage, are confined to the ovary, and are often large.  When type I 
tumors, specifically clear cell and mucinous cancers, are not detected early, they usually have a 
worse prognosis than type II cancers due to low response to chemotherapy (Koshiyama, 
Matsumura et al. 2014).  Type II tumors are highly aggressive and account for the majority of 
high-grade serous and high-grade endometrioid tumors.  Type II tumors are typically invasive 
tumors that develop de novo from the OSE of tubal surface.  While within each subtype different 
pathways can be activated and genes mutated, the frequency of TP53 or BRCA1/2 mutations is 
low in Type I cancers while Type II cancers have been found to have high percentages 
mutations in these genes (Kurman and Shih Ie 2010).  Generally Type I tumors are more 
genetically stable than Type II tumors, but recurrent gene mutations found within each subtype 
of Type I tumors can include mutations in KRAS, BRAF, PTEN, PI3KA, and CTNNB1(Cho and 
Shih Ie 2009).  However, recent molecular profiling data suggest that these groupings no longer 
accurately reflect our knowledge surrounding the various origins of these genetically diverse 
tumors. 
 Epithelial ovarian cancers (EOC) were for years believed to arise primarily from the 
ovarian surface epithelium.  In fact, Godwin and colleagues were some of the first investigators 
to establish ovarian surface epithelial cultures from rat and human ovaries and model incessant 
ovulation in vitro as a mechanism for transformation and tumorigenesis (Godwin, Testa et al. 
1992, Godwin, Testa et al. 1993, Perez, Hamaguchi et al. 1993, Testa, Getts et al. 1994, 




Salazar, Godwin et al. 1996, Abdollahi, Godwin et al. 1997, Abdollahi, Getts et al. 1999, Kruk, 
Godwin et al. 1999, Roberts, Williams et al. 2002, Yang, Smith et al. 2002, Roland, Yang et al. 
2003).  Epithelial ovarian cancers, serous, endometrioid, mucinous, and clear cell, account for 
more than 85% of all ovarian tumors.  Other subtypes are much less common and arise from 
germ, epidermoid, stromal and border cells.  Since EOCs are the most common and deadly 
form of ovarian cancer, I will refer to EOC as ovarian cancer for the remainder of this thesis and 
only discuss ovarian cancers of epithelial origin (Seidman, Horkayne-Szakaly et al. 2004, 
Braicu, Sehouli et al. 2011). 
 Typically, EOC is classified into five different histological subtypes: high-grade serous 
(HGS), low-grade serous (LGS), endometrioid, clear cell and mucinous.  Each subtype behaves 
as a discrete disease with differences in presentation, progression, mutation profile and 
response to chemotherapy (Table 2) (Vaughan, Coward et al. 2011).  Two distinct patterns of 
ovarian cancer have been observed for low-grade and high-grade tumors based on the extent of 
nuclear atypia and mitosis (Malpica, Deavers et al. 2004).  Low grade tumors are slower 
growing, more genetically stable and do not respond to chemotherapy as well as the faster 
growing, genomically instable high-grade tumors (Iwabuchi, Sakamoto et al. 1995, Groen, 
Gershenson et al. 2015, Oswald and Gourley 2015).  High-grade serous carcinomas are the 
most common ovarian cancer subtype (over 70%) followed by endometrioid, clear cell and low-
grade serous (Kurman 2013).  Each subtype has distinct histological protein expression 
patterns, mutations and even epigenetic signatures.  Further classification based on molecular 
profiles may provide insights into improving therapy selection (Tothill, Tinker et al. 2008, 
Bentink, Haibe-Kains et al. 2012). 
 High-grade serous tumors show a broad range of histological phenotypes with papillary, 
micropapilary, glandular, cribriform and trabecular structures involving columnar cells with pink 




both the majority of ovarian cancer diagnoses and deaths (Malpica, Deavers et al. 2004, 
Kurman 2013).  The majority of HGS tumors are diagnosed at late stages and are associated 
with genomic instability (Braicu, Sehouli et al. 2011) since almost all (>95%) high-grade serous 
cancers have TP53 mutations and over half have homologous DNA repair pathway deficiencies 
mainly represented by defects in BRCA1, BRCA2, or related proteins (Jazaeri, Yee et al. 2002, 
Turner, Tutt et al. 2004, Ahmed, Etemadmoghadam et al. 2010, Bell and Network 2011).  The 
deficiencies in DNA repair pathways associate with widespread copy number alterations 
(Gorringe, Jacobs et al. 2007) and make HGS cancer initially sensitive to platinum based 
chemotherapy (and PARP inhibitors) but develop therapy resistance which will be discussed 
later in this chapter.  However, half of all HGS tumors have functional BRCA pathways and 
pathologic mechanisms of these tumors still need to be elucidated (Bell and Network 2011). 
 The origins of HGS tumors are controversial since data suggest many may not arise from 
ovarian surface epithelial cells but instead originate from the fallopian tube epithelium 
(Kindelberger, Lee et al. 2007, Lee, Miron et al. 2007).  In genetic mouse models, conditional 
inactivation of commonly mutated ovarian cancer genes (BRCA1, TP53 and RB1) in ovarian 
surface epithelium cells leads to the formation of leiomyosarcomas and not HGSC following 
implantation into the mouse bursal sack (Akbari, Donenberg et al. 2014).  Due to the aggressive 
nature of HGS tumors and the presence of early genomic instability, it is hypothesized that HGS 
ovarian tumors are instead metastatic lesions from the fallopian tube epithelial cells.  
Microdissection of the fallopian tube epithelium from patients with a disposition to ovarian 
cancer showed lesions with BRCA and TP53 alterations that resemble HGS tumors (Piek, van 
Diest et al. 2001, Callahan, Crum et al. 2007, Crum, Drapkin et al. 2007, Gross, Kurman et al. 
2010).  Along with genetic alterations, fallopian lesions from BRCA patients showed gene 
expression profiles that mimicked HGS cancers (Tone, Begley et al. 2008).  Immortalization of 




transformed in vivo and in vitro by oncogenic RAS or MYC (Karst, Levanon et al. 2011).  In 
contrast to ovarian surface epithelial cells, the inactivation of Brca, Tp53 or Pten in Pax8 over 
expressing mouse fallopian tubal secretory cells led to the development of HGSC (Perets, 
Wyant et al. 2013).  To reduce the risk of HGS ovarian cancer in women BRCA mutation 
carriers it is beneficial to undergo a salpingo-oophorectomy (removal of both the ovaries along 
with the fallopian tubes) instead of just an oophorectomy (removal of only the ovaries) 
(Rebbeck, Lynch et al. 2002, Olivier, van Beurden et al. 2004). 
 Low-grade serous tumors are thought to be borderline tumors formed step-wise from the 
ovarian surface (Singer, Stöhr et al. 2005).  LGS tumors are more common in younger patients 
but are typically slower growing than the high grade counterpart and have more frequent 
mutations in KRAS and BRAF along with lower TP53 mutations (Hunter, Anglesio et al. 2015).  
Along with having functional p53, LGS tumors have a more stable genome with less 
rearrangements, mutations and tumor heterogeneity (Tone, McConechy et al. 2014).  However, 
due to more competent DNA repair pathways, LGS tumors do not respond to chemotherapy as 
well as HGS tumors. 
 Endometrioid tumors account for about 20% of all ovarian cancers.  Endometrioid tumors 
have a smooth outer surface with solid, cystic areas inside while the pathological phenotype 
involves high amounts of proliferative cells that resemble squamous or endometrioid 
differentiations with secretory cell features.  Tumors contain cystic spaces lined by 
gastrointestinal-type mucinous epithelium with stratification and may form filiform papillae with at 
least minimal stromal support; nuclei are slightly larger than cystadenomas; mitotic activity; 
goblet cells and sometimes Paneth cells are present, but stromal invasion is absent (Chiesa, 
Deavers et al. 2010).  The 5-year survival rate for endometrioid tumors is between 40 and 63%, 
mostly due to early stage presentation of the disease; however, there is no survival difference 




1998).  Likewise with serous tumors, endometrioid tumors can be both high and low-grade with 
similar growth patterns distinguishing the two (Mangili, Bergamini et al. 2012).  High-grade 
endometrioid tumors are very similar to HGS tumors in terms of genome stability and response 
to chemotherapy (Schwartz, Kardia et al. 2002).  15–20% of women diagnosed with 
endometrioid tumors also have concurrent endometriosis and the origin of endometrioid tumors 
is from the endometrial tissue, possibly from back flow during menstruation that implants onto 
the ovarian surface epithelium (Sampson 1925, Vercellini, Scarfone et al. 2000, Keita, AinMelk 
et al. 2011, Wang, Mang et al. 2015).  Mutation profiles of endometrioid tumors reveal frequent 
mutations in WNT-β-catenin pathways (Schwartz, Wu et al. 2003, McConechy, Ding et al. 
2014), ARID1A mutations (which helped link the origin to endometriosis) (Wiegand, Shah et al. 
2010), and PTEN is altered in endometrioid tumors more than any other subtype (Obata, 
Morland et al. 1998). 
 Mucinous ovarian cancer tumors are primarily unilateral, can be very large (Riopel, 
Ronnett et al. 1999) and are diagnosed at early stages (most are stage I or II) while invasive 
disease accounts for less than 10% of all cases (Seidman, Kurman et al. 2003, Leitao, Boyd et 
al. 2004).  The pathological definition of mucinous ovarian cancer dictates intracytoplasmic 
mucin is mandatory, although many mucinous tumors lack obvious apical mucin in large parts of 
tumor, thereby imparting an endometrioid appearance.  Mucinous tumors are often 
heterogeneous that can be endocervical-like or intestinal-like cells with gastric superficial/ 
foveolar and pyloric cells, enterochromaffin cells, argyrophil cells, and Paneth cells.  Mucinous 
disease is mostly thought to originate from the gastrointestinal tract (Zaino, Brady et al. 2011) 
though molecular mechanisms of the disease are still not fully elucidated besides KRAS 
mutations identified in almost all mucinous tumors (Vereczkey, Serester et al. 2011) and HER2 
amplifications (Lin, Kuo et al. 2011).  While the overall survival for mucinous disease is high due 




outcome (Hess, A'Hern et al. 2004) and low response to chemotherapy due to the high 
expression of genes involved in drug resistance including ABC transporters (Wamunyokoli, 
Bonome et al. 2006). 
 Ovarian clear cell carcinoma accounts for approximately 5% of all ovarian cancer patients, 
is primarily diagnosed at early stages and is more common in Asian women (Sugiyama, Kamura 
et al. 2000, Tung, Goodman et al. 2003, Seidman, Horkayne-Szakaly et al. 2004).  Clear cell 
carcinomas are primarily large, unilateral tumors that display only papillary, tubulocystic and 
solid architectures with hobnail cells containing clear cytoplasm.  In terms of molecular 
mechanisms, clear cell carcinomas (CCC) are complex at the genomic level and can have 
mutations in ARID1A, PIK3CA, KRAS and PTEN (Tan, Iravani et al. 2011, Zannoni, Improta et 
al. 2014), with PIK3CA mutated in ~33% of patients (Campbell, Russell et al. 2004).  While the 
pathogenesis of CCC is unknown, gene expression studies indicate clear cell ovarian cancer 
does not cluster with other ovarian cancers and more closely resembles lung cancers, 
endometriosis and renal cell carcinoma (Schwartz, Kardia et al. 2002, Zorn, Bonome et al. 
2005, Domcke, Sinha et al. 2013, Kandalaft, Gown et al. 2014).  Clinically, CCC cancer has a 
low response to chemotherapy, especially at later FIGO stages and drug response correlated to 
CD44 isoform expression (Sancho-Torres, Mesonero et al. 2000). 
Table 2: Subtypes of Ovarian Cancer 
Sub Type Frequency Mutations Clinical Prognosis 
High-grade serous ~65% TP53, BRCA1, BRCA2, CDK12 
Often diagnosed at late stage and 
chromosomally unstable. 
Low-grade serous ~5% BRAF, KRAS, NRAS, ERBB2 
Often diagnosed in younger patients, less 
aggressive, gnomically stable. 
Endometrioid ~20% PTEN, CTNNB1, PPP2R1α, MMR deficient 
Favorable prognosis and response to 
chemotherapy. 
Clear-cell carcinoma ~5% PIK3CA, KRAS, PTEN, ARID1A 
Low response to chemotherapy and 
intermediate prognosis. 





Ovarian Cancer Dissemination 
Dissemination of ovarian cancer occurs differently from traditional models of cancer metastasis.  
Most notably, ovarian cancer disseminates primarily through the peritoneal cavity and is rarely 
found in patient blood.  Secondly, ovarian cancer forms multicellular aggregates, or spheroids, 
in the peritoneal cavity that can be isolated from patient ascites fluid and play a potentially 
critical role in late-stage EOC growth, progression, spread and disease recurrence (Allen, Porter 
et al. 1987, Shield, Ackland Ml Fau - Ahmed et al. 2009).  A majority of patients present with 
ascites fluid during initial diagnosis and almost all patients will develop ascites by late-stage 
disease.  Ascites fluid containing tumor cells and spheroids is known as malignant ascites and 
is associated with poor prognosis.  Spheroid formation is thought to occur after single cells shed 
from the primary tumor, aggregate and form spheroids which can resist anoikis and survive 
within the peritoneal fluid.  Spheroid formation has been associated with decreased patient 
survival, increased metastasis and drug resistance in ovarian cancer (Sodek, Ringuette et al. 
2009, Lee, Mhawech-Fauceglia et al. 2013).  Tumor spheroids have the ability to adhere to and 
invade mesothelial cells in the peritoneal cavity to form secondary lesions (Burleson, Casey et 
al. 2004).  Secondary lesions on different peritoneal organs can cause comorbidities such as 
pleural effusion, bowel obstruction, thrombocytosis, thromboembolism and lymphedema.  
Complications from these comorbidities are often the cause of patient mortality.  Buildup of 
ascites fluid can be up to several liters and must be managed to prevent complications through 
paracentesis to remove excess fluid.  However, ascites fluid returns with differing frequency and 
multiple rounds of paracentesis can lead to many complications including sepsis.  Malignant 
ascites fluid also contains many soluble factors that can promote tumor growth, spheroid 
formation, inflammation and angiogenesis.  Therapy specifically targeted towards tumors cells in 





Ovarian Cancer Risk Factors 
Ovarian cancer risk is causally linked to both lifestyle and genetics.  Firstly, hereditary ovarian 
cancer (or familial ovarian cancer) accounts for approximately 5-15% of all cases (Ziogas, 
Gildea et al. 2000) and are often diagnosed at an earlier age than sporadic disease.  
Furthermore, hereditary ovarian cancer tends to be of the high-grade serous variety (Bewtra, 
Watson et al. 1992).  Therefore, patients with a primary relative with ovarian cancer have an 
increased risk of developing the disease.  Specifically, there is a 2.5% risk of ovarian cancer if a 
sister has had the disease and a 9% risk if the mother has had ovarian cancer (Ziogas, Gildea 
et al. 2000).  Familial breast and ovarian cancer were first observed in Lynch syndrome (a 
disease associated with familial cancer due to inherited mutations in DNA repair machinery) in 
the 1970s (Lynch and Krush 1971, Lynch, Guirgis et al. 1974).  Patients with familial breast and 
ovarian cancer led to the identification of BRCA1 (Miki, Swensen et al. 1994) and BRCA2 
mutations (Wooster, Neuhausen et al. 1994, Wooster, Bignell et al. 1995).  BRCA1 and BRCA2 
are mutated in the germ line of approximately 9-13% patients with hereditary ovarian cancer 
(Ford, Easton et al. 1994, Easton, Ford et al. 1995, Rubin, Blackwood et al. 1998).  The lifetime 
risks of developing ovarian cancer for the women ranges from 40-60% for BRCA1 mutation 
carriers and 10-20% for BRCA2 mutation carries (Antoniou, Pharoah et al. 2003, King, Marks et 
al. 2003, Sogaard, Kjaer et al. 2006).  Most subtypes have been linked to BRCA1 or BRCA2 
germ line mutations but the development of HGS disease is the most common in these women 
carriers (Castilla, Couch et al. 1994).  BRCA1 and BRCA2 mutations are more common in 
Ashkenazi Jewish women (Berman, Costalas et al. 1996, Tonin, Weber et al. 1996, Struewing, 
Hartge et al. 1997) as well as women from the Bahamas (Akbari, Donenberg et al. 2014).  
Despite having a higher risk for developing ovarian cancer, BRCA1/2 carriers have a better 
clinical outcome in terms of survival, with BRCA2 carriers having a more favorable outcome 




due to BRCA2 carriers responding better to platinum based chemotherapy (Liu, Yang et al. 
2012).  However, the survival benefit decreases when examined over 10 years in HGS instead 
of 5 years (Candido-dos-Reis, Song et al. 2015).  Over time, this could be possible due to 
secondary intragenic mutations in BRCA1 and BRCA2 that restore the wild-type reading frame 
(conversion back to a functional BRCA) and losing favorable responses to chemotherapy 
(Gorodnova, Sokolenko et al. 2015).  Location of the alteration in BRCA1 or BRCA2 may vary 
the risk of breast and ovarian cancer (Rebbeck, Mitra et al. 2015), including the presence of 
single nucleotide polymorphisms (SNPs) such as BRCA2 SNPs in rs10088218, rs2665390, 
rs717852, rs9303542 and BRCA1 SNPS in rs10088218 and rs2665390, indicating further 
elucidation of risks in carriers (Ramus, Antoniou et al. 2012). 
 However, mutations in either BRCA1 or BRCA2 do not result in a 100% rate of 
development of ovarian cancer.  Further screening of these patients might be necessary to 
better predict the development of ovarian cancer.  Concurrent mutations in 1p36 (WNT4), 4q26 
(SYNPO2), 9q34.2 (ABO), and 17q11.2 (ATAD5) increased risk of all EOC subtypes while 
1q34.3 (RSPO1) and 6p22.1 (GPX6) mutations increased the risk of serous ovarian cancer in 
BRCA carriers (Kuchenbaecker, Ramus et al. 2015).  BRCA1 carries can have reduced risk with 
concurrent mutations in CASP8 D302H polymorphism (Engel, Versmold et al. 2010).  PALB2, a 
BRCA2 interacting protein, has increased promoter hypermethylation which results in 
decreased BRCA2 function and increased risk of ovarian cancer (Potapova, Hoffman et al. 
2008). 
 Genetic risk factors outside of BRCA1 or BRCA2 mutations are not as well defined but 
often take place in genes involved in genomic integrity, most commonly mismatch repair (MMR).  
SNPs in the TERT locus (rs2242652 and rs10069690) were associated with decreased 
telomere length and increased breast and ovarian cancer risk in BRCA mutation carriers 




patients with ovarian cancer revealed BARD1, BRIP1, CHECK2, MREA11, MSH6, NMN, 
PALB2, RAD51C, or TP53 were mutated in 24% of the 360 patients enrolled (Walsh, Casadei et 
al. 2011).  Genes within the Fanconi anemia pathway are also associated with developing 
ovarian cancer, including: RAD51C, RAD51D, and BRIP1 (Pennington and Swisher 2012, 
Song, Dicks et al. 2015).  Other MMR genes associated with Lynch syndrome and ovarian 
cancer risk MLH1, PMS2, MSH2, and MSH6 (Malander, Rambech et al. 2006, Ketabi, Bartuma 
et al. 2011, Crispens 2012).  Mutations outside of DNA repair pathways such as KRAS variants 
have also been associated with sporadic and familial ovarian cancer without BRCA1/2 
mutations (Ratner, Lu et al. 2010). 
 Environment and lifestyle also play a risk for developing both hereditary and sporadic 
ovarian cancer (Figure 1) by either increasing or decreasing the lifetime risk of developing 
ovarian cancer.  Like many cancers, age is a risk factor for ovarian cancer with most cases 
being diagnosed after the age of 60 and the disease being extremely rare in patients under 40 
years of age (Gwinn, Lee et al. 1990).  As previously discussed, surgical procedures such as 
tubal ligation, salpingectomy and unilateral or bilateral oophorectomy have varying degrees of 
success for the development of ovarian cancer by removal of the organs from which the cancer 
develops (Rice, Hankinson et al. 2014, Gaitskell, Green et al. 2016).  The effects can change for 
each subtype given the nature of development from different tissues, hence why bilateral 
oophorectomy has a stronger influence on the development of HGS disease, since it is believed 
to develop from the fallopian tubes.  Lifestyle factors which influence complete cycling during 
menstruation have some of the strongest effects on the risk of developing ovarian cancer.  This 
hypothesis is attributed to incessant ovulation, in which the release of eggs from the ovary, the 
fusion on the fallopian tube and the rebuilding of the uterine wall all contribute to pathogenesis 
of ovarian cancer (Fathalla 1971, Godwin, Testa et al. 1992).  One of the most common factors 




increase in use of oral contraceptives could be attributed to the decrease in ovarian cancer in 
the last decade.  The longer use of oral contraceptives has been shown to correlate to lower risk 
of developing ovarian cancer (Beral, Doll et al. 2008, Havrilesky, Moorman et al. 2013).  The 
risk is reduced in both BRCA wild type and mutant carriers (Moorman, Havrilesky et al. 2013)  
(Bassuk and Manson 2015).  The risk of developing each subtype is decreased following oral 
contraceptive use, with the exception of clear cell carcinoma (Wentzensen, Poole et al. 2016).  
However, the associated side effects make it a poor treatment for prevention alone (Havrilesky, 
Gierisch et al. 2013).  Another factor that can influence menstrual cycles and the risk of ovarian 
cancer is child birth (Hankinson, Colditz et al. 1995), in specific the age at first birth and the 
number of births.  In fact, it was discovered the risk of ovarian cancer decreases by 
approximately 10% for each 5-year increment in age at first birth (Adami, Hsieh et al. 1994).  
Also, the number of births for a given women has additive decrease in the risk of ovarian 
cancer, decreasing by about 8% for each birth (Tsilidis, Allen et al. 2011).  However, the age of 
each woman at the onset of menopause has a weak association at best (Schildkraut, Cooper et 
al. 2001, Tung, Goodman et al. 2003). 
 Other lifestyle factors can influence the risk of ovarian cancer, such as hormone 
replacement therapy, breast feeding, obesity and inflammation.  Hormone replacement therapy 
increases the risk of developing ovarian cancer, depending on the therapy.  For instance, the 
use of estrogen increases the risk of developing ovarian cancer by 22%, while the combination 
of  estrogen and progesterone only has about a 10% chance of developing ovarian cancer 
(Morch, Lokkegaard et al. 2009, Pearce, Chung et al. 2009, Hildebrand, Gapstur et al. 2010).  A 
meta-analysis showed a similar risk for developing both HGS and endometrioid ovarian cancer 
in menopausal women (Beral, Gaitskell et al. 2015).  Conversely, hormone replacement given 
for menopause symptoms may improve survival of ovarian cancer patients (Eeles, Morden et al. 




lead to a reduced the risk of developing ovarian cancer (Gwinn, Lee et al. 1990, Tung, 
Goodman et al. 2003).  Meta-analysis also suggests the duration of lifetime breastfeeding is 
additive in reducing the risk of developing ovarian cancer (Luan, Wu et al. 2013).  Like many 
other cancers, cigarette smoking and alcohol consumption have at least some association with 
increasing the risk of developing ovarian cancer.  Specifically, smoking is associated with an 
increased risk of developing clear cell and endometrial ovarian cancer but not serous (Beral, 
Gaitskell et al. 2012).  Smoking increased the risk of mucinous ovarian cancer, but cessation 
returns can reduce the risk over time (Jordan, Whiteman et al. 2006) while heavy smoking (>10 
packs per day) more than doubles the risk of developing ovarian cancer (Gram, Lukanova et al. 
2012).  Alcohol consumption increased the risk of ovarian cancer, but seems to have an effect 
only in heavy drinkers.  Consumption of more than 20 drinks per week is associated with 
increased risk (Gwinn, Webster et al. 1986) while with moderate use the risk is less pronounced 
or significant (Genkinger, Hunter et al. 2006, Rota, Pasquali et al. 2012).  Obesity is associated 
with less common subtypes of ovarian cancer and not HGS (Olsen, Nagle et al. 2013) and the 
lifetime risk decreases with recreation physical activity (Cannioto and Moysich 2015).  Finally, 
inflammation increases the risk of developing ovarian cancer (Ness and Cottreau 1999) while 
the use of aspirin was shown to reduce risk of developing ovarian cancer from between 20-34% 
(Trabert, Ness et al. 2014).  The use of other non-steroidal anti-inflammatory drugs (NSAIDs) 





Figure 1: Risk Factors for the Development of Ovarian Cancer 
Ovarian Cancer Therapy 
The current standard of care for advanced ovarian cancer is cytoreductive surgery followed by a 
combination of platinum-based chemotherapy and paclitaxel, which has resulted in a 5-year 
survival rate of ~44%.  The approval of platinum-based chemotherapy over alkylating agents, 
such as melephan or cyclophosphamide, was based on studies with the combination of cisplatin 
and cyclophosphamide as well as cisplatin alone (Omura, Blessing et al. 1986, Tate Thigpen, 
Blessing et al. 2004).  These drugs showed much higher activity than other early 
chemotherapeutics such as 5-fluorouracil or dactinomycin (Park, Blom et al. 1980).  While both 
the platinum-based carboplatin and cisplatin show similar responses in terms of efficacy, 
carboplatin was approved over cisplatin due to reductions in side effects in carboplatin treated 
patients (du Bois, Luck et al. 2003).  Oxaloplatin, another derivative of cisplatin, has less 
efficacy but can be used if patients develop allergies to other platinum-based chemotherapy 
(Fracasso, Blessing et al. 2003).  Paclitaxel was approved following trials that showed efficacy 
as single agent infusion every three weeks in both platinum-sensitive and platinum-resistant 
patients (Thigpen, Blessing et al. 1994) and an increase in both median survival (38 months vs 
24 months) and PFS (18 months vs 13 months) in combination with cisplatin when compared to 
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cisplatin and cyclophosphamide (McGuire, Hoskins et al. 1996).  Combination of carboplatin 
and paclitaxel showed significant improvements in both OS and PFS (Parmar, Ledermann et al. 
2003), and is now the standard of care for the majority of ovarian cancer patients.  The 
development of paclitaxel from lab bench to the clinic will be discussed in the next section.  
Frontline carboplatin and paclitaxel chemotherapy for ovarian cancer following cytoreductive 
surgery shows good initial response and many patients show minimal to no evidence of residual 
tumor.  The presence of any residual tumor following primary therapy is the most prognostic 
factor of patient response (Bristow, Tomacruz et al. 2002).  However, the majority of patients will 
ultimately still experience disease recurrence.  Upon recurrence, patients continue to receive 
the same chemotherapy until the tumor is classified as drug-resistant.  Tumors are considered 
to be drug-resistant when the disease reoccurs in 6 months or less.  Recurrence between 6 and 
12 months is considered partially-resistant, and patients will often continue to receive frontline 
chemotherapy (Figure 2).  Duration of previous platinum treatment is highly predictive of 
response to secondary platinum treatment (Markman, Markman et al. 2004).  The standard of 
care following front line chemotherapy and the diagnosis of drug resistant disease is 
observation until disease recurrence.  Observation includes physical exam every 3 months and 
CA125 serum screening.  Any evidence of physical changes or elevated CA125 is followed by 
CT or other imaging to confirm disease recurrence (Salani, Backes et al. 2011).  However, 
following CA125 to start treatment earlier than detected by imaging doesn’t improve patient 
survival (Markman, Glass et al. 2003).  The majority of ovarian cancer deaths are due to the 
development of resistant disease and most resistant patients with succumb to the disease within 
one year of the diagnosis (Griffiths, Zee et al. 2011).  Developing new drugs for the treatment of 
resistant disease has been one of the primary goals in ovarian cancer research.  Mechanisms 
associated with drug resistance and treatments to improve chemotherapy response will be 




 Other therapies outside of the frontline therapy for ovarian cancer have shown some 
survival benefit.  Since optimal cytoreductive surgery is the highest prognostic factor for patient 
survival (Bristow, Tomacruz et al. 2002), neoadjuvant chemotherapy before surgery helps 
reduce tumor burden to levels where complete resection is possible (Vergote, Trope et al. 2010, 
Kehoe, Hook et al. 2015).  However, secondary cytoreductive surgery has no survival benefit to 
patients but does help to predict PFS and OS based on disease burden (Rose, Nerenstone et 
al. 2004, Rose, Java et al. 2016).  Since ovarian cancer dissemination is primarily through the 
peritoneal cavity, intraperitoneal (IP) chemotherapy has been evaluated to improve drug 
delivery to the location of disease.  IP paclitaxel in combination with platinum-based 
chemotherapy showed improved OS (65.6 months vs 49.7 months) when compared to 
intravenous (IV) paclitaxel and platinum; however, only 42% of patients enrolled in the IP arm 
completed the trial due to side effects or complications with the peritoneal port used to 
administer the chemotherapy (Omura, Blessing et al. 1986, Armstrong, Bundy et al. 2006).  
More data supports the use of IP paclitaxel (Rothenberg, Liu et al. 2003), but many physicians 
and patients are not comfortable administering the drug in this route.  Further development to 
improve the administration and reduce the side effects of IP paclitaxel are needed to increases 
the frequency of use in the clinic.  Repurposing paclitaxel into microparticles can circumvent the 
use of chremophor, increase the intraperitoneal bioavailability of paclitaxel (Roby, Niu et al. 
2008), and reduce the side effects (Williamson, Johnson et al. 2015).  Consequently, IP cisplatin 
has been more controversial in terms of improvement in survival rates in ovarian cancer patients 
and was associated with high rates of hypertension, nausea, and vomiting (Alberts, Liu et al. 
1996, Walker, Brady et al. 2016). 
 Targeted therapies for ovarian cancer have been difficult to develop due to the high degree 
of heterogeneity between patients and within tumors.  Anti-angiogenic compounds have had the 




against the angiogenesis promoting factor VEGF-A, was approved in Europe for the front line 
therapy of ovarian cancer based on GOG-218 (Burger, Brady et al. 2011) and ICON-7(Perren, 
Swart et al. 2011).  However, approval for front line therapy in the United stated has not been 
implemented since improvements in PFS or OS have not been observed (Oza, Cook et al. 
2015) and bevacizumab is associated with a wide range of GI side effects (Cannistra, Matulonis 
et al. 2007).  However, bevacizumab is approved in both Europe and the United States for the 
treatment of chemotherapy resistant disease based on the AURELIA trial (Pujade-Lauraine, 
Hilpert et al. 2014, Poveda, Selle et al. 2015).  Dose dense bevacizumab improves PFS in 
ovarian cancer patients and is a promising therapy for further development (Chan, Brady et al. 
2016).  Another angiogenesis inhibitor approved for ovarian cancer therapy is the VEGF 
tyrosine kinase inhibitor cediranib.  Cediranib has some single agent activity in chemotherapy 
sensitive and resistant chemotherapy, it can be used in combination with platinum-based 
chemotherapy, or used as maintenance in platinum-sensitive disease (Matulonis, Berlin et al. 
2009, Liu, Barry et al. 2014, Ledermann, Embleton et al. 2016).  Finally, the most promising 
recent breakthrough approved for the treatment of ovarian cancer is poly ADP ribose 
polymerase (PARP) inhibitors.  PARP regulates genomic integrity, DNA repair and cell death 
mechanisms (Herceg and Wang 2001).  Therefore, PARP inhibitors can induce DNA damage 
and cell death.  Specifically, in BRCA deficient, or other homologous repair deficient cells, 
PARP inhibitors induce the error prone DNA repair pathway non-homologous end joining (Fong, 
Boss et al. 2009).  Therefore, PARP inhibitors were investigated for efficacy in ovarian cancer 
due to the high number of patients with BRCA and/or homologous recombination (HR) deficient 
tumors (Audeh, Carmichael et al. 2010).  Olaparib (an oral PARP inhibitor) is effective as a 
maintenance therapy after platinum therapy response in patients with platinum-sensitive HGSC 
compared with placebo (Ledermann, Harter et al. 2012, Oza, Cibula et al. 2015) and has been 
given accelerated approval for maintenance therapy in Europe.  However, accelerated approval 




PFS.  Olaparib was recently granted accelerated approval for the use in patients that received 
at least three rounds of chemotherapy (Domchek, Aghajanian et al. 2016).  Trials are ongoing 
for the treatment of both platinum sensitive and resistant disease in which olaparib has shown 
increased function in combination with platinum-based chemotherapy (Ledermann, Harter et al. 
2012).  Second generation PARP inhibitors, such as niraparib, are not as dependent on loss of 
BRCA function in ovarian tumor cells (Mirza, Monk et al. 2016), which could be the result of a 
novel mechanism of trapping PARP proteins to the DNA damage site (Murai, Huang et al. 
2012).  Despite these advances, there is still urgent need for better understanding of 
chemotherapy resistance and the development of new drugs for ovarian cancer. 
 






Development of Paclitaxel for the Treatment of Ovarian Cancer 
In 1992, paclitaxel was the last drug approved for the primary treatment of ovarian cancer.  To 
reach clinical approval paclitaxel (Taxol) had to go through extensive discovery studies.  
Paclitaxel was founded in a natural products drug screening program through the Cancer 
Chemotherapy National Service Center (CCNSC) of the National Cancer Institute (NCI).  The 
focus on plant extracts was based on screening in both sarcoma and leukemia (L1210 and 
P388) cell lines that discovered podophyllotoxin from Podophyllum pelatutm and vincristine and 
vinblastine from Catharanthus roseus (Carter and Livingston 1976).  Hits from CCNSC 
screening were subjected to bioassay-guided fractionation and animal tumor model testing for 
identification and validation (Driscoll 1984, Venditti, Wesley et al. 1984).  Taxus brevifolia 
(Pacific Yew) bark was collected by the USDA in 1962 to be included in screening and activity of 
Taxus extracts were confirmed through Kenacid Blue (KB) cytotoxicity assays in 1964.  
Recollection, fractionation and structural confirmation showed the active fraction of Taxus bark 
was a diterpene compound named Taxol (Wani, Taylor et al. 1971).  Taxol showed the most 
activity against melanoma cell lines (B16) in 1975 and was accepted for preclinical development 
in 1977.  The most promising discovery to promote the development of Taxol was the 
elucidation of the cell mechanism.  Unlike alkylating agents that promoted break down of 
tubulin, Taxol promoted polymerization and stabilization of tubulin, leading to cellular 
catastrophe (Carter and Livingston 1976, Kumar 1981, Parness and Horwitz 1981).  Not only 
did Taxol cause mitotic arrests, it was also shown to inhibit migration of fibroblasts following 
tubulin stabilization (Schiff and Horwitz 1980).  It also promotes stabilization of tubulin and has 
been found to have different binding sites compared to other agents in the N-terminal 31 amino 
acids of beta-tubulin (Rao, Krauss et al. 1994). 
 Phase I approval for Taxol started in 1983 but factors such as limited supply, solubility and 




needed compared to Vinca alkaloids led to the use of chremophor (a solubilizing agent linked to 
allergic reactions) at twice the normal dosage (Lassus, Scott et al. 1985, Davignon and Cradock 
1987).  However, the results from a Phase II trial in ovarian cancer brought Taxol back to 
leading edge of clinical development.  Briefly, 47 patients with drug-refractory ovarian cancer 
who had one or more measureable lesions were selected for the treatment with a 24-hour 
infusion with doses from 10 to 250 mg/m2 of Taxol (based on adverse reactions) every 22 days.  
Of the 47 patients, 45 were eligible for toxicity evaluation and 40 were eligible for response 
evaluation at the end of the study.  Twelve patients responded to Taxol (30%) for periods of 3 to 
15 month progression free survival (McGuire, Rowinsky et al. 1989).  The ovarian cancer trial 
and subsequent success in breast cancer (Seidman, Reichman et al. 1992), melanoma (Einzig, 
Hochster et al. 1991) and head and neck cancer (Forastiere, Neuberg et al. 1993) created an 
increasing demand for Taxol isolation that Taxus bark could not sustain.  
 The isolation of bark from the Pacific Yew was an extensive process could only be 
completed in the spring or summer when sap was being produced.  Likewise, the process of 
scraping off bark from the tree was often damaging to the tree, and not a renewable resource.  
To obtain 1.3 kg of drug between 2,000 and 15,000 pounds of bark were needed.  Even after 
obtaining sufficient bark, the purification process was extremely time consuming-requiring 
multiple rounds of extraction, chromatography, and crystallization were needed to produce 
Taxol drug.  To produce synthetic Taxol a precursor was needed since the compound contains 
11 chiral centers, as well as 2,048 diastereomeric isomers, making de novo synthesis extremely 
problematic (Figure 3).  The first synthetic method to produce Taxol was using semisynthetic 
conversion of baccatin III derivatives, isolated from the needles instead of the bark (Denis, 
Green et al. 1988, Cragg, Schepartz et al. 1993).  The needles can be harvested year round 
and required minimal damage to the tree itself, making this a renewable supply of Taxol.  Later 




(Danishefsky, Masters et al. 1996, Mukaiyama, Shiina et al. 1999, Kusama, Hara et al. 2000, 
Fuse, Miyamoto et al. 2006). 
 Trials continued with Taxol in ovarian cancer to improve administration (Weiss, 
Donehower et al. 1990) and evaluate granulocyte-colony stimulating factor (G-CSF) to treat 
adverse symptoms of the delivery (Sarosy, Kohn et al. 1992).  These continued to show 
success in reducing disease progression so two conformation Phase II trials were performed.  In 
1992, data in 34 patients with metastatic ovarian cancer receiving dosages of Taxol from 180 to 
350 mg/m2 showed 1 patient with complete response, 5 patients with partial response and a 
median survival of 27 months (Einzig, Wiernik et al. 1992).  In 1994, a second Phase II trial 
used Taxol as a salvage therapy in patients with recurrent, persistent or progressive ovarian 
cancer with an overall response rate of 34% (Thigpen, Blessing et al. 1994). 
 Following these salvage trials Taxol, now under the trade name paclitaxel, was taken to 
Phase III trials in combination with carboplatin.  In the GOG-111 trial IV patients with advanced 
ovarian cancer with a residual mass > 1cm were treat with either paclitaxel (125 mg/m2 over 24 
hours) combined with cisplatin (75mg/m2) or cyclophosphamide (750 mg/m2) and cisplatin.  
Overall 410 patients were enrolled and 386 completed the trial.  The overall response rate for 
the paclitaxel arm was 73% compared to 60% in the cyclophosphamide arm.  While a similar 
complete response was observed, the paclitaxel treatment had a longer PFS (18 months vs 13) 
and OS (38 months vs 24) when compared to cyclophosphamide (McGuire, Hoskins et al. 
1996).  In a conformation Phase II trial in Europe and Canada, patients with advanced ovarian 
cancer were treated with the same regimen but with three hour infusion of paclitaxel instead of 
24 hours.  Overall 680 patients were enrolled and the overall response rate was increased in the 
paclitaxel arm (59%) when compared to cyclophosphamide (45%).  Similar increases in PFS 




promising results for the development of paclitaxel, there is still an urgent need for further drug 
development in ovarian cancer. 
Drug resistance in Ovarian Cancer 
While front line chemotherapy produces promising responses in most ovarian cancer patients, 
the majority of patients will develop recurrent and drug resistant disease.  Drug resistance in 
ovarian cancer is one of the primary reasons for patient mortality and better understanding of 
the mechanisms is urgently needed.  Drug resistance in ovarian cancer is multifaceted as it can 
be influenced by genetic changes, physical restriction of drug entry into cells, cell environmental 
changes, metabolism, hypoxia, inflammation and many other phenotypes (Figure 4).  
Resistance can arise by the evolution of intrinsically resistant cells following selection pressure 
of chemotherapy (Cooke, Ng et al. 2010, Gerlinger and Swanton 2010) or by phenotypic and 
cellular changes induced by drugs themselves leading to the promotion of compensatory or 
survival mechanism (Friedman 2016).  Whether drug resistant ovarian cancers are clonally 
selected or induced as a response to chemotherapy, a better understanding of different 
mechanisms associated with drug resistance is pertinent to developing new therapies to 
improve the survival of ovarian cancer patients. 
Figure 3: Structure and Chiral Centers of Taxol. 




 Specific cell alterations that prevent the binding of drugs to their target can drive 
resistance to paclitaxel and platinum drugs.  Changes that alter the expression of tubulin or 
microtubule dynamics promote drug resistance (Mozzetti, Ferlini et al. 2005, McGrail, 
Khambhati et al. 2015).  Mutations in tubulin can block paclitaxel binding and prevent tubulin 
stabilization in many cancers (Monzo, Rosell et al. 1999, Wang, O'Brate et al. 2005, Hari, 
Loganzo et al. 2006), but mutations are not as common in ovarian cancers (Lamendola, Duan et 
al. 2003, Mesquita, Veiga et al. 2005).  Another mechanism that prevents drug-target interaction 
involves physical or biochemical restriction of drugs entering into the cell or nucleus where the 
target is located.  Paclitaxel penetration into solid tumor xenografts is determined by tumor 
density and blocks drug induced apoptosis (Kuh, Jang et al. 1999).  The specific entry or efflux 
of platinum drugs and paclitaxel is driven by the expression of drug efflux pumps.  Over 
expression of drug transporters such as ABCB1 (also known and MDR1) promotes both 
paclitaxel and cisplatin or carboplatin resistance in ovarian cancer (Johnatty, Beesley et al. 
2008, Eyre, Harvey et al. 2014, Sun, Jiao et al. 2015, Wang, Liu et al. 2015, Vaidyanathan, 
Sawers et al. 2016).  Likewise, nuclear efflux of carboplatin or paclitaxel is driven by ABCC2 
overexpression and nuclear membrane localization which promotes increased drug resistance 
in ovarian cancer (Surowiak, Materna et al. 2006).  Inversely, protein stability and efflux is 
decreased in certain ABCC2 variants and enhances patient survival (Tian, Ambrosone et al. 
2012).  The generation of stable, cisplatin resistant cell lines led to the identification of some of 
the first mechanisms of drug resistance such as glutathione synthesis (GSH).  GSH expression 
was increased in cisplatin-resistant derived ovarian cancer cell lines and multidrug resistance 
was also associated with GSH expression (Godwin, Meister et al. 1992, Hamaguchi, Godwin et 
al. 1993).  Glutathione is involved in the suppression of oxidative stress (Anderson 1998) and 
expression leads to the formation of GSH-drug conjugates that are exported from the cell 
(Colvin, Friedman et al. 1993).  While the glutathione analog prodrug canfosfamide, or trade 




(Kavanagh, Gershenson et al. 2005), Phase III trials showed no benefit of the drug on either 
PFS or OS (Vergote, Finkler et al. 2009).   
 The more adept a tumor is at repairing genomic alterations, the less effective carboplatin 
and paclitaxel become since cisplatin cross links DNA and paclitaxel stabilizes tubulin 
preventing chromosome separation during anaphase.  The ability of ovarian cancer cells to 
repair DNA damage, specifically interstrand crosslinks, is enhanced in platinum resistant 
ovarian cancer cell lines suggesting a correlation to DNA repair and drug resistance (Johnson, 
Swiggard et al. 1994).  Whole genome analysis of ovarian cancer patients across different 
levels of drug sensitivity revealed many alterations associated with drug resistance such as: 
DNA alterations in the coding region for other tumor suppressors such as RB1, NF1, RAD51B 
and PTEN. Alternatively, CCNE1 amplification, which alters cell cycle progression and promotes 
BRAC expression or the restoration of BRCA1 or BRCA2 function through reversions of 
mutations can reduce the risk of ovarian cancer  (Patch, Christie et al. 2015).  This study 
highlights specific DNA repair mechanisms associated with genomic stability and drug 
resistance in ovarian cancer.  As previously discussed, patients with mutant BRCA1 or BRCA2 
have better survival than patients without, primarily due to better response to chemotherapy 
(Bolton, Chenevix-Trench et al. 2012) and the reversion of mutant BRCA2 to wild type promotes 
cisplatin resistance (Sakai, Swisher et al. 2008).  BRCA1 mutations also enhance sensitivity to 
both radiation and paclitaxel in ovarian cancer cells (Zhou, Smith et al. 2003), which can also be 
restored by secondary mutations (Swisher, Sakai et al. 2008).  The expression of different DNA 
polymerase (DNA pol) subunits can affect the ability of ovarian cancer cells to respond to 
platinum based chemotherapy.  Specifically, DNA pol η (eta) can bypass GG DNA adducts 
caused by either oxalplatin or cisplatin and maintain replication fork stability during replication 




increases cisplatin resistance and the expression of the pol η regulating miR-93 restores 
sensitivity to cisplatin (Srivastava, Han et al. 2015). 
 Many cellular changes that do not affect drug delivery or DNA integrity can also confer 
drug resistance in ovarian cancer.  These changes can be related to cell growth, metabolism, 
inflammation, hypoxia, cell survival and the tumor microenvironment (Helleman, Smid et al. 
2010).  Chemotherapy treatment induces a phenotypical change in cell growth and morphology 
known as the epithelial to mesenchymal transition (EMT), measured by the loss of expression of 
epithelial markers such as E-cadherin and the increase of mesenchymal markers such as 
SNAIL, SLUG, and TWIST (Kajiyama, Shibata et al. 2007, Haslehurst, Koti et al. 2012).  EMT 
can be promoted through several pathways following drug treatment or by neighboring cells in 
the tumor associated stroma.  Interestingly, the promotion of drug resistance via cross talk 
between pro-tumorigenic stromal cells and drug sensitive cells can happen through the 
secretion of inflammatory markers such as POSTN, LOX, and FAP (Ryner, Guan et al. 2015) or 
through the release of extracellular vesicles, or specifically exosomes, carrying regulatory 
biomolecules such as miR21 (Au Yeung, Co et al. 2016, Crow, Atay et al. 2017).  Targeting 
pathways that promote EMT such as PI3K can block EMT during drug response (Du, Wu et al. 
2013).  Additionally, EMT is a dynamic cellular process that can be reversed through the 
mesenchymal to epithelial transitions (MET).  Promotion of MET by epimorphin, which induced 
the expression of E-cadherin and reduced the expression of snail and slug, increased the 
sensitivity of ovarian cancer cells to carboplatin (Yew, Crow et al. 2013).  Another factor from 
the tumor environment that promotes drug resistance is cellular hypoxia.  As solid tumors grow 
away from blood vessels, their oxygen supply is limited and cells become hypoxic.  Hypoxia 
exposure in breast and ovarian cancer cell lines promotes a MDR phenotype that is maintained 
following in vivo transplant, depending on the cell line and amount of time exposed to hypoxia 




stabilization and expression of the hypoxic regulator HIF1-α, and induced cell cycle arrest in 
ovarian cancer A2780 cells (Huang, Ao et al. 2010).  HIF1-α also regulates cell mechanisms 
such as metabolism and cell death pathways (Favaro, Nardo et al. 2008).  Hypoxia resistant 
metabolism drives spheroid formation, engraftment, metastasis and drug resistance in ovarian 
cancer cell lines (Liao, Qian et al. 2014).  Targeted knockdown of HIF1A enhanced the efficacy 
of doxorubicin chemotherapy in ovarian cancer cells (Wang, Saad et al. 2008).  Metabolism 
changes can be driven by hypoxia (Ai, Lu et al. 2016) as well as mitochondrial mechanisms 
such as oxidative stress and reactive oxygen species (Sherman-Baust, Becker et al. 2011, 
Chen, Huang et al. 2015).  Intrinsic inflammation which is common in malignant ascites (Lane, 
Matte et al. 2015) and the associated pro-inflammatory microenvironment can predict drug 
resistance before chemotherapy treatment (Koti, Siu et al. 2015).  Induced inflammation from 
immune responses or cellular debris following apoptosis can also trigger chemotherapy 
resistance through TLR-4 signaling (Kelly, Alvero et al. 2006).  Cytotoxic drugs like paclitaxel 
and platinum based chemotherapy can induce cell survival mechanism such as autophagy 
(Zhang, Wang et al. 2015), anti-apoptosis pathways to confer chemotherapy resistance 
(Strobel, Tai et al. 1998, Marchion, Cottrill et al. 2011), and cell cycle regulators (Han, Yu et al. 
2009).  All of these mechanisms can occur independently and be induced by different factors, 
there is a clear need for a better understanding the cellular development of each and how they 
may be connected. 
 Finally, cancer stem cells or stem-like cells (cancer cells with stem cell properties) have 
been shown to be resistant to chemotherapy in ovarian cancer.  The origin and pathways of 
cancer stem cells will be discussed in Chapter 3, for now the focus is on the role of cancer stem 
cells in drug resistance.  Stemness, for this purpose of this document is defined as the 
expression of stem cell-associated genes, is increased following primary therapy in both in vivo 




Upregulation of CD44, ALDH1A, or CD133 have all been shown to induce drug resistance in 
ovarian cancer (Baba, Convery et al. 2009, Deng, Yang et al. 2010, Cioffi, D'Alterio et al. 2015, 
Gao, Foster et al. 2015).  One of the common characteristics of cancer stem cells is their 
genomic and phenotypic plasticity which allows them to adapt to harsh environments or evolve 
in response to different stimuli such as chemotherapy (Quintana, Shackleton et al. 2010, Pisco 
and Huang 2015).  This adaptation ability allows cancer stem cells to regulate or be induced by 
a number of previously discussed mechanisms of drug resistance, connecting multiple 
pathways at one through a common cell phenotype.  Cellular hypoxia can induce stemness in 
ovarian cancer cells via the expression of many different stem cell genes CD133, OCT4, SOX2, 
and NANOG (Liang, Ma et al. 2012, Wu, Du et al. 2014, Ramadoss, Sen et al. 2016) and the 
knock down of different stem cell genes increases the sensitivity to chemotherapy (Landen, 
Goodman et al. 2010, Seo, Kim et al. 2016).  Ovarian cancer stem cells also can better repair 
platinum induced DNA adducts (Srivastava, Han et al. 2015) have increased expression of drug 
transporters (Kobayashi, Seino et al. 2011) and can promote EMT and inflammation (Yin, Chen 
et al. 2010).  Interestingly, a long term (28 day) analysis of ovarian cancer cells as they recover 
from chemotherapy showed a multistep process which started with the induction of genomically 
unstable cells due to polyploidy followed by EMT, inflammation, and stemness (Rohnalter, Roth 
et al. 2015).  These data support stemness as a common up and downstream mediator of 
several drug resistance pathways in ovarian cancer, making it a promising area of development 









Failures of drug development in ovarian cancer 
 While there has been some success in drug development for ovarian cancer, the relative 
survival rate has been stagnant since the 1990s (Figure 5).  Many approaches have been tried 
to improve survival in ovarian cancer patients.  Some have improved PFS but not OS which 
leads to an urgent need for the development of new drugs.  One of the most common 
approaches has been to increase the amount of chemotherapy given via increased dosage or 
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associated with chemotherapy resistance, adding more chemotherapy to patients may be 
counterintuitive.  For instance, maintenance therapy adding more cycles of chemotherapy for 
three cycles, six cycles, and 24 weeks showed no improvement in PFS or OS (Bell, Brady et al. 
2006, Pecorelli, Favalli et al. 2009, Mannel, Brady et al. 2011).  Maintenance therapy for 12 
months did show some increase in PFS, but no effect on OS (Markman, Liu et al. 2003, 
Markman, Liu et al. 2009).  Likewise, therapies that increased paclitaxel dosage and dose 
dense infusions of paclitaxel showed change in PFS but not OS, and were associated with 
higher degrees of toxicity (Omura, Brady et al. 2003, Katsumata, Yasuda et al. 2009, 
Katsumata, Yasuda et al. 2013).  The GOG-182 and ICON5 trails addressed whether the issues 
of adding more chemotherapy having limited effects were due to specific resistance to platinum-
based chemotherapy and paclitaxel.  These trials added a third cytotoxic agent to the front line 
therapy of platinum-based chemotherapy and paclitaxel.  These cytotoxic agents were 
gemcitabine (a nucleoside analog), doxorubicin (a DNA intercalating agent), and topotecan (a 
topoisomerase inhibitor).  None of the third cytotoxic agents improved the activity of front line 
chemotherapy in ovarian cancer patients (Bookman, Brady et al. 2009).  These data support a 
multi-drug resistance phenotype that requires additional activities besides more chemotherapy 
or cytotoxic drugs to improve the survival of ovarian cancer patients. 
 While some targeted therapies have had success in ovarian cancer as previously 
discussed, the majority of clinical trials with targeted therapies demonstrate limited success.  
This was most notably observed in the GOG-170 trials where 12 different agents, many of which 
had been approved for other cancers, were tested in refractory ovarian cancer patients and only 
1 showed improved in patient survival.  Bevacizumab, an angiogenesis inhibitor, showed 
improvement in clinical response when combined with carboplatin in platinum-sensitive ovarian 
cancer (Burger, Sill et al. 2007).  The other 11 drugs showed minimal to no clinical response, 




inhibitor gefitinib (Schilder, Sill et al. 2005, Posadas, Liel et al. 2007), a pan-kinase inhibitor 
sorafenib (Matei, Sill et al. 2011), a dual HER2/EGFR inhibitor lapatanib (Garcia, Sill et al. 2012, 
Leslie, Sill et al. 2012), an mTOR inhibitor temsirolimus (Behbakht, Sill et al. 2011), a protein 
kinase C beta inhibitor enzastaurin (Usha, Sill et al. 2011), a synthetic progesterone inhibitor 
mifepristone (Rocereto, Brady et al. 2010), a pan-kinase inhibitor motesanib (Schilder, Sill et al. 
2013), a uPAR inhibitor urokinase-derived peptide (A6) (Gold, Brady et al. 2012), an IL-12 
plasmid EGEN-001(Alvarez, Sill et al. 2014) and the monoclonal antibody against HGF 
rilotumumab (Martin, Sill et al. 2014).  Likewise, the GOG-146 trials (C, D, F, H, J, K, L, N, O, P, 
Q) evaluated single agents in recurrent ovarian cancer and the majority of trials failed due to 
lack of efficacy (Markman, Blessing et al. 2000, Plaxe, Blessing et al. 2002, Armstrong, Blessing 
et al. 2003, Hoffman, Blessing et al. 2003, Miller, Blessing et al. 2003, Miller, Blessing et al. 
2005, Secord, Blessing et al. 2008, Aghajanian, Blessing et al. 2009, Schilder, Blessing et al. 
2010, Herzog, Sill et al. 2011), while two trials failed due to low accrual or toxicity (McGuire, 
Blessing et al. 2000, Covens, Blessing et al. 2006).  Many of these drugs showed promising 
preclinical activity yet had little to no effects in patients (typically less than 10% clinical response 
as defined by improvements in PFS or OS when compared to the standard of care).  For 
instance, dasatanib showed strong inhibition of ovarian cancer cells lines through SRC kinase 
signaling, and synergy with paclitaxel and carboplatin (Teoh, Ayeni et al. 2011, Xiao, Xu et al. 
2015).  Gefitinib (or the trade name Ireesa) was shown to regulate DNA damage responses and 
synergize with carboplatin in ovarian cancer cell lines (Smith, Gaikwad et al. 2008, Ohta, 
Ohmichi et al. 2012).  Many other promising drugs have failed clinical trials in ovarian cancer.  
Overall, 101 clinical trials were reviewed here for the treatment of ovarian cancer.  These were 
classified as failure based on limited to no clinical response, success based on modest to 
significant clinical improvement in survival or toxicity profile, or toxic based on trials ended early 
due to clinical side effects.  Of these 101 trials, 58.4% were classified as failure, 34.6% were 




suggest limitations of pre-clinical development that need to be improved in order to identify new 
drugs for ovarian cancer.  The focus of my thesis will be to apply this knowledge of 
chemotherapy resistance in clinical models to improve the in vitro representation of ovarian 






























Table 3: Clinical Trials for the Treatment of Ovarian Cancer 
Trial Treatments Outcome Reference 
 
• Doxorubicin and cyclophosphamide 
• Doxorubicin, cyclophosphamide and 
carboplatin 
Complete response rate was 
increased from 26% to 51% with 
the addition of cisplatin 
(Omura, Blessing 
et al. 1986) 
 
• IV cisplatin and paclitaxel 
• IP cisplatin and paclitaxel and IV 
paclitaxel with bevacizumab 
Bevacizumab does not provide an 
increase in PFS and adds 
additional risk to bowel obstruction. 
(Konner, Grabon 
et al. 2011) 
 
• IV carboplatin and paclitaxel 
• IV carboplatin and paclitaxel followed 
by six cycles of paclitaxel 
Maintenance therapy with 
paclitaxel does not prolong PFS or 
OS. 
(Pecorelli, Favalli 
et al. 2009) 
 
• IV carboplatin and paclitaxel 
• IV carboplatin and paclitaxel with 
epirubicin 
No improvement in survival or time 
to treatment failure in patients. 
(du Bois, Luck et 
al. 2003) 
 
• IV carboplatin and paclitaxel 
• IV carboplatin and paclitaxel with 
topotecan 
No improvement in OS or PFS. (Pfisterer, Weber et al. 2006) 
 
• IV carboplatin and paclitaxel 
• IV carboplatin and paclitaxel with 
epidoxorubicin 
No change in 3-year survival (79% 
and 78.7%) with the addition of 
epidoxorubicin. 
(Bolis, Danese et 
al. 2006) 
 • IV cetuximab dose escalation to skin rash 
Cetuximab showed minimal activity 
in patients with recurrent ovarian 
cancer, patients with elevated 
serological markers had a higher 
cancer of early progression. 
(Schilder, Pathak 




• Carboplatin and  gemcitabine 
Addition of gemcitabine improved 
PFS but not OS. 
(Pfisterer, Plante 




• IV cisplatin and paclitaxel 
• IV carboplatin and paclitaxel 
No significant difference in PFS or 
overall survival between treatment 
arms. Better tolerability to 
carboplatin. 
 




• Carboplatin and paclitaxel 
• Carboplatin and paclitaxel with 
nintedanib 
Improvement in PFS, but more 




Kristensen et al. 
2016) 
AURELIA 
• Paclitaxel with or without 
bevacizumab 
• Pegylated liposomal doxorubicin with 
or without bevacizumab 
• Topotecan with or without 
bevacizumab 
Paclitaxel plus bevacizumab was 
the best combination — increased 
response rate, PFS and overall 
survival. 
(Pujade-Lauraine, 
Hilpert et al. 2014, 




• Primary surgery followed by six 
cycles of chemotherapy 
• Three cycles of primary 
chemotherapy, then surgery, 
followed by three more cycles of 
completion chemotherapy 
Chemotherapy before surgery is 
an acceptable standard of care. 
(Kehoe, Hook et 
al. 2015) 
EORTC 
• Primary debulking surgery followed 
by platinum-based chemotherapy 
• Neoadjuvant platinum-
based chemotherapy followed by 
debulking surgery 
Neoadjuvant chemotherapy was 
similar to primary chemotherapy as 
complete debulking was the 
strongest predictor of survival. 





Trial Treatments Outcome Reference 
GOG-170D • IV bevacizumab 
Bevacizumab showed a 21% 
response rate with 40.3% of 
patients with progression over 6 
months in recurrent or persistent 
ovarian cancer patients. 
(Burger, Sill et al. 
2007) 
GOG-111 • IV cisplatin and cyclophosphamine 
• IV cisplatin and paclitaxel 
Increase in PFS and overall 
survival with cisplatin and 
paclitaxel treatment with an 
increase in median survival (38 
months vs 24 months) and PFS 
(18 vs 13 months). 
(McGuire, Hoskins 
et al. 1996) 
GOG-218 
• Carboplatin, paclitaxel and 
bevacizumab with bevacizumab 
maintenance 
• Carboplatin, paclitaxel and 
bevacizumab with placebo 
maintenance 
• Carboplatin, paclitaxel and placebo 
with placebo maintenance 
Increase of PFS by 3.8 months 
with the addition of bevacizumab. 
(Burger, Brady et 
al. 2011) 
GOG-0170M • Oral dasatanib 
Dasatanib as a single agent had 
no effect of recurrent ovarian 
cancer patients. 
(Schilder, Brady et 
al. 2012) 
GOG-1 
• Surgical resection only 
• Melphalan 
• Radiation 
All patients appeared to benefit 
from chemotherapy following 
surgical resection compared to 
radiation or no treatment. 
(Hreshchyshyn, 




• IV paclitaxel followed by IV cisplatin 
• IV high dose carboplatin followed by 
IV paclitaxel then IP paclitaxel 
11 month improvement in OS in 
the high dose carboplatin and IP 
paclitaxel treatment, along with 
increased toxicity. 
(Markman, Bundy 
et al. 2001) 
GOG-126D • IV pyrazoloacridine 
Pyrazoloacridine had modest 
activity in patients with platinum 
resistant cancer, with 1 complete 
responder in 24 patients. 
(Plaxe, Blessing et 
al. 2002) 
GOG-126E • Oral valspador and IV paclitaxel 
Combination of paclitaxel and 
valspador showed minimal effects 
in patients with paclitaxel-
resistance cancer. 
(Fracasso, Brady 
et al. 2001) 
GOG-126G • IV Ledoxantrone Ledoxantrone has minimal activity against platinum resistant disease. 
(Hoffman, 
Blessing et al. 
2000) 
GOG-126I • IV 9-aminocamptothecin 
9-aminocamptothecin showed 
limited activity in platinum-resistant 
ovarian cancer. 
(Miller, Blessing et 
al. 2005) 
GOG-126J • Docetaxel 
Docetaxel is active in 4% of 
paclitaxel-resistant patients with 
significant hematological toxicity. 
(Rose, Blessing et 
al. 2003) 
GOG-126L • Cisplatin plus gemcitabine 
Gemecetbine combination with 
cisplatin showed modest activity 
with an overall response rate of 
16%. 
(Brewer, Blessing 
et al. 2006) 
GOG-126N • IV paclitaxel weekly 
Weekly paclitaxel showed a 
response rate of 20.9% is platinum 
and paclitaxel-resistant patients. 
(Markman, 





Trial Treatments Outcome Reference 
GOG-126O • IV 3-AP before carboplatin for four days, every 21 days 
Platinum sensitivity based on DNA 
damage was restored with 3-AP 
combination but the trial was 
halted before survival was 






• IV nanopaicle, albumin-bound (nab) 
paclitaxel 
Nab-paclitaxel showed promising 
response with median PFS of 4.5 
months and OS of 17.4 months in 
recurrent ovarian cancer. 
(Coleman, Brady 
et al. 2011) 
GOG-126T 
• IV belinsostat with carboplatin on a 
three day cycle for six cycles 
Belinostat addition to carboplatin 
showed little activity (ORR of 
7.4%) is patients with platinum-
resistant ovarian cancer. 
(Dizon, Blessing 
et al. 2012) 
GOG-132 
• IV Cisplatin 
• IV Paclitaxel 
• IV Cisplatin and paclitaxel 
Cisplatin alone showed better PFS 
than paclitaxel alone.  Combination 
therapy showed similar OS but 
better toxicity profile. 
(Muggia, Braly et 
al. 2000) 
GOG-132 • IV Oxaliplatin 
Minimal activity with partial 
response (4.3%) and stable 
disease (39.1%) in platinum 
resistant ovarian cancer. 
(Fracasso, 





• IP α-interferon 
• Observation 
Trial was closed early but indicated 
possible improvement in 
recurrence and survival. 
(Alberts, Hannigan 




• IV paclitaxel 135 mg/m2 
• IV paclitaxel 117mg/m2 
• IV paclitaxel  250 mg/m2 
Dosage response for response 
rate but no survival benefit and 
higher toxicity at higher dosages. 
(Omura, Brady et 
al. 2003) 
GOG-146C 
• 30 min infusional topotecan for 5 
days 
Topotecan showed a 33% 
response rate in patients with 
platinum sensitive ovarian cancer, 
but with a significant hematological 
response. 
(McGuire, 
Blessing et al. 
2000) 
GOG-146D • IV pyrazoloacridine 
Pyrazoloacridine exhibited partial 
response in platinum sensitive 
patients. 
(Plaxe, Blessing et 
al. 2002) 
GOG-146F • 24-h infusional topotecan 
Response rates are much lower 
than longer administrations of 
topotecan in platinum sensitive 
patients. 
(Markman, 
Blessing et al. 
2000) 
GOG-146H • IV byrostatin 
Inactive as a single agent in 
recurrent or persistent platinum-
sensitive cancer. 
(Armstrong, 
Blessing et al. 
2003) 
GOG-146J • IV dolastatin-10 Minimal activity in recurrent platinum-sensitive ovarian cancer. 
(Hoffman, 
Blessing et al. 
2003) 
GOG-146K • IV topotencan for 3 days Well tolerated but less response than 5 day infusion. 
(Miller, Blessing et 
al. 2003) 
GOG-146L • IV capecitabine 
Trial closed after first stage of 
accrual due to low response rate in 
patients with platinum-sensitive 
cancer. 
(Miller, Blessing et 
al. 2005) 
GOG-146M 
• IV tirapazamine followed by IV 
cisplatin 
Combination of tirapazamine 
followed by cisplatin showed 
robust response (55%) and an 
increase in OS from 10.9 months 
to 26.4 months.  However, 
tirapazamine was associated with 
significant toxicity. 
(Covens, Blessing 




Trial Treatments Outcome Reference 
GOG-146N • IV bortezomib 
Bortezomib as a single agent in 
recurrent, platinum-sensitive 
disease had an objective response 
rate of 3.8%. 
(Aghajanian, 
Blessing et al. 
2009) 
GOG-146O • IV irofulven 
Irofulven had modest activity in 
patients with recurrent ovarian 
cancer with 12.7% partial 
responders and 54.6% stable 
disease. 
(Schilder, Blessing 
et al. 2010) 
GOG-146P • IV Cetuximab and carboplatin 
Modest activity of cetuximab in 
combination with carboplatin in 
recurrent ovarian cancer patients. 
(Secord, Blessing 
et al. 2008) 
GOG-146Q 
• IV topotecan every 5 days 
• IV topotecan every 7 days 
Topotencan showed limited activity 
in both the every 5 day (27%) and 
every 7 days (12%) in patients with 
recurrent ovarian cancer. 
(Herzog, Sill et al. 
2011) 
GOG-152 
• Chemotherapy alone 
• Secondary cytoreductive surgery 
following chemotherapy 
No survival benefit to secondary 
surgery, but residual disease does 
predict PFS and OS. 
(Rose, 
Nerenstone et al. 
2004, Rose, Java 
et al. 2016) 
GOG-157 
• Three cycles of adjuvant carboplatin 
and paclitaxel 
• Six cycles of adjuvant carboplatin 
and paclitaxel 
No change in recurrence rate 
between three or six cycles. 
(Bell, Brady et al. 
2006) 
GOG-158 
• IV cisplatin and paclitaxel 
• IV carboplatin and paclitaxel 
Carboplatin and paclitaxel were not 
inferior to cisplatin and paclitaxel.  
Less toxicity in the carboplatin arm 
 
(Ozols, Bundy et 
al. 2003) 
GOG-160 • IV trastuzumab Low rate of response in recurrent or refractory ovarian cancer. 
(Bookman, Darcy 
et al. 2003) 
GOG-162 
• IV cisplatin and IV paclitaxel for 24 
hours 
• IV cisplatin and IV paclitaxel for96 
hours 
No significant change in response 
for prolonged infusion of paclitaxel 
for 96 hours. 
(Spriggs, Brady et 
al. 2007) 
GOG-170C • oral gefitinib 
Gefitinib had limited clinical activity 
across recurrent ovarian cancer 
patients.  Prescreening for patients 
with mutant EGFR may improve 
activity. 
(Posadas, Liel et 
al. 2007) 
(Schilder, Sill et al. 
2005) 
GOG-170F • Oral sorafenib 
Sorafenib had modest activity in 
recurrent but was associated with 
substantial toxicity. 





• Oral Lapatanib 
Lapatanib has minimal activity in 
recurrent ovarian cancer patients 
but may have benefits to patients 
with mutant EGFR (E690K). 
(Garcia, Sill et al. 
2012) (Leslie, Sill 
et al. 2012) 
GOG-170I • IV Temsirolimus 
Temsirolimus showed modest 
activity below the PFS threshold 
for advancement in recurrent 
ovarian cancer patients.  Could be 
considered for selection based on 
cyclin D 1. 
(Behbakht, Sill et 
al. 2011) 
GOG-170J • Oral enzastaurin Enzastaurin had no effect across recurrent ovarian cancer patients. 
(Usha, Sill et al. 
2011) 
GOG-170K • Oral mifepristone 
In patients with recurrent ovarian 
cancer mifepristone had a 
response rate of 4.5%. 
(Rocereto, Brady 




Trial Treatments Outcome Reference 
GOG-170L • Oral Motesanib 
High central nervous system 
toxicity in recurrent ovarian cancer 
patients. 
(Schilder, Sill et al. 
2013) 
GOG-170N 
• Twice daily subcutaneous urokinase-
derived peptide (A6) 
No responses were observed in 
patients with persistent or recurrent 
ovarian cancer. 
(Gold, Brady et al. 
2012) 
GOG-170P • IV rilotumumab every 14 days 
Limited activity of rilotumumab in 
recurrent ovarian cancer patients 
(3.2% complete response and 
6.5% 6-month PFS). 
(Martin, Sill et al. 
2014) 
GOG-170Q 
• IP EGEN-001, an IL-12 plasmid 
,weekly 
EGEN-001 showed limited activity 
with 35% stable disease and 30% 
had a PFS greater than 6 months. 
(Alvarez, Sill et al. 
2014) 
GOG-172 
• IV cisplatin and paclitaxel 
• IP cisplatin and paclitaxel and IV 
paclitaxel 
Increase in OS in the IP paclitaxel 
arm (65.6 months vs 49.7 months).  
However, only 42% of IP patients 
completed the study due to side 
effects and complications. 
(Omura, Blessing 
et al. 1986) 
(Armstrong, 
Bundy et al. 2006) 
GOG-175 
• IV carboplatin and IV paclitaxel for 3 
courses followed by weekly 
paclitaxel 
• Observation 
Maintenance paclitaxel for 24 
weeks showed no increase in 
recurrence-free interval. 




• IV carboplatin and paclitaxel 
• carboplatin, paclitaxel, and 
gemcitabine 
• Carboplatin, paclitaxel, and 
doxorubicin 
• carboplatin plus topotecan, then 
carboplatin plus paclitaxel 
• carboplatin plus gemcitabine, then 
carboplatin plus paclitaxel 
No improvement in PFS or OS 
following the addition of a third 
cytotoxic agent. 
(Bookman, Brady 
et al. 2009) 
GOG-186C • IV Paclitaxel pliglumex 
PPX showed modest activity as a 
second or third line agent in 
recurrent ovarian cancer with a 
response rate of 58% with either 
partial response or stable disease. 
(Sabbatini, Sill et 
al. 2008) 
GOG-186D • IV karenitecin 12% response rate in recurrent disease. 
(Kavanagh, Sill et 
al. 2008) 
GOG-186F 
• IV docetaxel followed by trabectedin 
with filgrastim, pegfilgrastim or 
saragramostim  every 3 weeks 
Combination is well tolerated and 
showed an increase in PFS (4.5 
months) and OS (16.9 months) 
compared to single agent taxane in 
recurrent ovarian cancer. 
(Monk, Sill et al. 
2011) 
GOG-198 
• Oral thalidomide 
• Oral tamoxifen 
There was no difference is 
response between thalidomide and 
tamoxifen in delaying the 
recurrence of ovarian cancer. 
(Hurteau, Brady et 
al. 2010) 
GOG-239 
• Oral selumetinib twice daily until 
progression 
Selumetinib treatment in recurrent 
low-grade carcinoma showed 15% 
objective response, 65% stable 
disease, and 1.9% complete 
response. 




• IP cisplatin, and IV and IP paclitaxel 
and bevacizumab 
• IP carboplatin, and IV weekly 
paclitaxel and bevacizumab 
• IV carboplatin, and IV weekly 
paclitaxel and bevacizumab 
No difference in PFS between 
study arms and higher rates of 
hypertension, nausea and vomiting 
in the IP cisplatin group than in the 
other study arms 
 





Trial Treatments Outcome Reference 
GOG-262 
• IV carboplatin and paclitaxel every 
21 days with or without bevacizumab 
• IV carboplatin every 21 days and IV 
weekly paclitaxel with or without 
dose-dense bevacizumab 
Increase in PFS in patients 
receiving dose-dense treatment 
versus those receiving dosing 
every 21 days who were not given 
bevacizumab. 
 
(Chan, Brady et 
al. 2016) 
GOG-26C • IV Cisplatin 
Overall response rate of 20% 
showed the first evidence of 
cisplatin against ovarian cancer. 
(Tate Thigpen, 
Blessing et al. 
2004) 
GOG-26C • IV Taxol every 3 weeks 
The overall response rate was 
37% for patients with either 
platinum sensitive or resistant 
ovarian cancer. 
(Thigpen, Blessing 
et al. 1994) 
GOG-3 
• Melphalan 
• Melphalan plus 5-fluorouracil 
• Melphalan and 5-fluorouracil plus 
dactinomycin 
• fluorouracil and dactinomycin plus 
cytoxan 
Melphalan alone was not improved 
by the addition of 5-fluorouracil or 
dactinomycin. 




• Adjuvant IP radioactive chromic 
phosphate 
• Adjuvant cyclophosphamide and 
cisplatin 
No significant differences in 
survival and lower recurrence in 
cisplatin treated patients. 
(Young, Brady et 
al. 2003) 
GOG-9919 
• Dose dense carboplatin/ paclitaxel 
for six cycles 
While the overall response rate 
was high (58%) severe neuopathy 
and thrombcytpenia limited further 
development. 






• Carboplatin and paclitaxel 
Superior PFS and OS in patients 
with platinum sensitive ovarian 
cancer with the addition of 
paclitaxel 
(Parmar, 
Ledermann et al. 
2003) 
ICON6 
• Platinum-based chemotherapy and 
cediranib with cediranib maintenance 
therapy 
• Platinum-based chemotherapy 
Significant improvement in PFS. 
(Ledermann, 
Embleton et al. 
2016) 
ICON7 
• Carboplatin, paclitaxel and 
bevacizumab with bevacizumab 
maintenance 
• Carboplatin and paclitaxel 
Increase in PFS with the addition 
of bevacizumab.  But not OS 
benefit based on long term follow 
up. 
 
(Perren, Swart et 
al. 2011) (Oza, 
Cook et al. 2015) 
JGOG 3016 
• IV carboplatin and paclitaxel every 
21 days 
• IV carboplatin every 21 days and 
dose-dense weekly paclitaxel 
28.0 month PFS for dose-dense 
paclitaxel compared to 17.2 month 
PFS in the standard of care.  Dose 
dense paclitaxel showed higher 
patient drop out due to side effects. 
(Katsumata, 
Yasuda et al. 
2009, Katsumata, 




• Oral niraparib maintenance therapy 
for 28 days 
21.0 month PFS in BRCA germline 
mutant patients compared to 5.5 
months is placebo.  Survival 
increased was lower with treatment 
in non-gBRCA mutants (9.5 
months vs 3.9 months). 
(Mirza, Monk et al. 
2016) 
MITO-2 
• Carboplatin and paclitaxel 
• Carboplatin and pegylated liposomal 
doxorubicin 




et al. 2011) 
MITO-7 
• Weekly carboplatin and weekly 
paclitaxel 
• Carboplatin and paclitaxel every 3 
weeks 
No Difference in PFS or OS 
survival. 
(Pignata, Scambia 




Trial Treatments Outcome Reference 
MITO-11 
• IV paclitaxel 
• IV paclitaxel plus oral pazopanib 
daily 
In patients with recurrent or 
refractory ovarian cancer 
pazopanib prolonged PFS to 6.35 
months compared to 3.49 months. 
(Pignata, Lorusso 
et al. 2015) 
NCT007535
45 
• Platinum-based chemotherapy 
• Platinum-based chemotherapy with 
olaparib maintenance therapy 
Significant increase in PFS with 
olaparib maintenance. 
(Ledermann, 
Harter et al. 2012) 
NCT008666
97 
• IV platinum and taxane 
chemotherapy followed by placebo 
maintenance 
• IV platinum and taxane 
chemotherapy followed by pazopanib 
maintenance 
Improved PFS with the addition of 
pazopanib but no difference in 
overall survival between groups 
 
(du Bois, Floquet 
et al. 2014) 
NCT010819
51 
• Carboplatin and paclitaxel 
• Carboplatin and paclitaxel with 
olaparib maintenance therapy 
Increase in PFS with olaparib 
maintenance therapy. 
 





• Olaparib and cediranib 
Increase in PFS when cediranib is 
added to olaparib. 
(Liu, Barry et al. 
2014) 
OCEANS 
• Carboplatin and gemcitabine 
• Carboplatin, gemcitabine and 
bevacizumab with bevacizumab 
maintenance therapy 
Increased PFS with the addition of 
becacizumab. 
(Aghajanian, 
Blank et al. 2012) 
S0009 
• Neoadjuvant IV paclitaxel and 
carboplatin 
Neoadjuvant therapy of cisplatin 
and paclitaxel in bulky disease had 
a PFS of 29 months and an OS of 
34 months. 
(Tiersten, Liu et al. 
2009) 
S0200 
• IV carboplatin and pegylated 
liposomal doxorubicin on a 4 week 
schedule 
Combination showed an 
improvement in PFS but not OS 
after long term follow up. 
(Alberts, Liu et al. 
2008, Markman, 
Moon et al. 2010) 
S0904 
• IV docetaxel 
• IV docetaxel plus oral vandetanib 
Combination of docetaxel with 
vandetanib in recurrent ovarian 
cancer patients did not prolong 
PFS compared to docetaxel alone. 
(Coleman, Moon 
et al. 2014) 
S9618 
• Treatment regimen of carboplatin 
and paclitaxel based on CA-125 
serum levels 
No improvement in 2-year survival 
based on historical control. 
(Markman, Glass 
et al. 2003) 
S9619 
• Combined IV cisplatin and paclitaxel 
with IP paclitaxel over 21 day cycles 
for 6 cycles 
In 68 women with optimally 
debulked ovarian cancer the 
combination of IV and IP 
chemotherapy showed a 91% 2-
year survival rate and a median 
survival of 51 months. 
(Rothenberg, Liu 
et al. 2003) 
S9912 
• IV pegylated liposomal doxorubicin 
with IP cisplatin and paclitaxel and IP 
paclitaxel 
Liposomal doxorubicin did not 
improve PFS (25 months) with a 
median survival of 51 months. 
(Smith, Moon et 
al. 2009) 
SCOTROC 
• IV carboplatin and paclitaxel 
• IV carboplatin and docetaxel 
Similar PFS. Docetaxel is 
associated with greater 
neutropenia while paclitaxel is 
more likely to induce sensory 
peripheral neuropathy 





Trial Treatments Outcome Reference 
SWOG-8412 
• IV cisplatin plus IV 
cyclophosphamide 
• IV carboplatin plus 
cyclophosphamide 
Carboplatin plus 
cyclophosphamide showed a 
significantly better therapeutic 
index than cisplatin plus 
cyclophosphamide with similar 
response rates (61 and 52% 
respectively) and lower toxicity in 
the carboplatin arm. 
(Alberts, Green et 
al. 1992) 
SWOG-8501 
• IV cisplatin plus cyclophosphamide 
• IP cisplatin plus cyclophosphamide 
The median survival was longer in 
the IP cisplatin group (49 months) 
than the IV cisplatin (41 months) 
and has fewer side effects. 
(Alberts, Liu et al. 
1996) 
SWOG-8835 
• IP mitoxantrone 
• IP floxuridine 
Floxuridine treatment showed a 
PFS exceeding 15% at 1 year with 
less toxicity in ovarian cancer 
patients with minimal residual 
disease. 
(Muggia, Liu et al. 
1996) 
SWOG-9106 
• CMC- Carboplatin (1500 mg/m2), 
mitoxantrone (75 mg/m2), and 
cyclophosphamide (120 mg/m2) 
• CTC- Cisplatin (165 mg/m2), thiotepa 
(600 mg/m2), and cyclophosphamide 
(5625mg/m2) with stem cell rescue 
CMC was the favorable treatment 
when compared to CTC when 
comparing OS (29 months to 
22months) and PFS (13 months 
and 8 months). 
(Stiff, Shpall et al. 
2004) 
SWOG-9324 • IV vinorelbine 
Vinorelbine 6-month survival rate 
for women with recurrent ovarian 
cancer was 65% with a median 
survival of 10.1 months. 
(Rothenberg, Liu 
et al. 2004) 
SWOG-9326 
• Oral alteramine in four dosages over 
14 days every 28 days 
Alteramine treatment in patients in 
complete clinical remission showed 
a 2-year survival rate of 75%. 
(Rothenberg, Liu 




• IV carboplatin and paclitaxel 
• IV carboplatin and paclitaxel followed 
by 12 months of paclitaxel 
Significant increase in PFS 
following 12 months of paclitaxel. 
(Markman, Liu et 
al. 2009) 







Chapter 2: Exploiting Three-Dimensional Cell Culture to 







3D Culture History 
Since the early 1900s the ability of scientists to isolate and grow cells from humans in the 
laboratory has led to incredible and significant scientific breakthroughs.  One of the most 
commonly used cell lines (HeLa) was developed from Henrietta Lacks’ cervical cancer sample 
in the early 1950s (Scherer, Syverton et al. 1953).  To this day, HeLa cells are still used in cell 
biology research.  Traditionally cells were grown on flat surfaces such as glass cover slips or 
plastic petri dishes where they were able to attach to and propagate.  However, the phenotype 
of these cells often did not represent the structure or function of the tissue or organ from which 
they were isolated since their growth was limited to a two-dimensional (2D) surface.  The use of 
improved cell culture methods to better replicate three-dimensional (3D) biological structures 
have been in demand since the 1970s.  It was discovered that using non-adherent cell culture 
conditions (also known as 3D cell culture) such as agarose coated cell culture plates led to cell 
aggregation and changes in morphology (Yuhas, Li et al. 1977).  3D culture of mammary 
epithelial cells induced morphological differentiation and induced secretory function that was 
maintained for up to one month in vitro (Emerman and Pitelka 1977).  Using collagen overlay of 
Madin-Darby canine kidney (MDCK) and normal murine mammary gland (NMuMG) cell lines 
formed lumens that more resembled tissues of origin for each cell culture (Hall, Farson et al. 
1982).  The use of 3D culture has even led to cell-based engineering of functional organoids 
capable of animal implantation (Toda, Watanabe et al. 2002).  The use of 3D cell culture with 
cancer cell lines forms solid, multicellular structures known as multicellular-tumor spheroids 
(MCTS) (Durand and Sutherland 1972, Sutherland and Durand 1976).  The primary objective of 
this chapter will be to use 3D cell culture to better replicate clinical drug response in ovarian 




3D Culture Methods 
The basis of 3D culture needs only two elements: a surface on which the cells cannot attach 
and a way of bringing cells into close proximity to enhance cell-to-cell contact.  There are many 
different methods for 3D cell culture that include agarose coated or round-bottom non-adherrent 
plates that bring cells together on a concave surface (Yuhas, Li et al. 1977, Friedrich, Seidel et 
al. 2009, Hribar, Finlay et al. 2015); a hanging drop culture method that uses small, suspended 
droplets in which gravity pulls the cells together at the bottom of each drop (Timmins, Harding et 
al. 2005, Timmins and Nielsen 2007); a magnetic levitation method that elevates cells above the 
culture dish within a condensed magnetic field (Lin, Chu et al. 2008, Guo, Loh et al. 2014); and 
a rotating cell culture method that uses centripetal force to bring cells together and prevents 
them from attaching to the moving surface (Granet, Laroche et al. 1998, Jessup, Frantz et al. 
2000, Rhee, Zhau et al. 2001).  Derivations of these methods using biological scaffolds such as 
solid or semi-solid extracellular matrix (ECM) can aide formation of 3D cultures (Chevallay and 
Herbage 2000, Carletti, Motta et al. 2011).  The type of scaffold can change cell behavior and 
differentiation based on physical and chemical properties of the scaffold (Zheng, Yang et al. 
2014, Tan, Fang et al. 2015).  Recent advances in 3D printing allow for cells to be physically 
constructed in specific positions to generate organoids more similar to human tissue (Dai, Ma et 
al. 2016, Mandrycky, Wang et al. 2016, Vanderburgh, Sterling et al. 2016). 
MCTS as a Model for Resistant Disease 
One of the limiting factors in developing therapies for EOC is that in the majority of the studies 
the cell culture models don’t recapitulate patient tumors.  Standard 2D cell culture models have 
physiological limitations in modeling solid tumors.  However, using non-adherent, three-
dimensional (3D) cell culture of standard cell lines can induce the formation of MCTS.  MCTS 
formation induces morphological, histological, and gene expression changes, which more 
accurately reflect both tumor xenografts and patient tumors compared to traditional 2D cultures 




changes are driven by heterogeneous populations of cells that contribute to spheroid formation, 
including actively proliferating, quiescent, hypoxic, and inner necrotic cells (Sutherland, 
MacDonald et al. 1977, Freyer and Sutherland 1980).  Furthermore, transition to MCTS alters 
extracellular matrix (ECM) remodeling, cell adhesion and metabolism which have all been 
associated with both drug resistance and tumor reoccurrence in EOC (Huang, Ao et al. 2010, 
Steg, Bevis et al. 2012, Chien, Kuang et al. 2013).  MCTS formation in the patient ascites is also 
thought to be a critical mechanism for EOC growth and dissemination in advanced disease 
(Burleson, Casey et al. 2004, Shield, Ackland Ml Fau - Ahmed et al.).  3D culture can provide an 
intermediate method between the rapid, low cost 2D culture models, and the slower, more 
biologically relevant in vivo models (Figure 6). 
 MCTS formation and growth are associated with many drug resistance mechanisms.  
Large MCTS, with a diameter greater than 300 µm, exhibit many morphological, signaling and 
growth changes.  As with large solid tumors, many drugs cannot penetrate the spheroid, 
lowering their effective dosage (Minchinton and Tannock 2006).  Lower molecular weight, 
hydrophobic drugs have been shown to enhance spheroid penetration (Minchinton and Tannock 
2006, Fayad, Rickardson et al. 2011).  However, MCTS drug resistance is not just attributed to 
decreased drug availability.  A myxoma-virus model showed spheroid cells have intrinsic 
resistance to apoptosis through signaling pathways acquired upon aggregation and not reflected 
in 2D cultures (Correa, Komar et al. 2012).  Limited nutrient and oxygen diffusion at the 
spheroid center creates gradients in cell proliferation, hypoxia, and necrosis across the MCTS 
(Sutherland and Durand 1984).  Metabolic changes, cellular senescence, hypoxia, and 
alterations in other signaling pathways have been identified as potential critical modulators of 
drug and radiation therapy resistance in different MCTS (Sutherland and Durand 1976, Graham, 
Kobayashi et al. 1994, Desoize and Jardillier 2000).  Using MCTS in frontline drug screening 




Using 3D Culture to Enhance Drug Development 
“The valley of death” has been used to describe the poor success rate of cancer drug 
development (Adams 2012).  Only one out of every 1,000 drug candidates enter into a clinical 
trial and most of these agents fail to move into Phase III studies due to a lack of efficacy 
(Marchetti and Schellens 2007, Zaenker and Entschladen 2009).  The use of MCTS as a model 
for improved drug development was proposed over 10 years ago (Abbott 2003, Kunz-
Schughart, Freyer et al. 2004) and recent advances in screening methods have shown 2D drug 
screening favors the selection of mitotic inhibitors while 3D screening has identified inhibitors of 
mitochondrial function that can block hypoxia-resistant and stem-like cell mitochondrial 
metabolism (Fayad, Rickardson et al. 2011, Pasto, Bellio et al. 2014, Wenzel, Riefke et al. 
2014, Zhang, Fryknas et al. 2014).  However, the paradigm shift for using MCTS in drug 
screening has been slower than predicted.  Methods to reliably produce MCTS and to measure 
spheroid viability have been major limiting factors in the routine use of 3D culture in drug 
screening.  3D culture systems require additional time and effort to plate and grow spheroids as 
compared to traditional 2D culture models (Figure 6).  Without improvements in culturing 
methods and evidence that using tumor spheroid models are superior in identifying 




unappreciated anti-tumor drugs compared to 2D cultures, the use of MCTS in drug screening 
will remain limited.  While 3D drug screening has been shown to identify unappreciated drugs 
and predict in vivo efficacy in ovarian cancer cells, this model focused on the attachment of 
single cells to omentum cells, more representative of early stage disease (Kenny, Lal-Nag et al. 
2015).  The use of alternative MCTS models that represent late stage disease is needed to 
develop drugs for patients who prognosis is substantially worse than those diagnosed at an 
early stage.  The focus of this chapter will be to develop a 3D cell culture model that reflects 
aspects of drug resistant ovarian cancer that cannot be appreciated using traditional 2D cultures 






Ovarian cancer cell lines used in these studies were previously described in detail (Godwin, 
Meister et al. 1992, Yao, Godwin et al. 1995, Pathak, Zhou et al. 2015).  All of the cell lines were 
maintained in normal growth media consisting of RPMI 1640 media supplemented with fetal 
bovine serum (FBS) (10% (vol/vol)), insulin (7.5 μg/mL), penicillin (100 U/mL), and streptomycin 
(100 μg/mL) at 37°C in a humidified atmosphere with 5% CO2.  Immortalized and non-
tumorigenic human ovarian surface epithelial (HOSE) cells, immortalized via SV40 large T 
antigen (Capo-Chichi, Smith et al. 2002, Roland, Yang et al. 2003), were cultured in medium 
199 and MCDB 105 (1:1) supplemented with FBS (15% (vol/vol)), insulin (0.25 U/mL), L-
glutamine (2 mM), penicillin (100 U/mL), and streptomycin (100 µg/mL). 
Spheroid Formation 
Spheroids were formed using the liquid-overlay method with agarose coated 96-well plates, 
modified from a previous publication (Friedrich, Seidel C Fau - Ebner et al. 2009).  Briefly, 1.5% 
agarose was dissolved in RMPI 1640 media and then used to coat the bottom of 96-well flat 
bottom plates with 50 µL of the agarose solution.  Agarose was allowed to solidify for a 
minimum of 30 minutes and then 3,000 cells were plated in 50 µL using standard cell culture 
media.  These plated cells were then allowed to form spheroids undisrupted for four days.  On 
day 4 spheroids were visually inspected and 50 µL of fresh, standard media was supplemented 




In Vivo Tumorigenicity  
All procedures involving mice were approved by the University of Kansas Medical Center 
(KUMC) Institutional Animal Care and Use Committee (IACUC).  Female 5 to 6 week-old C.B-17 
severe combined immunodeficient (SCID) mice (Harlan) were used for this study.  Cell lines 
including the tumorigenic A1847 cell line and the non-tumorigenic cell lines HIO80, HIO107, 
HIO114, HIO117, and HIO120 were grown to ~80% confluency in conditions previously 
described.  Mice were randomized by weight and 1x106 cells were suspended in 500 µL 
phosphate-buffered saline and injected intraperitoneally into three mice per cell line.  Health 
checks were performed twice a week to evaluate any signs of distress or a body weight 
decrease of greater than 10%.  If either of the above symptoms occurred, or six months from 
date of injection passed, exploratory necropsies were performed to evaluate internal 
tumorigenesis and/or ascites formation.  All tumors were collected for both RNA extraction and 
formalin-fixation followed by hematoxylin & eosin (H&E) stain.  Images were taken using a 
Nikon Eclipse 80i microscope with MetaMorph 7.7 (Molecular Devices). 
Secondary Spheroid Assays 
For secondary assays, spheroids were removed from each well using wide bore pipette tips and 
pooled together from 96 wells for each single treatment.  Spheroids were centrifuged at 2,000 
RPM for 5 minutes at 4°C to pellet, the media was removed, and the spheroids washed with 
96 well flat-bottom plates 
Coated with 50 µl 1.5 % 
agarose in RPMI 
Cells harvested from 2D 
culture and plated in standard 
media 
3-4 days later spheroids are 
formed 




sterile PBS.  Following another spin and removal of PBS, spheroids were dissociated in a 1:1 
(vol/vol) combination of trypsin and Accutase (10mL) for 30 minutes at 37°C, with mild shaking 
every 3 to 10 minutes.  Disassociated cells were diluted in complete media and spun at 2,000 
RPM for 5 minutes at 4°C, rinsed with sterile PBS, spun again, and suspended in standard cell 
culture media.  Cells were then plated overnight on a 10 cm cell culture dish.  Following, 
overnight seeding, viable cells were counted for subsequent assays following standard 
protocols. 
Cell Cycle Analysis 
Cells were grown as 2D cultures in 6 cm dishes (2 x 105 cells/dish) for 24 h, 48 h, or 72 h or as 
3D culture spheroids as described above for 4 days and 7 days.  Cells were collected from 2D 
cultures by trypsinization and from spheroids using trypsin/Accutase treatment as described 
above.  Cells were immediately fixed using 70% ice-cold ethanol and stored overnight at -20°C 
before cell cycle analysis using propidium iodide staining (Guava Cell Cycle reagent, EMD 
Millipore) following the manufacturer’s established protocol.  The cell cycle assays were 
performed three independent times with two technical replicates for each sample.  A Guava 
Easycyte HT instrument (EMD Millipore) was used to measure the changes in cell cycle 
distribution of the cells. 
Immunofluorescence 
Sections (4 μm) from formalin-fixed, paraffin-embedded (FFPE) cell line spheroids were made 
for immunofluorescence (IF) staining.  After deparaffinization and rehydration, tissue sections 
were treated using citrate buffer (pH 6.0) for antigen retrieval.  Then, sections were blocked with 
1% normal goat serum for 1 h, and then incubated with Ki67 rabbit mAB (1:1,000, Cell Signaling 
Tech) in a moist chamber overnight at 4 °C.  On the following day, the cells were washed with 
PBS and then incubated with secondary antibody (goat anti-rabbit IgG, DyLight 594, Thermo 




were mounted onto glass slides in VECTASHIELD® mounting medium with DAPI (Vector Labs, 
Inc.).  Pimonidazole staining was performed following the manufacture’s protocol 
(Hypoxyprobe).  Briefly, spheroids were incubated for 2 h with 200 μM pimonidazole from 
Hypoxyprobe-1 and then fixed for 30 minutes in formalin and sectioned as described above.  
Primary mouse antibody (Hypoxyprobe-1 Mab1; 1:100, HPI) was incubated overnight at 4°C 
followed by secondary antibody (FITC-Mab 4.3.11.3, HPI) for 1 h at room temperature.  
Fluorescence digital images were captured using a Nikon Eclipse 80i microscope attached with 
a Nikon Q-imaging camera adaptor.  MetaMorph Image Analysis software (version 7.7.0.0) was 
used to acquire and analyze images. 
Western Blot Analysis 
All lysates were extracted using RIPA buffer supplemented with protease inhibitors (Roche 
Molecular Biochemicals) and phosphatase inhibitors (Fisher Scientific).  2D culture lysates were 
prepared by washing cells with cold PBS, scraped in lysis buffer and incubated for 10 min on 
ice.  3D culture lysates were collected by combining spheroids from one 96-well plate, spheroids 
were centrifuged at 2,000 RPM for 5 min at 4°C to pellet, washed with cold PBS, spun again, 
suspended in lysis buffer for 30 minutes on ice, and then briefly sonicated.  Lysates were spun 
at 14,000 RMP for 10 min at 4°C and the supernatant was collected for quantification and 
western blots.  Protein concentration was measured using the DC Protein Assay (Bio Rad) 
following manufacture’s protocol.  For each sample, 30 µg of whole-cell extract was 
electrophoresed on a 4-20% precast gradient polyacrylamide gel (Bio-Rad) and transferred onto 
nitrocellulose membranes using the Trans-Blot Turbo (Bio-Rad).  After blocking with 5% skim 
milk (Difco), membranes were incubated overnight at 4°C with primary antibodies, HIF1-α 
(1:1,000, Cell Signaling) and PARP (1:500, Cell Signaling).  After incubation with HRP-
conjugated secondary antibody (1:1,000) at room temperature, development was carried out 




using Image-J software (NIH).  Changes in protein levels were normalized to loading controls 
and expressed as fold change relative to treatment controls. 
RT-PCR and RNASeq Analysis 
RNA was isolated using Trizol and Phase Lock Gel Heavy tubes (5 Prime) followed by RNeasy 
Mini Kits (Qiagen) following manufacture’s protocols.  RNA quality (260:280 ratio > 1.8) and 
quantity was assessed using the Infinite 200Pro (Tecan). For TaqMan qRT-PCR, 1 µg of RNA 
of subjected to reverse transcription using random primers, 5X first strand buffer, 0.1 M DTT, 10 
mM dNTPs, and SuperScript III (ThermoFisher) following manufacture’s protocol.  For 
amplification, 10 µL of TaqMan Gene Expression Master Mix (2x) (AppliedBiosystems) was 
combined with 2 µL of diluted cDNA (1:2), 7 µL of sterile water, and 1 µL of TaqMan primers 
(PROM1, NANOG, POU5F1, SOX2, CD44, KLF4, ALDH1A, LOX, JMJD1A, VEGF, PPIA, 
BACTIN, and GAPDH).  Amplification was performed by initial polymerase activation for 10 min 
at 95°C, and 40 cycles of denaturation at 95°C for 15 sec, annealing and elongation at 60°C for 
10 minutes on the Bio-Rad CFX96 (BioRad).  The fluorescence threshold value was calculated 
using the CFX96 real-time system software (BioRad).  The relative change in mRNA levels was 
measured by the delta-delta method normalizing to the geometric mean of all three 
housekeeping genes (PPIA, BACTIN, and GAPDH). 
 For transcriptome sequencing, RNA was isolated from 2D cultures at 80% confluency, 
from 3D cultures at 7 days of spheroid growth, and from A1847 xenograft tumor tissue samples 
harvested at terminal necropsy.  RNA was prepared for paired end sequencing on a HiSeq 2500 
using a stranded library prep kit (Illumina).  Initial analyses were prepared using RSEM 
expected gene counts.  First, data was filtered to remove non/low-expressed genes.  This 
resulted in a total of ~14,000 genes examined for differential expression between the different 
models of cell growth.  Next, normalization factors were calculated to scale the library sizes 




compared that were 1.5-fold upregulated or down regulated in either 3D cultures or tumor 
xenografts compared to 2D cultures. 
Colony Forming Assay 
For soft agarose colony forming assays, 500 viable cells were counted and plated into 6-well 
plates in 0.6% agarose in RPMI 1640 with fetal bovine serum (10% (vol/vol)), insulin (7.5 
µg/mL), penicillin (100 U/mL), and streptomycin (100 μg/mL), on top of a base of 1.4% agarose 
in the same media conditions.  Colonies grew for 2 weeks at 37 °C in a humidified atmosphere 
with 5% CO2.  Colonies were stained with crystal violet and imaged using the Alpha View 
Imager (Alpha Innotech Corperations) for colony counting.  Colony diameter was measured 
using 10 random images from each well using the Micromaster (Fisher Scientific) and colony 
diameter was measured for each colony 3 times using Micron Software (1.09, Westover 







Formation of Multicellular Tumor Spheroids in Established Ovarian Cancer Cell 
Lines Using Agarose Coated Plates 
To form MCTS from ovarian cancer cell lines, 3D culture models need two basic properties: (1) 
to prevent cell adherence to the culture plate and (2) to bring cells together in a restricted space 
to increase cell-cell contact and limit spheroid size (Figure 8A).  Ovarian cancer cell lines 
adhered to standard low-attachment plates in round bottom 96-well plates that would have 
limited the size of spheroids (Figure 8B).  However, soft agar coated 10 cm tissue culture 
dishes prevented cells from attaching to the surface of the plate but do not restrict the area of 
growth to form consistent spheroids (Figure 8C).  Likewise, soft agar allowed the cells to invade 
into the media, making spheroid recovery for secondary assays burdensome.  These data 
support the need to develop a 96-well plate format that both prevents cell adherence to the 
culture plate and bring cells together in a restricted area. 
 In order to develop more relevant in vitro models for drug screening, qualitative 
comparisons of a variety of ovarian cancer cell line-based 3D culture methods were performed.  
These methods were selected based on using a 96-well plates and included agarose coated 
plates, hanging drop cultures, ultra-low attachment (ULA) plates, and magnetic levitation 
cultures.  Protocols were compared for liquid handling, the use of artificial or biological reagents, 
cost, reproducibility, and if spheroids needed to be transferred after formation.  Methods low in 
cost and most similar to handling 2D cultures provided the best system for directly comparing 
cellular differences between cultures.  Based on the minimal use of artificial reagents (inert 
agarose), low cost, single spheroids formed per well, and minimal spheroid transfer, the 
agarose coated-liquid over-lay method for 3D culturing of ovarian cancer cells (Table 4) was 
selected for subsequent experimentation.  The agarose coated 96-well plates were established 




ovarian cancer cell lines were cultured under these conditions in standard growth media and 
spheroid formation was measured after four and seven days using light microscopy.  Tight 
spheroids were formed after four days in the majority of cell lines (A1847, SKOV3, OVCAR3, 
OVCAR8, C30, PEO1, OVCAR5, OVCAR10, and OVCAR4) while three of the cell lines formed 
loose aggregates that dissociated during pipetting (UPN275, CP70, and A2780) (Figure 9).  
The agarose coated plates prevented cell adherence to the surface, formed on spheroid per 
well of consistent size, and prevented spheroids from invading the solid surface for future 
biological assays.  This method provided an in-well 3D culture protocol that did not require 
transferring spheroids or specialized media that can be developed for studying ovarian cancer 
drug resistance. 
MCTS Formation Induced Multiple Cellular Changes Associated with Solid 
Tumors and Drug Resistance 
To evaluate the phenotypes associated with spheroid formation (MCTS), cellular changes were 
measured using a variety of biological assays in 2D and 3D cultured cells.  The most notable 
changes associated with 3D culturing included reduced cell proliferation, induction of cellular 
hypoxia, and induction of stem-like gene expression and function. 
 Cell proliferation in MCTS was measured using immunofluorescence (IF) staining and cell 
cycle analysis of spheroid sections and 2D cultures of A1847 cells.  Staining for the proliferation 
marker Ki67 showed a gradient of positive cells on the spheroid surface and Ki67 negative cells 
in the inner mass of the spheroid (Figure 10A).  However, near ubiquitous positive staining of 
Ki67 was observed in 2D cultures (Figure 10A).  Cell cycle analysis of single cells 
disassociated from A1847 spheroids showed an increased accumulation of cells in G1 phase 
(58% at day 4 and 53% at day 7) as compared to cells grown in 2D cultures (40%, 45%, and 
34% at 24 h, 48 h and 72 h, respectively) (Figure 10B).  These data indicate lower proliferation 




 The potential presence of cellular hypoxia was detected using pimonidazole staining in 
A1847 spheroid sections.  Pimonidazole staining was positive in the inner spheroid mass of 
spheroids at day 4 (Figure 11A) and was not detected in any of the cells cultured in 2D (data 
not shown).  To confirm cellular hypoxia, HIF-1α stabilization was measured in A1847 cells in 
both 2D and 3D cultures using Western blot analysis.  HIF-1α is stabilized in A1847 cells when 
cultured under hypoxic conditions (1% oxygen) but not when cultured under atmospheric 
oxygen levels (Figure 11B).  However, when cells are grown under 3D conditions, HIF-1α is 
stabilized in A1847 spheroids at day 4 under atmospheric oxygen levels (Figure 11B).  Gene 
expression analysis of hypoxia regulated genes (JMJD1A, LOX, VEGF) using qRT-PCR was 
performed across four ovarian cancer cell lines (A1847, OVCAR3, OVCAR4 and OVCAR8) and 
one non-tumorigenic ovarian surface epithelial cell line (HIO107) when grown under 2D and 3D 
culture conditions.  Significant increases (p< 0.05, n=3, t-test) of the hypoxia-related genes were 
observed in the 3D cultured cells relative to the 2D cultured cells (Figure 11C). 
 In addition, expression of stem cell genes associated with drug resistance in ovarian 
cancer (ALDH1A, CD133, CD44) and traditional stem cell markers (NANOG, OCT4, SOX2) 
were measured in tumor cells from both 2D and 3D cultures.  The expression of ALHD1A, 
NANOG, and OCT4 was significantly increased (p< 0.05, n=3, t-test) in 3D cultures compared to 
2D cultures across all four ovarian cancer cell lines (Figure 12A).  The other stem cell markers 
(CD133, CD44, and SOX2) were significantly increased (p< 0.05, n=3, t-test) in A1847, 
OVCAR3, and OVCAR4 cell lines (Figure 12A).  None of these stem cell markers were 
significantly increased in the HIO107 cell line spheroids, indicating the drug induction of stem-
like properties may be specific to tumorigenic cells in propagated in 3D cultures.  Finally, stem 
cell function was measured using a soft agar colony forming assay.  Cells from 2D cultures and 
viable cells from dissociated spheroids of both A1847 and OVCAR8 cell lines were used for 




cells compared to their 2D cultured cells as indicated by an increased number of colonies 
formed (Figure 12B).  Taken together, these data suggest there is an increase in multiple 
cellular mechanisms associated with clinical drug resistance in 3D cultures when compared to 
2D cultures in ovarian cancer cell lines.  
MCTS Displayed Intermediate Gene Expression Between 2D Cultures and Tumor 
Xenografts 
Similar to MCTS, a gradient of Ki67 positive staining was observed in A1847 mouse tumor 
xenografts and not in 2D cultures (Figure 13A).  A comparison of expression levels for hypoxia 
related and stem-like genes indicated the 3D cultures of A1847 cells express an intermediate 
level between the 2D cultures and in vivo tumors (Figure 13B-C).  Comparison of the gene 
expression data derived from RNA sequencing of 2D and 3D cultured cells and the mouse 
xenografts showed over half of the genes (148 out of 269) overexpressed by at least 1.5-fold in 
A1847 3D cultures compared to 2D cultures were also overexpressed in the A1847 tumor 
xenografts compared to 2D cultures (Figure 13D).  These data support the hypothesis that 3D 
cultures might provide a better reflection of in vivo solid tumors than 2D cultures, while taking 
less time and money to develop than in vivo tumors. 
Properties Specific to Tumorigenic Cell Lines 
To test if the stem-like properties included in 3D cultures were specific to ovarian cancer cell 
lines, non-tumorigenic cell lines from the human ovarian surface epithelium were used.  Primary 
HOSE cells were previously immortalized using SV40 large T antigen to derive HIO80, HIO107, 
HIO114, HIO118, and HIO120 (Auersperg, Maines-Bandiera et al. 1995, Dyck, Hamilton et al. 
1996, Kruk, Godwin et al. 1999, Grobelny, Godwin et al. 2000, Capo-Chichi, Smith et al. 2002, 
Roland, Yang et al. 2003, Smith-Beckerman, Fung et al. 2005).  The in vivo tumorigenicity of 
A1847 cell lines was compared to each HIO cell line implanted via Intraperitoneal (i.p.) injection.  




up to 25 weeks after implantation (Figure 14A-D).  In 3D cultures, the HIO cell lines formed 
spheroids smaller than the A1847 cell lines and did not change in size from day 4 to day 7 
(Figure 15A).  Consequently, spheroids from the HIO cells were negative for pimonidazole, had 
almost ubiquitous expression of Ki67 (Figure 15B).  Unlike that of ovarian MCTS, spheroids 
from HIO cells did not express higher levels of stem cell-related gene when compared to 2D 
cultures (Figure 12A).  These data reveal that 3D culture of non-tumorigenic cell lines do not 
alter the phenotype in the same ways as tumorigenic cell lines, making the changes observed in 
ovarian cancer cell lines specific to their growth in 3D and not an artifact of the agarose plate 
method. 
Reduced Sensitivity of Ovarian MCTS to Paclitaxel Compared to 2D Cultures 
In order to determine differences in drug sensitivity between 2D and 3D cultured cells the dose 
response was measured for paclitaxel, one of the front-line therapy drugs for ovarian cancer.  
Cells were plated overnight before the addition of paclitaxel (from 3 µM to 1.3 nM) to 2D 
cultured cells or for four days to 3D cultured cells in order to allow the spheroids to form.  Cell 
viability to paclitaxel was measured 72 hours after drug treatment (Figure 16A).  Viability 
measurements performed 3 days after the addition of drug, showed cells in spheroids to have a 
substantial decrease in drug sensitivity to paclitaxel compared to the parental 2D cultures 
(Figure 16B).  The established IC50 values clearly show decrease in paclitaxel sensitivity in the 
MCTS compared to the 2D cultures (A1847, 168 nM vs 7 nM; OVCAR3, >3,000 nM vs 8 nM; 
OVCAR8, 97 nM vs 7 nM; OVCAR4, >3,000 nM vs < 1.3 nM).  To measure drug resistance, the 
viability of cells surviving high dosages of paclitaxel (333 nM, 1 µM, and 3 µM) in MCTS 
compared to 2D cultures was measured using the average cell viability for each dosage.  For 
each of the four cell lines there was a significant increase (p< 0.05, n=9, t-test) in the percent 
viability across the three highest dosages of paclitaxel in 3D cultures compared to 2D cultures: 




and OVCAR8 (42% 3D vs 11% 2D) (Figure 16B).  While it was previously shown that drug 
resistant pathways and mechanisms were upregulated in 3D cultures, these data directly 
support 3D cell culture as a direct model of drug resistance in ovarian cancer cell lines. 
Paclitaxel Treatment Reduced Proliferation and Increased Stemness 
The effect of paclitaxel treatment on expression of stem cell-related markers and proliferation 
was measured.  In both patient tumor samples and in vivo PDX models there is a reported 
decrease in Ki67 levels and an increase in gene expression of stem cell markers following 
chemotherapy (Steg, Bevis et al. 2012, Dobbin, Katre et al. 2014).  These phenotypes were 
evaluated in the MCTS model.  Ki67 staining was evaluated in spheroids treated with vehicle 
(DMSO) or 1 µM paclitaxel.  A decrease in Ki67 positive cells (41% positive in the vehicle 
treated group compared to 24% positive in the paclitaxel treated group) was detected (Figure 
17A).  Additionally, ovarian MCTS showed a significant (p< 0.05, n=3, t-test) and robust 
increase in multiple stem cell markers by qRT-PCR following 1 µM paclitaxel treatment in A1847 
(CD133, NANOG, OCT4, and SOX2), OVCAR3 (ALDH1A, CD133, KLF4, and SOX2), OVCAR4 
(ALDH1A, CD133, SOX2), and OVCAR8 (CD133, ALDH1A, and KLF4) (Figure 17B).  These 
data support the hypothesis that the response to paclitaxel in ovarian MCTS mimic that of 
observed responses in ovarian cancer patients where the cells that survive and repopulate 
following chemotherapy are more stem-like as the disease progresses (Steg, Bevis et al. 2012, 
Dobbin, Katre et al. 2014).  Modeling this phenomenon will provide a better understanding of 
disease progression and drug response, and potentially provide a platform for unappreciated 
drug screening to improve patient survival. 
Paclitaxel Resistance and Stem-Like Phenotype was Maintained in 2D Cultures of 
MCTS Derived Cells 
Drug resistance in MCTS can be associated with the lack of drug penetration to cells within the 




cells isolated from MCTS and subsequently grown in 2D cultures would support cellular 
changes as opposed to limitations associated with physical properties of drug delivery in MCTS.  
To test if phenotypic changes in MCTS are contributing to the changes in paclitaxel response, 
MCTS were disassociated into single cells following either vehicle control or paclitaxel treatment 
for 3 days and viable cells were grown in 2D cultures overnight.  The drug sensitivity of these 
MCTS-derived cells grown as a monolayer was then compared to the drug sensitivity of the 
parental 2D cultures (Figure 18A).  Cells derived from untreated MCTS showed reduced 
sensitivity to paclitaxel compared to parental 2D cultures of both A1847 and OVCAR8 cells 
(Figure 18B, blue curves).  Cells derived from paclitaxel treated MCTS showed an even greater 
decrease in paclitaxel sensitivity when plated into 2D cultures (Figure 18B, red curves).  To 
support these changes in dosage response the IC50 from cells derived from untreated MCTS 
was measured to be ~47 nM, which was approximately 6-fold higher than the IC50 calculated for 
the parental A1847 2D cultured cells (~7 nM).  Of significance, the IC50 for A1847 cells derived 
from paclitaxel treated MCTS was not observed at concentration up to 3 µM, indicating a robust 
retention of paclitaxel resistance that is not just a phenomenon of 3D culture.  A similar pattern 
of response to paclitaxel was observed for OVCAR8 cells (IC50 values were ~7 nM, ~18 nM, and 
> 3 µM for parental, untreated MCTS-derived, and paclitaxel treated MCTS-derived cells, 
respectively). 
 In order to demonstrate that the phenotypic changes produced within MCTS are 
persistent, gene expression of stem cell markers was measured in cells derived from MCTS 
after seeding into 2D cultures from both vehicle and paclitaxel treated spheroids.  The 
expression of stem cell markers was maintained in the 2D cultures of cells derived from vehicle 
treated spheroids for three days (days 9 to 12 from spheroid plating) for CD133, ALDH1A, 
KLF4, NANOG, and OCT4 (Figure 19, blue lines).  Interestingly, in cells derived from paclitaxel 




day 12 in CD133, ALDH1A, KLF4, SOX2, NANOG, and OCT4 (Figure 19, red lines).  Taken 
together, these data support that the drug resistant phenotype is not just due to physical 
restrictions of 3D culture, but it is a stable phenotype that is transferrable to 2D cultures while 




(A) MCTS formation needs a confined space to increase cell-cell contact and limit spheroid size 
as well as a culture surface that blocks cell adherence.  (B) 96-well low-attachment plates 
provide a confined space but do not prevent adherence of ovarian cancer cell lines to the 
culture plate.  (C) 10 cm dishes coated with soft agarose allow spheroid formation but there is 
not size limitation and spheroids can be large (vertical black arrow) or much smaller (horizontal 
black arrow).  
Low-attachment plates create small areas but allow cell adherence 
10 cm plates coated with soft agar prevents adherence but don’t confine space 
B 
C 
A 3D cell culture needs to prevent adherence and confine space 
Increase cell contact in 
space 
Prevent attachment to culture 
dish 




Table 4: Qualitative Comparison of 3D Culture Methods. 
Methods Liquid Handling 
Reagents 






Yes, used to 
coat plates 
Yes. Inert 
agarose Low Yes No 
Hanging Drop Yes, used to form droplets No Low 
Low, droplets fall 
from plate easily. 
Yes, 
centrifugation 




and artificial High Yes 
Yes.  Remove 
magnets 
 
3D cell culture methods were qualitatively compared to select a protocol for further 
development.  Methods were compared based on differences between traditional 2D culture 
protocols.  Features that were compared included the amount of liquid handling required to plate 
cells, the use of artificial reagents, the overall cost, the reproducibility of spheroid formation, and 






Light microscopy images of MCTS of EOC cell lines on agarose coated 96-well plates 4 and 7 
days following cell seeding.  Images were taken at either 10x (green scale bars) or 40x (red 
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(A) Immunofluorescence staining of Ki67 for A1847 cell MCTS (day 7) sections and 2D cultures 
(day 4) shows a decreased in proliferation in MCTS.  (B) Cell cycle analysis using propidium 
iodine reveals an increase in G1 cell populations at both day 4 and day 7 for A1847 cells 
cultured as MCTS, compared to 2D cells at 24 h, 48 h and 72 h.  All bar graphs are represented 


















(A) Piminidozole staining of A1847 cells indicates cellular hypoxia in the inner cells at day 7, 
A1847 MCTS.  Cell nuclei were labeled with DAPI.  (B) Western blot analysis shows HIF-1α 
protein in A1847 2D cultures under hypoxia (0.5 % oxygen) and in A1847 MCTS, but not in 
A1847 2D cultures under atmospheric oxygen.  (C) Expression of hypoxia related genes 
(JMJD1A, LOX, and VEGF), as measured using qRT-PCR, were increased in a panel of ovarian 
cell line grown as MCTS compared to parenteral 2D cultures under atmospheric oxygen at day 











(A) Expression of stem-like gene transcripts were measured using TaqMan qRT-PCR.  Several 
stem-like genes (ALDH1A, CD133, CD44, NANOG, OCT4 and SOX2) were upregulated in a 
panel of ovarian cancer cell line at day 7 for MCTS compared to parenteral 2D cultures (*= 
p<0.05, t-test).  All bar graphs are represented as mean +/- SD, n=3. (B) A1847 and OVCAR8 
MCTS after 7 days were separated into single cells to compare colony formation in soft agar to 
parental 2D cultures.  Viable cells following dissociation were counted and either 1,000 or 500 
cells were plated into soft agar dishes and total colonies were counted after 14 days in culture. 








(A) Ki67 staining in tumor sections from A1847 xenografts reveals higher proliferation of cells on 
the periphery of the tumor as compared to those within the tumor mass.  (B) Expression of 
hypoxia related genes (JMJD1A and LOX) in MCTS, as measured using qRT-PCR, were lower 
than levels detected in A1847 xenografts (highest) and higher than levels measured in 
parenteral 2D cultures (lowest).  VEGF expression was higher in 3D cultures than both 2D and 
A1847 xenografts.  (C) Expression of stem-like genes transcripts were measured using TaqMan 
qRT-PCR.  The relative expression level of all of the stem-like genes (ALDH1A, CD133, CD44, 
NANOG, OCT4 and SOX2) were again intermediates in the MCTS when compared to 2D 
cultures (lowest) and A1847 xenografts (highest).  (D) Gene expression was measured using 
RNA-sequencing and analyzed for genes which are increased or decreased in A1847 MCTS 
and xenograft models compared to 2D cultures.  Shown is the Gene Ontology (GO) analysis of 
the transcripts with at least a 1.5-fold increase or decrease in expression between either A1847 
MCTS or ovarian tumor derived xenografts in mice when compared to A1847 2D cultured cells.  
All bar graphs are presented as mean +/- SD, n=3.  
Figure 13: MCTS Displayed Intermediate Gene Expression Between 2D Cultures 







(A) Weight (in grams) of any visible tumor collected during terminal necropsy of intraperitoneal 
xenografts of A1847, HIO80, HIO107, HIO114, HIO118, or HIO120 cell lines.  No tumor was 
visible to collect for any of the HIO implanted cell line, while ~1 gram was collected from A1847 
xenografts between 10 and 15 weeks.  (B) Number of small (< 2 mm), medium (2-4 mm), or 
large (> 4 mm) tumor nodules counted in the peritoneal cavity during terminal necropsy of 
A1847 tumor xenografts.  There were no visible nodules in the HIO cell line transplants.  (C) 
Volume of ascites fluid (mL) collected from the peritoneal cavity during terminal necropsy shows 
~3 mL of fluid in A1847 xenografts with no collectable fluid from HIO xenografts.  (D) Survival 
curve for A1847 and HIO xenografts shows A1847 cell lines cause terminal disease between 10 
and 13 weeks in mouse xenografts, while mice implanted with HIO cells remained healthy 
through 25 weeks. 
  
Mouse xenografts 




(A) Light microscopy demonstrate that 3D culture spheroids from HIO cells are smaller than 
A1847 spheroids and do not expand significantly in size from day 4 to day 7.  (B) 
Immunofluorescence staining of Ki67 and pimonidazole in a cross section of HIO114 and 
HIO118 spheroids at day 7 show little to no pimonidazole staining and high levels of Ki67 




































Figure 15: HIO Cell Spheroids Demonstrated Low Levels of a Hypoxia Marker and High 





(A) Ovarian cell lines were grown in both 2D and 3D cultures and treated with a serial dilution of 
paclitaxel for 72 h.  2D cultured cells were seeded 24 h prior to drug addition, while MCTS were 
cultured for 4 days prior to the addition of drug.  Drug response in both 2D and 3d was 
measured using CellTiter-Glo and normalized to vehicle treated viability.  (B) MCTS showed a 
robust decreased in paclitaxel sensitivity compared to 2D cultures in A1847, OVCAR3, 
OVCAR4, and OVCAR8 cell lines.  All data are represented as mean +/- SD, n=3.  
Figure 16: Paclitaxel Resistance in MCTS Compared to 2D Cultures. 






(A) Immunofluorescence detection of Ki67 and DAPI staining of nuclei reveal a decrease in Ki-
67 expression following paclitaxel treatment in MCTS.  (B) Expression of stem-like genes 
(ALDH1A, CD133, KLF4, OCT4 and SOX2) was measured using TaqMan qRT-PCR.  Gene 
expression was increased following 1 uM paclitaxel treatment in MCTS compared to 2D cultures 
(n=3) (*= p< 0.05, t-test). All data are represented as mean +/- SD, n=3. 
  
Figure 17: Paclitaxel Reduced Proliferation and Increased Stemness in MCTS. 






(A) Graphical representation of methods to measure paclitaxel response in cells derived from 
pretreated MCTS.  (B) Paclitaxel dosage response in A1847 and OVCAR8 cells from 2D 
cultures, vehicle (DMSO) treated MCTS derived cells, or 1 µM paclitaxel treated MCTS derived 
cells.  MCTS derived cells in 2D culture retain paclitaxel resistance compared to 2D cells.  
Paclitaxel pretreatment further decreased the dosage response of A1847 and OVCAR8 MCTS 
derived cells.  All data are represented as mean +/- SD, n=3.    
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Figure 19: Stem Cell Gene Expression was maintained in 2D Cultures in Cells Derived 
from MCTS. 
Gene expression was measured in 2D cultured cells derived from both vehicle and paclitaxel 
treated spheroids.  The expression of gene associated with a stem cell phenotype is maintained 
in cells from day 8 to day 11 in vehicle treated spheroids (blue line) while expression is 
increased in the cells from paclitaxel treated spheroids (red line).  All data are represented as 






There continues to be an important and essential need to improve in vitro models of ovarian 
cancer to support drug development to discover new therapies that improve patient survival.  
Furthermore, a recent study has shown discrepancies between established ovarian cell lines 
and patient samples with respect to mutation profiles and gene expression (Domcke, Sinha et 
al. 2013), suggesting these discrepancies between cell lines and clinical disease could be 
limiting the effectiveness of drug development.  To enhance the clinical representation of 
ovarian cancer cell lines, a 3D culture model was developed using the liquid-overlay method on 
agarose coated 96-well plates.  This method produced single MCTS per well across a panel of 
ovarian cancer cell lines, without the need for specialized media or the transfer of spheroids 
between wells.  Since the spheroids could also be recovered through pipetting, biological 
assays were easy to perform and changes in various cellular properties between 2D and 3D 
cultures, specifically those associated with response to paclitaxel, could easily be measured.  
Any changes in properties between these two models would be strictly from the physical 3D 
growth of the cells and not from any biological agent and would better represent changes in 
solid tumors that are missing when cells are exclusively propagated in 2D cultures. 
 The majority of ovarian cancer patients will succumb to drug resistance and methods to 
improve patient therapy using additional chemotherapy or cytotoxic agents have not proved 
successful in clinical trials.  Drug screening models that more accurately reflect drug resistant 
disease are urgently needed.  Using a 3D culture model, cells took on characteristics associated 
with drug resistance, including reduced proliferation rates, increase in cellular hypoxia, and 
expression of cancer stem cell associated markers when compared to 2D cultures (Baba, 
Convery et al. 2009, Deng, Yang et al. 2010, Milane, Duan et al. 2011, Cioffi, D'Alterio et al. 
2015, Gao, Foster et al. 2015).  As shown in Figure 20 the properties of spheroids developed 




proliferation, increased cellular hypoxia in spheroids cores, and increased stem-like phenotypes 
and function. 
 While the nature of cancer stem cells will be discussed in the next chapter, stem-like 
properties can be induced through the cellular mechanisms identified to be upregulated by 
hypoxia and senescence (Mani, Guo et al. 2008, Molina, Hayashi et al. 2010, Shuang, Wu et al. 
2014, Wu, Du et al. 2014, Dosch, Ziemke et al. 2015, Inukai, Hara et al. 2015).  The hypoxic 
and stem-like signatures were specific to ovarian cancer spheroids and not induced in the non-
tumorigenic HIO cell lines.  This could be due to the genomic plasticity and adaptability of 
cancer cells (Quintana, Shackleton et al. 2010, Pisco and Huang 2015).  While the 3D culture 
model may be an intermediate between 2D cultures and in vivo tumor xenografts, the time and 
cost of 3D cultures are more similar to 2D cultures.  Over half of the genes upregulated in 3D 
culture compared to 2D culture were also upregulated in tumor xenografts.  However, there 
were 592 genes upregulated in the tumor xenografts that were not in 3D cultures.  This could be 
due to multiple cells types such as fibroblasts, endothelial cells, and immune cells from the host 
interacting with the tumor.  Further, the co-culture of non-tumorigenic cells could enhance the 
clinical representation of MCTS even further (Kwon, Smith et al. 2015).  However, the scope 
and experimental design of this study was to specifically compare the effects of culturing 
ovarian cancer cells in 3D versus 2D conditions. 
 Supporting the notion that 3D cultured cells behave more like in vivo tumors than 2D 
cultured cells, MCTS were more resistant to paclitaxel than their 2D parental cell lines.  As 
observed in clinical specimens following paclitaxel treatment and disease progression, stem-like 
markers were robustly increased and cell proliferation was reduced in ovarian MCTS (Steg, 
Bevis et al. 2012, Wang, Yo et al. 2012).  Not only was the stemness phenotype more apparent 
in MCTS, the percent of cells surviving paclitaxel treatment was greatly increased compared to 




cells (Baba, Convery et al. 2009, Kryczek, Liu et al. 2012, Cioffi, D'Alterio et al. 2015) and a 
model that enhances the surviving population could allow for better screening when screening 
for drugs that enhance chemotherapy efficacy.  These surviving cells may be a promising target 
for drug development since the majority of patients will develop disease recurrence following 
surgery and platinum-based chemotherapy.  Reducing this population of “cells in waiting” could 
delay or prevent disease recurrence in the clinical setting and improve patient survival. 
 While the drug resistance mechanisms are upregulated in ovarian MCTS, the physical 
properties of the spheroids could be contributing to the receded response to paclitaxel.  Physical 
penetration of drug through solid tumors can increase resistance (Ong, Zhao et al. 2010).  
However, my data demonstrate that the resistant phenotype is still maintained in 2D cultures 
from cells derived from tumor spheroids and provide more evidence that the biological changes 
such as stemness and hypoxia are more likely driving resistance in the MCTS model.  The cells 
derived from either vehicle or paclitaxel treated MCTS maintained stem-like gene expression for 
up to three days in 2D culture.  These data support the idea that a change in growth is not just a 
phenomenon of the 3D culture system.  Whether this is driven by epigenetic changes or just the 
positive feedback loop between stem cell transcription factors (Boyer, Lee et al. 2005, Ivanova, 
Dobrin et al. 2006) is an area for further investigation.  It is likely that both epigenetics and 
transcription regulation contribute to the coordination of multiple drug resistance mechanisms. 
Conclusion 
Using 3D culture, the MCTS model enhanced stem-cell and other drug resistant properties in 
ovarian cancer cells that are more indicative of clinical disease than traditional cell culture.  
Upon treatment with paclitaxel there were significantly more surviving cells in the 3D model at 
high dosages than 2D.  This method provides an in vitro model of drug resistance and an assay 




high-throughput drug screening could allow identification of drugs that target resistance in 
ovarian cancer.  The next chapter of this thesis will exploit this model in a proof of principle 
study using a mid-throughput drug screening library to identify unappreciated drug candidates 
that can target stem-like properties of ovarian cancer. 
 
Graphical representation of changes induced in MCTS of ovarian cancer cell lines.  Many of 
these changes were directly overserved in this chapter including reduced cell proliferation and 
hypoxia in the spheroids core (yellow circle and box) and more proliferative, drug sensitive cells 
on the spheroids exterior (green circle and box, left side).  The spheroid environment can 
change from the inside with low concentrations of oxygen and other nutrients (red box, right 
side) and high concentrations of oxygen and nutrients on the outside (green box, right side).  
Red scale bar represents 200 microns.  





















Chapter 3: 3D Culture Drug Screening Identified 
Unappreciated Anti-inflammatory Drug Candidates that 






Cancer Stem Cells 
While cancer is commonly thought of a disease of cell growth, however cells within tumors need 
repopulate over long periods of time and often survive harsh environments.  To adapt to harsh 
environments, such as radiation or chemotherapy, and long-term repopulate tumors some 
cancer cells use similar survival and adaptation mechanisms that are common in embryonic and 
tissue development.  These cells have been termed cancer stem cells (CSCs) and have 
provided novel insight into cancer growth and response (Wicha, Liu et al. 2006).  Understanding 
how these CSCs grow, adapt, and regulate different responses is critical to developing 
therapies that might improve patient survival. 
 This concept of CSCs has arisen from the striking degree of similarity noted between stem 
cells and cancer cells. Clinical and experimental observations have found that tumor structure, 
development, and behavior often mimicked that of somatic stem cells, including the fundamental 
abilities to self-renew and differentiate.  Adult or somatic stem cells exist throughout the body 
after embryonic development and are present in different types of tissues and organs.  These 
stem cells remain in a quiescent or non-dividing state for years until stimulated by the signals 
triggered by tissue renewal, damage, and remodeling processes.  Tumors are formed from large 
amounts of cells; however the individual cells within a tumor can be heterogeneous.  Different 
cells taken from the same tumor can differ in their ability to initiate tumor formation in serial 
transplants into mice, indicating that some cells form tumors better than others.  Also, the 
tumors formed from these tumor initiating cells contained  populations of both tumor forming and 
non-forming cells, showing an ability of tumor cells to self-differentiate  (Greene 1952). This 
heterogeneity in tumor formation and differentiation resembles those properties of normal stem 
cells, which also have the ability to serial transplant and differentiate.  Stem cells are small 




specific cell populations though the capability to differentiate into different cell types and have 
long-term self-renewal.  Normal stem cells are typically classified based on their ability to 
differentiate into different cells types as either totipotent, pluripotent, or multipotent.  Apart from 
differentiation properties, specific populations of stem cells are identified by surface markers via 
cell sorting.  Cancer cells with these similar properties have been observed and named cancer 
stem cells or cancer stem-like cells. 
 The ability of cancer cells to differentiate into different cell types was well established in 
teratocarcinomas which contained structures resembling many different types of the body 
(Pierce and Dixon 1959, Pierce, Dixon et al. 1960, Pierce and Verney 1961).  Differences in 
stem cells within cancer were shown to contribute growth and development differences such as 
colony formation and therapy response (Hamburger and Salmon 1977).  More recently, it has 
become clear that heterogeneity within individual tumors relates to developmental stem cell 
pathways regulates tumor development, progression, and response to chemotherapy.  These 
properties within individual cancer cells with clonal, long-term populating, and self-renewal 
capacity are the standards for identifying CSCs (Nguyen, Vanner et al. 2012).  CSCs are 
associated with cancer initiation, development, progression, and drug resistance. 
 The first study to directly identify specific populations of cells with the same tumor capable 
of initial tumor was in acute myeloid leukemia (AML).  In this study, AML cells were transplanted 
into severe combined immune-deficient (SCID) mice from patient samples that were either 
CD34+ or CD34- (a marker of myeloid differentiation).  Cells from the CD34+ population formed 
tumors while the CD34- did not.  Interestingly these cells were less differentiated than traditional 
colony forming cells isolated from AML samples, indicating a more stem-like phenotype 
(Lapidot, Sirard et al. 1994).  The expression of surface markers traditionally used to identify 
hematopoietic stem cells on the surface of  cancer cells (CD34++, CD38-) lead to the hypothesis 




populate tumors long term (Bonnet and Dick 1997).  The standard methods for identifying CSCs 
is the expression of stem cell surface markers, their ability to form colonies in soft agar, and 
most importantly the ability to form tumors in immunocompromised mouse using limited number 
of implanted cells (Clarke, Dick et al. 2006, Nguyen, Vanner et al. 2012).  Using these methods 
CSCs have also been discovered in solid tumors or breast (Marsden, Wright et al. 2009), brain 
(Singh, Clarke et al. 2003), prostate (Collins, Berry et al. 2005), colon (Ricci-Vitiani, Lombardi et 
al. 2007), and pancreas (Hermann, Huber et al. 2007).  CSCs from ovarian cancer have been 
characterized and will be discussed in next section (Bapat, Mali et al. 2005).  Single cell gene 
expression studies from colon cancer xenografts revealed genetic diversity similar to the normal 
developmental pathway of stem cells within the colon epithelium.  Gene expression 
heterogeneity of cells with stem and non-stem like features were observed in both the normal 
gut epithelium and colon tumors. Single cell xenografts from stem-like cells led to 
heterogeneous populations in the tumor of both stem-like and non-stem like cells. (Dalerba, 
Kalisky et al. 2011). 
 The nature of cancer stem cells have been extensively studied and led to controversy as 
to if cancers arise sequentially from mutations in somatic progenitor stem cells or if cancer cell 
plasticity can induce a stem cell phenotype in cancer cells from differentiated tissue (Kreso and 
Dick 2014).  The data presented above support the theory that normal somatic stem cells 
acquire oncogenic mutations, which in turn promotes expansion of these progenitor cells, thus 
increasing their predisposition to cancer development by promoting long-term survival and 
pluripotency over their normal tendency towards relative quiescence and proper differentiation.  
However, other data suggests there could be a back conversation of tumor cells due to selective 
pressure that induce the stem cell phenotype in malignant cells derived from differentiated cells 
(Figure 21).  The ability of normal, differentiated cells to revert back to stem cells through 




differentiate into cancer stem cells.  The ability of cancer cells to convert into a stem cell like 
phenotype has been observed in many tumor models (Molina, Hayashi et al. 2010, Gupta, 
Fillmore et al. 2011, Magee, Piskounova et al. 2012, Shuang, Wu et al. 2014, Dosch, Ziemke et 
al. 2015, Fessler, Borovski et al. 2015).  The mechanisms of this conversion can be related to 
many different tumor pathways.  One of the common characteristics of cancer cells is their 
genomic and phenotypic plasticity which allows them to adapt to harsh environments and evolve 
in response to different cellular changes or stimuli such as chemotherapy (Quintana, Shackleton 
et al. 2010, Pisco and Huang 2015), EMT (Ye, Tam et al. 2015), interactions with the tumor 
microenvironment (Charles, Ozawa et al. 2010, Vermeulen, De Sousa et al. 2010), and hypoxic 
conditions (Liang, Ma et al. 2012, Wu, Du et al. 2014, Ramadoss, Sen et al. 2016).  Specific 
drivers of these, such as the hypoxia response histone demethylase JARID1B, can promote 
tumor maintenance but are not essential for tumor initiation or progression (Roesch, Fukunaga-
Kalabis et al. 2010).  Cancer cells that acquire stem cell function but are not identified to be from 
developmental stem cells (linear CSCs) are often referred to as “stem-like” cells; however, the 





Stemness in Ovarian Cancer 
Since the origins and pathogenesis are still debated, evidence for the nature of somatic stem 
cell transformation in ovarian cancer is not well defined.  As discussed in Chapter 1, evidence is 
contradictive to either the ovarian surface epithelium or the of the fallopian tube epithelium being 
the origin of a subset of tumors, i.e., HGS ovarian cancer.  However both the ovarian surface 
epithelium and fallopian tube epithelium have stem cell niches with cells with regenerative 




properties (Bowen, Walker et al. 2009, Capel 2014, Ng, Tan et al. 2014).  Some evidence 
supports there could be a stem cell niche within the junction between the ovarian surface the 
fallopian tube that helps repair the damage to the ovarian surface following follicle release 
(Flesken-Nikitin, Hwang et al. 2013).  Notch and Wnt, canonical stem cell pathways, have been 
shown to regulate differentiation in fallopian tube organoids and could contribute to fallopian 
tube repair (Kessler, Hoffmann et al. 2015).  Fallopian stem-like cells (CD44+ and PAX8+) can 
be isolated from distal end of the tube and are capable of clonal growth and self-renewal (Paik, 
Janzen et al. 2012, Wang, Sacchetti et al. 2012).  Since these stem cell niches are located near 
the areas of ovarian and fallopian surface repair and precursor lesions they could be hotspots 
for the development of tumors from mutations in somatic stem cells.  One recent study has 
shown that SOX2 is overexpressed in the fallopian tubes of patients with HGS disease and in 
BRCA1/BRCA2 mutation carries (Hellner, Miranda et al. 2016), indicating a possible stem cell 
precursor lesion. 
 Despite unclear evidence as to the pathogenesis of CSC from somatic stem cells in 
ovarian cancer, there is evidence of stem-like cells and stemness related genes in ovarian 
cancer progression and drug response.  Stem-like cells from ovarian cancer were first 
discovered by isolating cells from patient ascites fluid and testing for sphere-forming ability and 
passage through SCID mice (Bapat, Mali et al. 2005).  Two canonical stem cell factors, CD133 
(promomin-1) and ALDH1A (Aldehyde dehydrogenase-1A1), define ovarian cancer stem-like 
cells (Ferrandina, Bonanno et al. 2008, Ferrandina, Martinelli et al. 2009, Kryczek, Liu et al. 
2012).  Other stem cells markers such as CD44, CD117, EpCAM (CD326), and CD24 have also 
been implicated as stem cell markers in ovarian cancer (Garson and Vanderhyden 2015).  
CD133 expression in cell culture models, animal models, and patient tumors is associated with 
enhanced tumorigenicity, drug resistance, and disease recurrence (Baba, Convery et al. 2009, 




expression has a negative correlation to progression-free survival in ovarian cancer patients and 
knockdown of ALDH1A has been shown to restore chemotherapy sensitivity in vitro by 
increasing dose response by over 40-fold in ALDH1A knock down cells (Landen, Goodman et 
al. 2010, Wang, Yo et al. 2012).  Co-expression of CD133 and ALDH1A in clinical ovarian 
cancer samples is associated with both increased time to recurrence and decreased overall 
survival (Silva, Bai et al. 2011).  In this same study, the expression of both CD133 and ALDH1A 
had additive effects in ovarian cancer cells where CD133+/ALDH1A+ were the most tumorigenic 
cells in SCID mice followed but CD133+/ALDH1A-, then CD133-/ALDH1A+, and finally CD133-
/ALDH1A cells showed no tumorigenic potential at all.  Single cells that were positive for both 
CD133 and ALDH1A had the ability for both self-renewal and differentiation into subpopulations 
of CD133+/ALDH1A-, CD133-/ALDH1A+, or CD133-/ALDH1A-, indicating a hierarchical order 
regulated by BMP2 (Choi, Ingram et al. 2015).  The markers, CD133 and ALDH1A, are 
expressed in ovarian and fallopian stem cells, and could indicate a potential progression from 
somatic stem cells to ovarian cancer through acquired oncogenic mutations in fallopian stem 
cells, mimicking the progression first observed in myeloid leukemia (Bonnet and Dick 1997, 
Flesken-Nikitin, Hwang et al. 2013).  But, the mechanisms have not been well established.  
However, it is clear stem-like characteristics contribute to drug resistance and disease 
recurrence in ovarian cancer.  Therefore, preclinical drug screening models that better replicate 
these stem-like properties in vitro could be useful in developing more efficacious drugs for 
ovarian cancer. 
Cancer Stem Cells and Drug Resistance 
Stem cell gene expression can be used to predict both disease progression and drug response 
in patients across many different cancer (Ginestier, Hur et al. 2007, Gentles, Plevritis et al. 
2010, Neumeister, Agarwal et al. 2010, Eppert, Takenaka et al. 2011, Merlos-Suarez, Barriga et 




following treatment with many different forms of chemotherapy and/or radiation when evaluated 
in tumor xenograft models.  Further, when the tumor repopulates with CSCs chemotherapy, the 
resulting tumor’s response to therapeutic treatment is decreased (Figure 22) (Bao, Wu et al. 
2006, Hermann, Huber et al. 2007, Dylla, Beviglia et al. 2008).  Some of these studies suggest 
the number of stem cells in the initial tumor reflect number of total cells that survive 
chemotherapy and/or radiation.  It has also been shown that stem cells propagate the tumor 
after chemotherapy and that inhibition of stemness blocks tumor repopulation (Chen, Li et al. 
2012).  In support of this observation, researchers have shown that stem cell gene expression 
of CD133, ALHD1A, and CD44 increased through the duration of treatment and in recurrence in 
ovarian cancer patient samples (Steg, Bevis et al. 2012).  Likewise, the amount of stem-like 
cells is increased in chemotherapy resistant ovarian cancer cell lines (Hosonuma, Kobayashi et 
al. 2011).  These data support the idea that CSCs or stem-like cancer cells contribute to drug 
resistance and recurrence in cancer.  The mechanisms which control drug resistance were 
discussed in Chapter 1.  Taken together, these studies suggest that acquisition of a stemness-
like phenotype is a central mechanism of drug resistance.  Furthermore, this change is 
associated with the induction of many other drug resistance phenotypes and also can be 
initiated or maintained in a feedback loop from exposure to hypoxia and other cellular stress. 
Targeting Cancer Stem Cells 
The previous data support the idea that targeting CSCs or stem-like cells may improve the 
response to chemotherapy in cancer.  The silencing of different stem cell-related genes using 
targeted siRNAs, increase the sensitivity of tumor cells to chemotherapy in ovarian cancer 
models (Landen, Goodman et al. 2010, Seo, Kim et al. 2016).  Drug screening methods have 
been adapted to targeting CSCs as well.  For instance, salinomycin was identified from a screen 
of over 16,000 compounds to selectively kill breast cancer stem cells; however, the clinical 




2009).  A larger library screen of 31,624 small molecules identified several candidates that could 
target glioblastoma CSCs using stem cell enriched media (Visnyei, Onodera et al. 2011).  In 
ovarian cancer, screening has identified mitotic inhibitors with activity against differentiated 
cancer cells and against stem-like cells (Mezencev, Wang et al. 2012).  Drugs targeting specific 
cellular processes pathways associated with CSCs such as EMT, metabolism, or Wnt/β-catenin 
signaling can inhibit stemness (Scheel, Eaton et al. 2011, Shank, Yang et al. 2012, Nagaraj, 
Joseph et al. 2015).  Targeting specific stem-cell proteins has been difficult; however, disulfiram 
(the anti-alcoholism drug) has been found to reduce ALDH1A activity and selectivity inhibit CSC 
growth (Yip, Fombon et al. 2011, Liu, Kumar et al. 2013, Liu, Wang et al. 2016). 
Using 3D Cell Culture to Target Stem-like Cells  
As shown in Chapter 2, MCTS formation has been shown to induce stem cell-like properties, 
including expression of stem cell markers including, CD133, ALDH1A, SOX2, OCT4 and 
NANOG.  This same phenomenon has been observed across many different cancer cell lines 
(Liu, Wang et al. 2013, Liao, Qian et al. 2014, Oktem, Bilir et al. 2014, Zhang, Hua et al. 2016).  
The use of MCTS models for drug development could help identify unappreciated or existing 
drugs capable of targeting these stem-like characteristics of patient tumors associated with drug 
resistance that are crucial for improving survival.  A drug screen against 2D cell cultures with 
low stem-like properties directly compared to a 3D culture drug screen with stem-like properties 




could identify drugs that specifically target stem-like cells.  In this chapter, I will explore using 3D 
cell culture drug screening to identify unappreciated drug candidates that target stem-like cells 
and improve the efficacy of chemotherapy in ovarian cancer. 
 
Methods 
All methods were performed as previously described in Chapter 2 unless otherwise noted. 
Transcriptome Sequencing and IPA Pathway Analysis 
For transcriptome sequencing (RNA-seq), RNA was isolated from 2D cultures at 80% 
confluency, from 3D cultures at 7 days of spheroid growth from twelve ovarian cancer cell lines 
(A1847, SKOV3, OVCAR3, OVCAR8, C30, PEO1, OVCAR5, OVCAR10, OVCAR4, UPN275, 
A2780, and CP70).  RNA was prepared for paired end sequencing on a HiSeq 2500 using a 
stranded library prep kit (Illumina).  Initial analyses were prepared using RSEM expected gene 
counts.  First, data were filtered to remove non/low-expressed genes.  This resulted in a total of 
~14,000 genes examined for differential expression between the different 2D and 3D cultures.  
Next, normalization factors were calculated to scale the library sizes followed by estimation of 
tag wise negative binomial dispersion values.  Genes were then compared that were 1.5-fold 
upregulated or down regulated in 3D cultures compared to 2D cultures.  To identify pathway 
regulators IPA Pathway Analysis (QIAGEN) was used and the top 5 regulators based on p value 
were measured. 
Drug Screening 
Four ovarian cancer cell lines (A1847, OVCAR3, OVCAR4, and OVCAR8) and two non-
tumorigenic cell lines (HIO107 and HIO118) were grown as both 2D and 3D cultures for drug 
screening.  2D cultures were plated overnight before drug treatment, while spheroids were 
grown for 4 days before the additional of drug.  A custom 304 drug library was purchased from 




in DMSO and then twice diluted in media by the Hamilton Nimbus 96 with the final dilution of 5 
µl drugs into 95 µl cell media, for a final concentration of 10 µM drug.  After 72 h of drug 
exposure, cell viability was measured using CellTiter-Glo incubated 1:1 to culture media for 1 h 
at 37°C.  Relative viability was established for the control (DMSO) treated cells and directly 
compared to the 2D and 3D cultures for each drug treatment.  Secondary screening was 
performed at 25 µM following the same plating protocol across all 3D hits and select hits from 
2D culture and hits from 2D and 3D culture.  For all dosage response and function assays 
licofelone powder was purchased from Santa Cruz Biotechnology and glafenine hydrochloride 
powder was purchased from Sigma Aldrich Inc. 
Cell Viability Assays 
When comparing cell viability assays all methods Cell-TiterGlo (Promega), picogreen 
(ThermoFisher), and acid phosphatase (Sigma Aldrich) were performed based on 
manufacture’s protocol.  For luciferase reporting vectors A8417 cells were previously 
transfected with the firefly luciferase vector pWZL-Luc.  Cells were grown in standard media 
with Geneticin (ThermoFisher).  For correlation to cell seeding number, cells were plated on 3D 
culture plates at 1,000, 2,000, 3,000, 4,000, 5,000 or 6,000 cells per well.  Spheroids were 
grown for 7 days and then viability assays were performed for single spheroids.  Standard 
curves were made using Graphpad Prism and r2 values were calculated.  Methods were also 
compared for ease of use for drug screening by qualitative measurements such as spheroids 
transfer and liquid handling. 
Drug Combination Assays 
Drug combination studies were performed using the combination index (CI) method described 
by Chou and Talalay (Chou and Talalay 1984).  Spheroids from A1847 and OVCAR8 cell lines 
were grown for 4 days before addition of either paclitaxel (1 µM or 250 nM) or licofelone (10 µM 




treated cells or serial dilutions of paclitaxel were added on top of the licofelone treated cells. 
Assays were performed as biological triplicate using triplicate wells within each experiment.  Cell 
viability following 72 h of treatment from the serial dilutions was evaluated using CellTiter-Glo as 
described above and the viability data were then analyzed using CalcuSyn (version 2.1, BioSoft, 
UK) to calculate the synergy between the two drugs at each molar ratio evaluated.  Drug 
combinations which yielded CI values less than 1 were considered to be synergistic as 
previously reported (Chang and Chou 2000, Chou 2008) and used in our laboratory (Pessetto, 






Cell Viability in Response to Drug Treatment in Ovarian MCTS 
While spheroids size can be used for spheroid forming assays, using spheroid size might not 
accurately measure drug response.  For example, when A1847 spheroids are treated with 
carboplatin from 400 µM to 12.5 µM for 72 hours, there is no discernable size between the 
spheroids.  When exposed to the high doses (100 - 400 µM) of drug, the spheroids appeared 
distressed but the overall “size” did not discernably change, indicating that the diameter or 
volume may not be useful in determining spheroid drug response (Figure 23A).  To more 
accurately measure drug response, four different cell viability assays were compared (CellTiter-
Glo, Pico Green, luciferase reporting vectors, and acid phosphatase) in order to establish an in-
well method which could measure a large dynamic range of cell survival.  Cells were plated at 
different initial densities of 1,000, 2,000, 3,000, 4,000, 5,000, or 6,000 cells per well.  After 7 
days of spheroid growth each viability assay was performed and correlated to initial cell seeding 
number.  All four assays showed a strong correlation to the initial plating number (r2> 0.9000), 
while CellTiter-Glo had the highest dynamic range (Figure 23B).  CellTiter-Glo and the 
luciferase reporting vector were the only two assays that did not require spheroid transfer.  To 
correlate the luminescence from CellTiter-Glo to cell number, total DNA was measured across 
each spheroid and the DNA concentration (in nanograms) was compared to the luminescence 
read out.  CellTiter-Glo luminescence significantly correlated to total DNA content using 
Pearson’s correlation (Figure 23C, p< 0.05).  Finally, drug response to carboplatin was 
measured in 2D and 3D cultures using CellTiter-Glo and showed a dosage response that would 
not have been observed using spheroid size (Figure 23D).  Taken together, these data 





MCTS Drug Screening Identified Unappreciated Drug Candidates 
To identify unappreciated therapeutics with an accelerated path for clinical development, an 
FDA-approved drug library available from Selleckchem was evaluated for screening.  However, 
even though the 3D model was developed in a 96-well format to support high-throughput 
screening, I chose to pilot the screening assay and select a subset of drugs from the original 
2,000+ compound library.  To select a narrower library RNA, sequencing was performed 
between 2D and 3D cultures to identify regulatory pathways upregulated in MCTS compared to 
2D cultures.  Twelve ovarian cancer cell lines were grown to 8% confluence in 2D cultures and 
for 7 days in 3D cultures and RNAs were isolated for transcriptome sequencing.  Following 
statistical analysis, robust changes under the two different growth conditions were observed.  In 
cell lines grown under 3D conditions, 630 genes showed a 1.5-fold over expression compared 
to 2D cultures with a False Discovery Rate (FDR) of less than 0.05 (Figure 24A, blue points).  
Likewise, 96 genes showed a 1.5-fold over expression with a FDR of less than 0.05 in 2D 
cultures when compared to 3D cultures (Figure 24A, red points).  Ingenuity Pathway Analysis 
(IPA) of the overexpressed genes in 3D cultures showed that the top upstream regulators were 
related to cellular hypoxia: HIF1A (p=1.34E-10), EPAS1 (p=4.55E-08), and cobalt chloride 
(p=1.22E-07) (Figure 24B).  Interestingly, the drugs predicted to inhibit 3D gene expression 
were a nonsteroidal anti-inflammatory drugs (NSAID), fluticasone (p=1.44E-09), and an anti-
diabetic, rosiglitazone (p=4.55E-07).  Increases in both inflammation and metabolic pathways 
have both been linked to increased drug resistance in ovarian cancer (Lane, Matte et al. 2015, 
Rohnalter, Roth et al. 2015, Ai, Lu et al. 2016).  Representative drugs representing known 
cancer therapeutics, and those that target inflammation and metabolic disorders were selected 
based on this IPA analysis Figure 24  In order to identify unappreciated drugs with the potential 
of greater in vivo efficacy and activity against stem-like cells, it was hypothesized that the use of 
MCTS for drug screening will yield candidates that have not been previously selected as anti-




selected subset of drugs from the Selleckchem library of FDA-approved drugs (n=304) was 
screened against EOC cells lines growing as 2D and 3D cultures.  For this screening, cells were 
grown in 3D culture for four days or in 2D culture overnight before 10 µM drug was added and 
incubated for 72 h (Figure 25A).  Relative viability to DMSO controls was directly compared 
between 2D and 3D cultures.  Drug hits were classified into three different classes: i) 2D only 
hits with more than 75% reduction in relative viability in 2D cultures and less than 25% reduction 
in relative viability in 3D cultures; ii) 2D and 3D hits with more than 75% reduction in relative 
viability for both 2D and 3D cultures; and iii) 3D only hits with more than 75% reduction in 
relative viability in 3D cultures and less than 25% reduction in relative viability in 2D cultures 
(Figure 25B-C).  Overall, there were 78 drugs classified as hits, with 38 2D only hits, 25 2D and 
3D hits, and 15 3D only hits (Figure 25B-C).  Interestingly, the 3D only hits were mostly 
comprised of drugs from the inflammatory (47%) and metabolic (26%) groups compared to 
anticancer drugs (20%) (Table 5).  When searching these drugs on PubMed for previously 
studies in ovarian cancer (numerator) or all cancers (denominator), there were very few positive 
results (Table 5), indicating these could be unappreciated candidates for drug repurposing in 
ovarian cancer.  Drug screening in the non-tumorigenic cell lines HIO107 and HIO108 showed 
no 3D only drug hits (Figure 26), indicating these compounds may target the more quiescent 
drug resistance cells found in the MCTS model.  However, through the primary screens at 10 
µM of each drug there were not any 3D only hits across multiple cell lines to select for further 
development.  Since some of these repurposed drugs are used at higher concentrations in 
patients, the 2D and 3D cultures were again screened using a higher concentration of drug (25 
µM) to validate hits with activity across at least three of the four ovarian cancer cell lines.  In the 
secondary screen the fifteen 3D only hits were rescreened, while only select hits from the 2D 
only and 2D and 3D hits were rescreened.  Two drugs, licofelone (drug 179) and glafenine (drug 
296) were validated as 3D only hits across at least three cell lines (Figure 27).  Interestingly the 




activity in secondary screening if they showed enough activity to be classified (Figure 28A).  
Validation of select his from 2D only hits (afatinib, drug 2) and 2D and 3D (bortezomib, drug 3) 
hits confirmed the activity across multiple cells lines and in a dose-dependent manor (Figure 
28B-C).  While these hits were outside of the scope of the study, they could be further used to 
test the ability of 3D cultures to predict in vivo drug efficacy and better select which drugs to 
take forward into pre-clinical development.  These results identified licofelone and glafenine, 
identified as candidate anticancer drugs with specific activity against ovarian MCTS that would 
not have been identified through traditional 2D cell culture drug screening. 
The Top 3D Specific Drugs, Licofelone and Glafenine, Reduced Stemness in 
Ovarian MCTS 
Licofelone, a dual COX/LOX inhibitor (Figure 29A) developed by Merckle and Ratiophar 
(Germany) to treat osteoarthritis (Laufer, Tries et al. 1994, Gay, Neidhart et al. 2001, Boileau, 
Martel-Pelletier et al. 2002, Tries, Neupert et al. 2002, Skelly and Hawkey 2003), was evaluated 
using a dosage response from 195 nM to 50 µM and showed preferential activity in 3D cultures 
compared to 2D cultures following 72 h treatments (Figure 29B).  Specifically, the IC50 values 
for licofelone were lower in 3D cultures than in 2D cultures across A1847 (21.6 µM vs 50+ µM), 
OVCAR3 (13.5 µM vs 50+ µM), OVCAR4 (33.5 µM vs 50+ µM), and OVCAR8 (17.4 µM vs 44 
µM) cell lines.  Glafenine (Figure 29C), an NSAID from the anthranilic acid derivative, was 
developed by Alecandria Co. (Egypt) for the relief of all types of pain; however, because of a 
high incidence of anaphylaxis and kidney failure has been withdrawn from the market in most 
countries (Raken 1972, Dechezlepretre, Lechat et al. 1975, Boeijinga and van der Vijgh 1977).  
When evaluated using a dosage response from 195 nM to 50 µM, glafenine also showed 
preferential activity in 3D cultures compared to 2D cultures following 72 h treatments (Figure 
29D).  The IC50 for glafenine were consistently lower in 3D cultures as compared to 2D cultures 
of A1847 (24 uM vs 33 uM), OVCAR3 (18.0 µM vs 50+ µM), OVCAR4 (30.3 µM vs 50+ µM), 




expression, A1847 and OVCAR8 MCTS were treated with licofelone and glafenine for 72 h at 
the calculated IC50 concentrations and RNA was isolated for gene expression analysis using 
qRT-PCR.  In A1847 spheroids, licofelone and glafenine significantly reduced the expression of 
CD133, ALDH1A, and KLF4 while the expression of NANOG, OCT4, and SOX2 were either not 
changed or actually increased (Figure 30A, * = p<0.05, t-test).  In OVCAR8 MCTS licofelone 
significantly decreased the expression of CD133, ALDH1A, KLF4, NANOG, and SOX2 while 
glafenine significantly decreased the expression of only ALDH1A and NANOG (Figure 30B, * = 
p<0.05, t-test).  Immunofluorescence analysis of A1847 spheroid sections following 72 h 
treatment with IC50 concentrations of either licofelone or glafenine showed an increased number 
of Ki67 positive cells (63.5% and 67.9%, respectively) when compared to vehicle treated MCTS 
(41%) (Figure 31).  In 2D cells derived from spheroids previously treated with paclitaxel for 3 
days (which maintain and/or induce a stemness phenotype as shown in Chapter 2), licofelone 
enhanced efficacy as measured by a reduction in IC50 compared to parental 2D cells (Figure 
32).  Interestingly, licofelone treatment showed stronger response than the COX-2 specific 
inhibitor celecoxib in A1847 spheroids (Figure 33), suggesting dual inhibition of COX/LOX 
better inhibits ovarian cancer spheroid growth than Cox-2 specific inhibition.  Taken together 
these data support two different anti-inflammatory drugs, licofelone and glafenine, inhibit stem-
like properties of ovarian cancer as measured by gene expression.  Inhibiting stem-like 
properties of ovarian MCTS and inducing a more proliferative phenotype could enhance the 
activity of paclitaxel by circumventing drug resistance in combination with licofelone or 
glafenine.  Licofelone was selected for further development of combination therapy with 




Pretreatment of Ovarian MCTS with Licofelone Synergistically Enhanced 
Paclitaxel Activity 
MCTS from A1847 and OVCAR8 cell lines were grown for four days before treatment with 
licofelone.  Two days later serial dilutions of paclitaxel were added for another three days 
(Figure 34A).  In A1847 spheroids, the combination of single pretreatment of either 10 µM or 20 
µM licofelone (dashed lines represent mean viability and grey bars SD) enhance the dose 
response to paclitaxel (Figure 34B).  There was a robust decrease in the IC50 for paclitaxel in 
the 10 µM (27±8.8 nM vs >3 µM) or 20 µM (52±7.1 nM vs >3 µM) licofelone pretreated 
spheroids.  To quantify the resistant population response, the minimum viability was decreased 
at 3 µM, 1 µM and 333 nM in licofelone pretreated spheroids.  The average viability across 
these dosages was significantly decreased (p< 0.05, n=9, t-test) for 10 µM licofelone 
pretreatments (34.4±.41%) and for 20 µM pretreatments (25.6±.61 %) compared to 56.2±.52 % 
in paclitaxel alone.  For OVCAR8 spheroids, a robust change in dosage response was seen for 
both 10 µM licofelone and 20 µM licofelone (Figure 34B).  The IC50 values for paclitaxel in both 
10 µM and 20 µM licofelone pretreatments were significantly reduced (p< 0.05, n=3, t-test), 
14±4.1 nM vs 448±67 nM and 3± 0.8 nM vs 448±67 nM respectively.  Similarly, the viability 
across the three highest concentrations was significantly lower (p< 0.05, n=9, t-test) in 10 µM 
licofelone (29.5±.9 %) and the 20 µM licofelone (23.6±1.12 %) pretreatments compared to 
paclitaxel alone (50.5± .90 %).  To quantify the effect of combining treatments, Combination 
Index (CI) values were calculated (CI values less than 1 were considered synergistic).  In A1847 
spheroids, higher dosages of paclitaxel were synergistic with both 10 µM licofelone and 20 µM 
licofelone (Figure 34C).  While in OVCAR8 spheroids, every dosage of paclitaxel was 
synergistic in 20 µM licofelone pretreatments, while only 1.3 nM paclitaxel was not synergistic in 




Pretreatment of Ovarian MCTS with Paclitaxel Synergistically Enhanced 
Licofelone Activity 
MCTS from A1847 and OVCAR8 cell lines were grown for four days before treatment with 
paclitaxel.  Two days later serial dilutions of licofelone were added for another three days 
(Figure 35A).  In A1847 spheroids, combinations of single pretreatment of either 1 µM or 250 
nM paclitaxel (dashed lines represent mean viability and grey bars SD) enhance the dosage 
response of licofelone (Figure 35B).  In A1847 spheroids, the IC50 for licofelone was 
significantly (p< 0.05, n=3,  t-test)  decreased following paclitaxel treatments of 1 µM and 250 
nM paclitaxel compared to licofelone alone, 573±187 nM vs 19.4±1.9 µM and 1.7±0.59 µM vs 
19.4 µM, respectively.  To quantify the resistant population response, the average viability in the 
three highest dosages of licofelone (50 µM, 25 µM, and 12.5 µM) was significantly lower (p< 
0.05, n=9, t-test) in the 1 µM paclitaxel pretreatment (11.3±.87 %) and the 250 nM paclitaxel 
pretreatment (23.3± 1.4 %) when compared to the licofelone alone treatment (73.9±2.1 %).  In 
OVCAR8 spheroids, the IC50 for licofelone was significantly (p< 0.05, n=3, t-test) decreased 
following paclitaxel treatments (1 µM or 250 nM) compared to licofelone alone, 235±47 nM vs 
35± 6.4 µM and 558±232 nM vs 35± 6.4 µM, respectively.  The average viability in the three 
highest dosages of licofelone (50 µM, 25 µM, and 12.5 µM) was significantly lower (p< 0.05, 
n=9, t-test) in the 1 µM paclitaxel pretreatment (18.1± 1.25 %) and the 250 nM paclitaxel 
pretreatment (22.2± 1.4 %) when compared to the licofelone alone treatment (63.0±3.0 %).  As 
before, the CI values were calculated and A1847 spheroids pretreated with 250 nM paclitaxel 
showed synergy at all concentrations of licofelone, except 390 nM while, pretreatment with 1 µM 
paclitaxel showed synergy at 1.56, 3.12, 6.25, 12.5, 25, and 50 µM licofelone (Figure 35C).  In 
OVCAR8 spheroids, 1 µM paclitaxel and 250 nM paclitaxel pretreatments showed synergy 




Licofelone Combination Enhanced Apoptosis and Reduced Stemness Induced by 
Paclitaxel 
A1847 and OVCAR8 spheroids were treated with either 1 µM paclitaxel or a combination of 1 
µM paclitaxel and 20 µM licofelone for 72 hours.  Licofelone combination with paclitaxel 
significantly reduced the expression of a number of stemness related gene in A1847 MCTS 
(ALDH1A, CD133, NANOG, OCT4, and SOX2) and OVAR8 MCTS (ALDH1A, CD133, and 
KLF4) when compared to paclitaxel treatment alone as measured using Taqman qRT-PCR 
assay (Figure 36, n=3, *= p<0.05, t-test).  The same combination therapy of 1 µM paclitaxel and 
20 µM licofelone in A1847 MCTS significantly increased the expression of cleaved PARP 
compared to total PARP (3-fold) when compared to vehicle treatment, as measured by Western 
blot analysis (Figure 37, n=3, *=p<.05, t-test).  The single treatment of 1 µM paclitaxel showed 
a trend towards an increase in the ratio of cleaved PARP to total PARP (2-fold) when compared 
to vehicle, but this difference was not deemed significant.  To test the stem-like function of 
MCTS cells that survived drug treatments, A1847 or OVCAR8 MCTS were treated with drug 
(vehicle, 1 µM paclitaxel, 20 µM licofelone, or 1 µM paclitaxel plus 20 µM licofelone) for 72 
hours.  Following drug treatment, MCTS were washed and disassociated into single cells with 
trypsin/accutase.  Recovered cells were plated onto 2D cell culture dishes and incubated 
overnight.  The following day cells were collected following trypsinization and the number of 
viable cells was established in order to evaluate their growth using either a soft agar colony 
forming assay or a MCTS forming assay.  For the A1847 cells, the number of colonies appears 
to be reduced following treatment with either paclitaxel or the combination, but not in the 
licofelone alone treatment group when compared to vehicle (Figure 38).  However, the size 
individual colonies were increased significantly increased in cells previously treated with 
paclitaxel when compared to vehicle treatments (Figure 38, n=30, p<.05, two way ANOVA).  
Interestingly, the combination of licofelone with paclitaxel significantly reduced colony size when 




OVCAR8 cells, paclitaxel treatment slightly reduced colony number, while the combination of 
paclitaxel and licofelone drastically reduced colony formation.  In comparison and somewhat 
unexpected, licofelone treatment completely inhibited colony formation (Figure 38).  Likewise, 
the size of colonies formed from paclitaxel treatment in OVCAR8 cells was significantly 
increased when compared to vehicle treatments and the combination of licofelone with 
paclitaxel significantly reduced colony size compared to paclitaxel alone (Figure 38, n=30, 
p<.05, two-way ANOVA).  Secondary spheroid assays were similarly performed following drug 
treatment in A1847 and OVCAR8 spheroids.  Viable cells were counted, serially diluted, and 
plated at 3,000, 1,000, 300, 100, 30 or 10 cells per well.  Following 7 days of incubation, the 
spheroid size was measured.  A1847 cells treated with 1 µM of paclitaxel showed a significant 
increase in spheroid size when compared to vehicle for the wells with 300, 100, 30 or 10 cells 
(Figure 39, n=3, *=p< 0.05, two-way ANOVA).  Consequently, the combination of 20 µM 
licofelone with 1µM paclitaxel significantly reduced spheroid size when compared to 1 µM 
paclitaxel for the wells seeded with 1,000, 300, 100, 30 or 10 cells (Figure 39, n=3, *=p< 0.05, 
two-way ANOVA).  OVCAR8 spheroids showed a different pattern where both 20 uM licofelone 
and the combination of 20 µM licofelone with 1µM paclitaxel both significantly reduced spheroid 
size when compared to vehicle in the wells with 1,000, 300, 100, 30 or 10 cells (Figure 39, n=3, 
*=p< 0.05, two-way ANOVA).  These studies suggest that licofelone combination can inhibit the 
stem-like phenotype observed to be induced following paclitaxel treatment.  Blocking the 
stemness phenotype that is induced during clinical disease progression could enhance the 






(A) Spheroid size and volume is a poor predictor of drug response.  Light microscopy of MCTS 
after 72 hr carboplatin treatments in A1847 MCTS (200 µM, 100 µM, 50 µM, 25 µM, 12.5 µM, 
6.25 µM, 1.125 µM and vehicle left to right).  (B) Correlation of A1847 spheroid plating density 
after 72 h and a variety of assays to measure cell viability or absolute DNA amount (r2 
calculated using the linear regression function in GraphPad Prism software).  (C) Pearson’s 
analysis shows a strong statistically significant correlation between cell viability measured using 
CellTiter-Glo and DNA amount measured using the PicoGreen assay.  (D) Dosage response to 
carboplatin in 2D (red) or 3D (blue) cultures measured using CellTiter-Glo. 
  
Figure 23: CellTiter-Glo Measured Cell Viability and Drug Response in MCTS. 











(A) Analysis of RNA-seq data identified genes expressed 1.5-fold greater in 3D cultures (blue) 
versus 2D and genes 1.5-fold greater in 2D cultures (red) versus 3D with a False Discovery 
Rates less than 0.05 (dashed line).  (B) The top five IPA pathway analysis regulators inferred 
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Figure 24: Pathway Analysis of Transcriptome Sequences Identified Inflammation and 




(A) Representative time-line for drug screening in 2D and 3D cultures.  (B) Relative viability 
compared to vehicle (DMSO) between both 2D and 3D cultures following 72 h treatment of 10 
µM drugs.  (C) Venn diagram representing unique and common drug hits: 2D only hits with 
more than 75% reduction in relative viability in 2D cultures and less than 25% reduction in 
relative viability in 3D cultures; 2D and 3D hits with more than 75% reduction in relative viability 
for both 2D and 3D cultures; and 3D only hits with more than 75% reduction in relative viability 
in 3D cultures and less than 25% reduction in relative viability in 2D cultures. 
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Table 5: 3D Hits from Primary Screening 
Drug Indication Target or Use Pub Med Hits 
Pizotifen malate Inflammation Serotonin antagonist 0/0 
Risedronic acid (Actonel) Metabolic Disease Osteoporosis drug 0/109 





Cytochrome P450 (CYP)2C8 and 
CYP3A4 3/529 
Mecarbinate Metabolic Disease Antihypertension 0/0 
Licofelone Inflammation COX/LOX 0/24 
OSI-420 (Erlotinib) Cancer EGFR 82/5077 
Geniposidie Inflammation Glucagon-like peptide-1 0/2 
Phenformin HCl Metabolic Disease Anti-diabetic. Glycolysis 2/129 
Cinepazide maleate Inflammation Calcium Channel blocker 0/0 
Beclomethasone dipropionate Inflammation Glucocorticoid 0/60 
Dexamethasone acetate Inflammation Glucocorticoid 302/14137 
Allylthiourea Inflammation Ammonia oxidation 0/3 
Bergapten Cancer DNA mutagen 0/76 
Glafenine Inflammation NSAID 0/4 
 
List of 3D specific drug hits (15) identified from the primary drug screen.  The disease indication 
from most drugs was from either inflammation or metabolic disease and not cancer.  The 
specific target or use for each specific drug as listed from the Selleckchem database.  PubMed 
search results for searching each drug with either “ovarian cancer” (numerator) or “cancer” 





Two HIO cell lines (HIO107 and HIO118) were grown as 2D and 3D cultures and screened 
using the established library of 304 FDA approved drugs.  The relative viability was compared to 
vehicle (DMSO) in both 2D and 3D cultures following 72 h treatment of 10 µM drug.  No 3D 
specific hits (75% reduction in relative viability in 3D cultures and less than 25% reduction in 
relative viability in 2D cultures) were observed in HIO cell lines (red box). 
  





Secondary screening in A1847 (blue squares), OVCAR4 (red circles), OVCAR8 (purple 
triangles) and OVCAR3 (green diamonds) was performed to validate hits across multiples cell 
lines.  The relative viability was compared to vehicle (DMSO) in both 2D and 3D cultures 
following 72 h treatment of 25 µM drug.  Secondary screening at 25 µM validates two hits (drug 
176 and 296) with specific activity in 3D cultures across at least three ovarian MCTS as show in 
the right panel (enlarged section of 3D drug response). 
  





(A) Plots of relative viability for both 2D and 3D drug response for each hit class identified in the 
secondary screening using 25 µM of drug.  2D only hits (red squares) and 2D and 3D hits 
(green triangles) validated within their own specific class.  3D only hits (blue circles) remained 
either 3D only hits or showed no change in viability.  (B) Bortezomib maintains 2D and 3D 
activity following dosage response treatment for 72 h.  (C) Afatanib was identified as a 2D 
specific drug as shown in the dosage response curves following 72 h drug treatment. 
Bortezomib (2d and 3D Hit) 
 








(A) The chemical structure of the dual COX/LOX inhibitor licofelone.  (B) Dosage response to 
licofelone as measured using CellTiter-Glo following treatment of the ovarian cancer lines grown 
as MCTS (blue line) or 2D cultures (red line) at 72 h.  (C) The chemical structure glafenine.  (D) 
Dosage response to glafenine as measured using CellTiter-Glo following treatment of the 











Expression of stem-like genes (ALDH1A, CD133, KLF4, OCT4 and SOX2) in MCTS following 
72 h treatment with IC50 concentrations of licofelone (solid bars) or glafenine (checkered bars).  
Expression was measured using qRT-PCR and compared to vehicle only treated spheroids 
(black bars).  (A) CD133, ALDH1A, and KLF4 expression is significantly (*= p< 0.05) reduced in 
A1847 MCTS.  (B) OVCAR8 MCTS demonstrated significant (*= p< 0.05) reduction in the 
expression of all genes measured except for OCT4.  All data are represented as mean +/- SD, 
n=3. 
  
Figure 30: The 3D Specific Drugs Licofelone and Glafenine Reduced 






Immunofluorescence evaluation of Ki67 (red) and DAPI (blue) reveals an increase in the 
number of inner proliferative cells following the treatment of spheroids with licofelone or 























(A) Graphical representation of the method used to measure licofelone response in 2D cells 
derived from paclitaxel treated MCTS.  (B) Dosage response of A1847 cells to licofelone in cells 
grown in 2D cultures or MCTS derived cells treated with 1 µM paclitaxel.  Paclitaxel pretreated 
cells (red) show enhanced response to licofelone when compared to cells grown in 2D (blue).  
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Comparison of drug response following 72 h treatment in A1847 MCTS to either celecoxib 
(black) or licofelone (red) as measured by CellTiter-Glo.  The dual COX/LOX inhibitor licofelone 
has stronger activity compared to the COX-2 specific inhibitor celecoxib. 
Figure 33: Licofelone had More Activity Against Ovarian Cancer Cell-Derived MCTS than 




(A) Representative time-line of drug combinations in A1847 and OVCAR8 spheroids.  (B) 
Dosage response to paclitaxel alone (black line) is lower than paclitaxel following 72h 
pretreatments with 10 µM licofelone (top) or 20 µM licofelone (bottom) (red lines).  Licofelone 
alone treatments of 10 µM or 20 µM are represented by the horizontal dashed lines (mean) and 
grey boxes (SD).  (C) Combination Index values for A1847 and OVAR8 spheroids show synergy 








Figure 34: Pretreatment of Ovarian Cancer Cell-Derived MCTS with Licofelone 




(A) Representative time-line of drug combinations in A1847 and OVCAR8 spheroids.  (B) 
Dosage response to licofelone alone (black line) is lower than licofelone following 72 h 
pretreatments with 250 nM paclitaxel (top) or 1 µM paclitaxel (bottom) (red lines).  Paclitaxel 
alone treatments of 250 nM or 1 µM are represented by the horizontal dashed lines (mean) and 
grey boxes (SD).  (C) Combination Index values for A1847 and OVAR8 spheroids show synergy 









Figure 35:  Pretreatment of Ovarian Cancer Cell-Derived MCTS with Paclitaxel 












Expression of stem-like genes (ALDH1A, CD133, KLF4, OCT4 and SOX2) following a 72 hr 
treatment with vehicle (DMSO) (black), 1 µM paclitaxel (red), or the combination of 1 µM 
paclitaxel and 20 µM licofelone (green) in A1847- or OVCAR8-derived spheroids.  Licofelone 
treatment significantly reduces stem cell gene expression induced by 1 µM paclitaxel in the 
ovarian cancer cell-derived MCTS (*= p< 0.05, t-test).  All data are represented as mean +/- SD, 
n=3. 
  
















Western blot analysis of PARP and cleaved PARP in A1847 spheroids (left panel) and 
densitometry analysis (right panel) show a significant increase of cleaved PARP to total PARP 
in the combination treatment of 1 µM paclitaxel and 20 µM licofelone.  Single treatment of 1 µM 





Figure 37: Combination of Licofelone and Paclitaxel Increased Apoptosis in 






(A) Relative size (µm) of colonies grown using a soft agar forming assay following drug 
treatment of A1847 or OVCAR8 MCTS with vehicle (DMSO) (black), 1 uM paclitaxel (red), 20 
µM licofelone (blue), or the combination of 1 µM paclitaxel and 20 µM licofelone (green) and 
disassociation into single cells.  Colony size was significantly increased following 1 µM 
paclitaxel and was decreased following 1 µM paclitaxel and 20 µM licofelone treatments (n>10, 
*=p<0.05, two-way ANOVA).  (B) Representative images of colonies formed using a soft agar 
forming assay following drug treatment of A1847 or OVCAR8 MCTS with vehicle (DMSO), 1 uM 
paclitaxel, 20 µM licofelone, or the combination of 1 µM paclitaxel and 20 µM licofelone and 
disassociation into single cells. 
  
















Figure 39: Licofelone Reduced the Secondary Spheroids Forming Ability of Paclitaxel 
Treated MCTS. 
Spheroid size (µm) of secondary A1847 or OVCAR8 spheroids formed from viable cells plated 
at 3,000, 1,000, 300, 100, 30 or 10 per well following drug treatment of MCTS with vehicle 
(DMSO) (black), 1 µM paclitaxel (red), 20 µM licofelone (blue), or the combination of 1 µM 
paclitaxel and 20 uM licofelone (green) and enzymatic disassociation.  Spheroid size from both 
A1847 or OVCAR8 cells was significantly increased following 1 uM paclitaxel and was 









Studies have used the in vivo representation of solid tumors in three-dimensional cell culture to 
validate primary drug screens (Fayad, Rickardson et al. 2011, LaBarbera, Reid et al. 2012, 
Kenny, Lal-Nag et al. 2015).  However, these approaches still rely on traditional drug screening 
methods in two-dimensional cultures.  The use of three-dimensional cell culture in primary 
screening has shown there could be drug targets that favor hypoxic and drug resistant 
properties demonstrated by MCTS (Wenzel, Riefke et al. 2014, Rotem, Janzer et al. 2015, 
Zhang, Hua et al. 2016).  Therefore, the activity of clinically repurposed drugs across 2D and 3D 
cultures was directly compared to identify new drug candidates, unappreciated by traditional 
screening in 2D cultures.  Developing a drug from the bench side to the clinical approval and 
use can take over 10 years and cost over 1 billion dollars (Paul, Mytelka et al. 2010).  Drug 
repurposing provides a cheaper and accelerated pathway to the clinic for drugs with new 
indications since they have known delivery and toxicity profiles from previously studies that were 
used to gain clinical approval (Weir, DeGennaro et al. 2012, Strittmatter 2014).  A previous 
study I participated in from my laboratory identified repurposed drugs that synergized with 
frontline chemotherapy (imatinib) in gastrointestinal stromal tumors (Pessetto, Ma et al. 2014), 
indicating repurposed drugs could be a promising pipeline for development in treating 
chemotherapy resistant ovarian cancer as well.  To compare drug response between these two 
methods, a subset of compounds were “cherry picked” from the Selleckchem FDA-Approved 
drug library based on the IPA Pathway analysis of genes selectively expressed in ovarian 
cancer cells grown in 3D cultures.  This selected drug library includes current cancer drugs as 
well as metabolic and inflammatory drugs, based on the top pathway regulators identified via 




route to clinical development, since they have already been through toxicity testing and other 
pre-clinical development. 
 Through my drug screens, compounds classified as 2D and 3D hits were predominantly 
from the current cancer therapeutic class in the drug screening.  Many of these drugs would 
have been developed in traditional 2D cultures and then brought to the clinical after they 
showed efficacy in animal models.  In fact, the top two hits from this class were the proteasome 
inhibitor bortezomib and the DNA intercalating agent, doxorubicin.  Both drugs have been 
evaluated in clinical trials with varying degrees of success (Aghajanian, Blessing et al. 2009, 
Gibson, Alzghari et al. 2013, Staropoli, Ciliberto et al. 2014).  Bortezomib and doxorubicin were 
used in combination in a phase II clinical trial in patients with relapsed ovarian cancer, but 
showed minimal antitumor activity (Parma, Mancari et al. 2012).  Our study showed three-
dimensional cell culture drug screening is an alternative to traditional screens by comparing the 
drug efficacy of a selected FDA-approved library in 2D cultures and 3D cultures.  Most of the 3D 
only hits came from metabolic or anti-inflammatory drugs that had not been extensively studies 
in cancer before based on literature searches and clinical trials.  To my knowledge, the top two 
3D only hits, licofelone and glafenine, have not been evaluated in preclinical or clinical studies 
for ovarian cancer.  This approach identified alternative drug hits, unappreciated by traditional 
drug screens. 
Inhibiting stemness in ovarian cancer could enhance chemotherapy response and improve 
progression free survival (Landen, Goodman et al. 2010, Silva, Bai et al. 2011, Wang, Yo et al. 
2012).  It is clear stem-like properties are a promising area for drug targeting in ovarian cancer.  
While specific inhibitors of CD133 are not available, genetic targeting CD133 reduced ovarian 
cancer progression in mice (Skubitz, Taras et al. 2013).  My thesis research identified two anti-
inflammatory drugs, licofelone and glafenine, through drug screening using ovarian cancer cells 




ALDH1A, CD133, KLF4, NANOG, OCT4, and SOX2 and decreased colony forming ability.  
OVCAR8 spheroids showed stronger reduction in the level of stem cell gene transcripts 
following licofelone treatment, which also corresponded to a complete loss of colony forming 
ability.  A1847 spheroids maintained some colony forming ability following licofelone treatment, 
which could be driven by the expression of NANOG, OCT4, and SOX2 which form a positive 
feedback loop (Boyer, Lee et al. 2005, Ivanova, Dobrin et al. 2006, Loh, Wu et al. 2006).  
Interestingly, licofelone and glafenine also induced proliferation, indicating they might not be 
promising single agents, but could enhance paclitaxel activity by driving a less stem, more 
proliferative phenotype.  Indeed, there was a synergistic combination between licofelone and 
paclitaxel following consequential addition of either drug.  Order of addition favored licofelone as 
a secondary therapy, reducing viability of ovarian MCTS to approximately 1% at higher dosages 
of licofelone.  However, both combinations regardless of the treatment scheme showed drug 
synergy.  Importantly, the combinations of licofelone with paclitaxel blocked the stem like 
properties induced by paclitaxel treatment as measured by gene expression, colony forming 
ability and the size of secondary spheroids following drug addition. 
 Licofelone is a novel non-steroidal anti-inflammatory (NSAID) that inhibits both COX-2/5-
LOX that was developed for the treatment of arthritis.  COX-2, or cyclooxygenase-2, is 
prostaglandin synthase that converts arachidonic acid to PGH2.  COX-2 is overexpressed in 
ovarian cancer patients and may play a role in tumor progression (Singhal, Spiegel et al. 2005, 
Lee, Choi et al. 2006).  Interestingly, COX-2 has shown to induce stem cells in breast cancer 
cell lines (Majumder, Xin et al. 2016).  5-LOX, or 5-lipoxygenase, is overexpressed in ovarian 
cancer and contributes to the HIF-1α mediated hypoxia response (Ji, Wang et al. 2013, Wang, 
Ma et al. 2014).  Likewise, LOX expression was significantly increased in ovarian MCTS when 
compared to 2D cultures.  The only cell line without significant overexpression of LOX, was 




in cancer therapy has been limited, it has been shown to inhibit cigarette smoke induced lung 
cancer (Balansky, Ganchev et al. 2015) and blocked pancreatic cancer induction with a marked 
decrease in stem cell markers (Mohammed, Janakiram et al. 2015).  While licofelone has not 
been evaluated clinically for ovarian cancer, celecoxib, a COX-2 specific inhibitor, enhanced 
chemotherapy in Phase II trial (Legge, Paglia et al. 2011).  However, licofelone showed 
enhanced efficacy in ovarian MCTS when compared to celecoxib and is known to have fewer 
side effects (Bias, Buchner et al. 2004).  In this study, licofelone was shown to inhibit stem-cell 
like characteristics of ovarian MCTS.  Glafenine is also a NSAID and was recently identified as 
an ABCG2 inhibitor in a drug repurposing screen (Zhang, Byun et al. 2009).  ABCG2, a member 
of the ATP Binding Cassette Sub-Family, is highly expressed in subpopulations of ovarian 
cancer stem cells (Dou, Jiang et al. 2011, Kryczek, Liu et al. 2012).  ABCG2 is highly 
expressed, along with other stem cell markers, in recurrent, chemotherapy resistant prostate 
cancer (Guzel, Karatas et al. 2014).  However, I chose to further evaluate licofelone as 
compared to glafenine which has been discontinued based on its associated toxicities.  While 
licofelone has not achieved FDA approval, it has been extensively studies in Europe for its role 
in arthritis and reduced side effects compared to COX-2 specific inhibitors (Bias, Buchner et al. 
2004). 
 Alternatively, both drugs are NSAIDs, which might indicate a role of mitochondrial 
regulation by blocking stemness in ovarian cancer MCTS via decreased mitochondrial function 
and metabolism (Vaish, Tanwar et al. 2011).  The use of NSAIDs, specifically aspirin, has been 
retrospectively shown to lower the risk of ovarian cancer in a dose and frequency dependent 
manor (Murphy, Trabert et al. 2012, Trabert, Ness et al. 2014).  Ovarian cancer stem cells have 
enhanced mitochondrial metabolism as noted by increased oxidative phosphorylation 
metabolism compared to glucose metabolism, shunted pyruvate to the Krebs cycle, and an 




favor the Krebs cycle to induce hypoxia resistant metabolism (Liao, Qian et al. 2014).  Targeting 
mitochondrial function by inhibiting complex III with atovaquone, a repurposed malaria drug, 
showed a reduction in OXPHOS and inhibited breast cancer stem cells (Fiorillo, Lamb et al. 
2016).  Licofelone is able to induce mitochondrial apoptosis in colon cancer cells independent of 
arachidonic acid cascade activity (Tavolari, Bonafe et al. 2008).  Taken together with these 
data, NSAIDS could be blocking mitochondrial function and limiting stem-like cell metabolism to 
inhibit stem-like cells.  This could help provide insight into the regulation of stem-like cell 
expansion or induction in ovarian cancer patient tumors. 
Conclusion 
The studies reported in this thesis shows that three-dimensional culturing of ovarian cancer cell 
lines provides an alternative to traditional drug screening models.  By screening a select drug 
library chosen based on identified pathway regulators in MCTS, drugs that specifically inhibit 3D 
cell cultures were identified.  Drugs with specific activity in ovarian MCTS showed the ability to 
inhibit stemness and to synergize with paclitaxel, as well as inhibit the stem-like phenotype 
induced in cells that survive paclitaxel (Figure 40).  These data support the further clinical 
development of licofelone for the treatment of patients with ovarian cancer and the use of 3D 
models in the identification and validation of newly formulated anti-cancer drugs.  By reversing 
the stem-like phenotype with licofelone, there were fewer viable cells that survive paclitaxel.  If 
this phenomenon was replicated in patients, it could decrease the cells that survive 
chemotherapy long term and replenish the tumor when therapy is complete and prevent disease 










Chapter 4:  Summary, Discussion, and Future Directions 
Summary 
My thesis provides a scientific rationale and supporting data to indicate that the 2D in vitro 
method used to screen for drug activity in ovarian cancer cells can provide many false positives 
and missteps in the drug development process.  Drug development for the treatment of primary 
ovarian cancer has been stagnant since the approval of paclitaxel in 1992.  This lack of success 
could be due in part to discrepancies between preclinical in vitro ovarian cancer models and the 
highly heterogeneous disease diagnosed in patients and treated by oncologist.  In this thesis I 
combined knowledge of clinical ovarian cancer and chemotherapy resistance, with a three-
dimensional cell culture approach to provide an alternative method to screen for drugs that 
might have better therapeutic activity in the clinic.  This approach led to the identification of a 
drug, licofelone, a dual COX/LOX inhibitor developed as a potential treatment for osteoarthritis.  
I found that licofelone can specifically target cells grown in 3D cell culture and reverse 
mechanisms of drug resistance such as stem-like characteristics, which could improve the 
efficacy of paclitaxel in patients with recurrent disease. 
 
 In Chapter 1, I provided a broad background of ovarian cancer and discussed the myriad 
of clinical trials using targeted therapies and the combination studies of cytotoxic drugs with 
these molecular therapies, which have for the most part failed to greatly improve the PFS or OS 
of patients with epithelial ovarian tumors (Bell, Brady et al. 2006, Bookman, Brady et al. 2009, 
Pecorelli, Favalli et al. 2009, Mannel, Brady et al. 2011).  Recent studies have called into 
question the capacity and usefulness of traditional 2D cell cultures in mimicking clinical disease, 
which is thought to be the limiting factor in the success of current drug screening and 
development approaches (Domcke, Sinha et al. 2013), and worse yet, providing false positive 




various research projects for my thesis, I decided to focus on applying knowledge of 
chemotherapy resistance in a clinical setting to improve the in vitro representation of drug-
resistant disease using ovarian cancer cell lines.  Designing cell culture models that better 
reflect cells that survive chemotherapy and repopulate tumors could identify unappreciated 
drugs that would not have otherwise been selected using traditional screening methods which 
have thus far not produced any efficacious drugs to date. 
 
 Towards this goal, in Chapter 2 I described the development and optimization of a 3D cell 
culture model that reflected various aspects of drug resistant ovarian cancer that cannot be 
appreciated using traditional 2D cultures and that can be easily and reproducibly adapted for 
further drug screening.  By using a 3D culture method, ovarian cancer cell lines formed MCTS 
that induced drug resistant mechanisms such as reduced cell proliferation, cellular hypoxia, and 
the expression of stem cell-related transcripts (Huang, Ao et al. 2010, Steg, Bevis et al. 2012, 
Dobbin, Katre et al. 2014, Liao, Qian et al. 2014).  Consequently, MCTS from 3D cultures of 
ovarian cancer cell lines were significantly more resistant to paclitaxel than their 2D cultured 
counterparts.  Mimicking progression of disease in a clinical setting, following paclitaxel 
treatment, cells within MCTS showed significantly higher expression levels of stem cell genes 
and reduced cell proliferation (Steg, Bevis et al. 2012).  The cells from MCTS maintained their 
stemness and drug resistance characteristics following disassociation and reseeding into 2D 
cultures, indicating that the drug resistant phenotype was stable and not just a phenomenon of 
3D culture alone. 
 
 Finally, in Chapter 3 I used the MCTS 3D drug screening model to screen a subset of a 
drug repurposing library in order to identify unappreciated drug candidates that target the stem-
like cells within MCTS and thereby improve the efficacy of chemotherapy in ovarian cancer.  




inflammatory compounds, licofelone and glafenine, reduced cell viability in 3D cultures more so 
than in 2D cultures.  Additional validation and follow-up experiments measuring gene 
expression and cell proliferation revealed that these two anti-inflammatory drugs reversed the 
stem-like properties of MCTS.  Furthermore, I showed that licofelone synergized with paclitaxel 
and reversed paclitaxel resistance and associated phenotypes in ovarian MCTS. 
 
 In summary, 2D cell cultures predominantly used for the vast majority of drug screening 
studies do not accurately represent the drug resistance present in recurrent clinical samples and 
therefore, produce misleading drug hits that ultimately do poorly when given to patients with 
ovarian cancer.  Using a 3D MCTS model with ovarian cancer cell lines for drug screening 
results in preferential selection of drugs, which target stem cell-like properties and synergize 
with paclitaxel.  While the top drug hits have potential for clinical development, application of this 
3D model in large scale drug screening of chemical libraries could yield additional drug and 
chemical probe hits with far more potential at improving patient survival than what has been 
achieved thus far using the classical 2D screen models.  Adapting the 3D culture approach to 
drug screening for ovarian cancer has the potential to aide in the identification and development 
of new drugs that complement existing front line therapy and improve patient survival for the first 
time in almost thirty years. 
Discussion and Future Directions 
With the completion of the proof-of-principle (PoP) mid-throughput drug screen in my thesis, I 
have provided sufficient evidence for the feasibility of successful and rapid 3D drug screen 
without the requirement of any special equipment.  My studies indeed identified two previously 
unappreciated drugs with anti-cancer activity against ovarian cancer cell.  However, the PoP 
studies were performed using a cherry-picked library of 304 drugs, a smaller number compared 




et al. 2009, Visnyei, Onodera et al. 2011).  The use of a smaller library was necessary in my 
screening method due to two factors both related to drug delivery.  Firstly, the 3D MCTS were 
formed using 96-well plates, which are less efficient than 384- and 1536-well plates for drug 
screening.  However, 96-well plates were needed for these screens as they provided a larger 
surface area to coat with agarose, while 384-well plates required a very small amount of 
agarose to cover the wells and thus lead to rapid solidification of the agarose in the wells and 
subsequent improper coating.  Secondly, in my screening model the drug was added on top of 
previously plated cancer cells, which limits the volume of additional liquid that could accurately 
be applied by robotics when using 384-well plates.  For volumes less than 5 µL, accurate 
delivery in mid- or high-throughput methods is typically performed by coating plates with 
microsprays and adding cell media on top of the drug.  In the absence of ready access to such 
sophisticated instruments, the 96-well platform was used for my PoP studies.  And while the use 
of 96-well plates was sufficient for the small scale drug library that was used in my screens, it is 
clear that any expanded scale drug screen will require technological modifications to the MCTS 
drug screening platform accommodate 384-well or 1536-well plates.  Combining my PoP data, 
the clinical properties of 3D cell culture, and its use in drug screening will aide in developing 
these more efficient screening techniques for large chemical compound libraries such as those 
available on the Lawrence campus of KU in the High Throughput Screening facility 
(https://hts.ku.edu/).  Furthermore, rapid adaptation of this model for other solid tumors will help 
development of additional unappreciated cancer therapeutics for other devastating diseases. 
 Based on my studies, there are several strategies that could be adapted for the current 3D 
screening platform to help improve its throughput.  One of these strategies is to form MCTS, 
treat with vehicle (or paclitaxel) (such as in Chapter 2, Figure 18), dissociate the cells and plate 
under 2D growth conditions for typical high throughput drug screening methods.  While I have 




resistance mechanisms such as cellular hypoxia signatures might not be retained in this 
method.  This method would retain the advantage of the low cost of agarose coated plates, 
while adding about 10 days to the cell preparation method compared to traditional 2D culture 
screening.  Secondly, using another 3D culture method that is adaptable to 384 or 1536 well 
plates could provide a more efficient model to apply drug directly to spheroids.  However, this 
could require high cost, low attachment plates and would not solve the problem of adding drug 
on top of the already plated media.  Lastly, since the spheroids do not invade the solid agarose, 
spheroids could be transferred following formation on top of plates with drugs that have been 
coated with small volumes of drug.  While each of these methods add either extra time or cost 
to my established model, the data I have shown support that the investment could be worthwhile 
in terms of identifying more unappreciated drugs to the treatment of ovarian cancer.  My proof-
of-principle screen provides further rationale to use this type of 3D cell culture model for future 
drug discovery and development in ovarian and potentially other cancers. 
 While the spheroid disassociation and re-plating experiments described above and in 
Chapter 2 could be used for scaling drug screening, they also provide a platform for studying 
long term drug resistance and how cells may survive chemotherapy and repopulate tumors 
several months later.  Maintaining drug resistance and stem cell gene expression from 3D cells 
into 2D culture could provide insight into longer term studies.  My study did not investigate how 
long this phenotype is stable and whether it is being driven by positive feedback loops between 
stem cell transcription factors (Boyer, Lee et al. 2005, Ivanova, Dobrin et al. 2006, Loh, Wu et 
al. 2006) or other long term factors such as epigenetic regulation.  Long term studies of drug 
resistance indicate drug resistance is likely driven by combinations of multiple mechanisms 
(Rohnalter, Roth et al. 2015).  Determining how long the drug resistant phenotype is maintained 
following 3D culture and paclitaxel treatment would require time course studies to identify 




to study cells that survive paclitaxel in my model is also advantageous since there can be 
around 3- to 5-fold more cells that survive compared to 2D culture, increasing the amount of 
biological and cellular assays that could be applied. 
 Another area that is supported for further development by my thesis is the pre-clinical and 
clinical development of licofelone for the treatment of ovarian cancer.  I showed promising data 
that both licofelone and glafenine can both recue the stem-like phenotype of ovarian MCTS 
while also increasing cellular proliferation.  Since licofelone is better tolerated in the clinic 
(glafenine has been pulled from the shelf due to the degree of severe side effects) I chose to 
evaluate it in combination with paclitaxel.  Licofelone showed synergy with paclitaxel regardless 
of the order of addition and could be included in front-line therapy or developed as a therapeutic 
approach to resensitize tumors once they have become refractory to chemotherapy.  Both of 
these approaches could seek to eliminate the cells that survive chemotherapy and eventually 
lead to disease recurrence and death of ovarian cancer patients.  The primary advantage of 
drug repurposing is that it creates an accelerated pathway to the clinic due to completion of 
previous clinical studies and a co-operative funding mechanism between academic laboratories 
and pharmaceutical companies (Weir, DeGennaro et al. 2012).  Since pharmaceutical 
companies own the intellectual property to the drug, they often collaborate with academic labs 
that have found off label uses to develop the product for other maladies by providing the 
compound or other financial support.  However, while licofelone was included in the 
Selleckchem FDA-approved drug library, it has only gone through clinical studies and achieved 
clinical approval in Europe, not the USA.  Working with pharmaceutical companies to obtain 
licofelone has also been problematic since it was developed in part by two German 
pharmaceutical companies, Merckle and Ratiopharm, which were later purchased by Teva 




creating contacts from there will be the key going forward.  Efforts to gain support for potential 
clinical development of licofelone for the treatment of ovarian cancer patients are still ongoing. 
 While my primary focus was on unappreciated drugs identified by 3D culture screening, 
another promising development based on my thesis would be the predictive value of 3D culture 
compared to 2D culture for in vivo drug delivery.  In vivo animal models are much more 
expensive and time consuming than in vitro cell models.  However, they are necessary for pre-
clinical drug delivery and development studies.  Using 3D culture to better predict the success of 
drugs in in vivo models could save valuable time and money invested in drugs that could be 
predicted not to have success.  When validating hits from primary drug screening in 2D cultures, 
one study found that the more hydrophobic the mitotic inhibitors identified from 2D cultures were 
the better they performed in 3D cultures (Fayad, Rickardson et al. 2011).  Interestingly, I found 
differences between the 3D culture responses between drugs with strong activity in 2D cultures 
(Chapter 3, Figure 28).  Specifically, afatinib had strong activity against ovarian cancer cells in 
2D culture but minimal response in 3D cultures while bortezomib had strong response in both 
2D and 3D cultures.  Validating more hits from both “2D only” and “2D and 3D” hits from my 
study could provide multiple drugs to compare the in vivo predictive value of 3D cultures. 
 Finally, the mechanism by which both anti-inflammatory drugs, licofelone and glafenine, 
inhibit ovarian cancer stem cells could provide insight into the progression of clinical disease.  
Specific targets of licofelone, COX/LOX, or glafenine, ABCG2, have roles in ovarian cancer 
progression, stemness, and drug resistance (Singhal, Spiegel et al. 2005, Lee, Choi et al. 2006, 
Dou, Jiang et al. 2011, Kryczek, Liu et al. 2012, Ji, Wang et al. 2013, Wang, Ma et al. 2014).  
However, general effects of anti-inflammatory drugs could be to block mitochondrial function 
which has also been related to cancer stem cell function and metabolism (Vaish, Tanwar et al. 
2011, Murphy, Trabert et al. 2012, Liao, Qian et al. 2014, Trabert, Ness et al. 2014).  Expanding 




identify targets for either drug repurposing or unappreciated drug development.  Likewise, if 
these drugs are targeting stem cells through independent, specific pathways, selecting patient 
cohorts in clinical trials could be performed based on target expression. 
Perspective 
The last front-line chemotherapy drug approved for ovarian cancer was almost 30 years ago 
(Einzig, Wiernik et al. 1992), before technological phenomena such as the iPhone (2007), 
Facebook (2004), Google (1998), Windows NT (1993), and home dial-up internet service, 
America Online (1993).  In the time from the internet being introduced to people’s homes (AOL 
and Windows NT) to it being at the tip of the fingers for almost 70% of the United States 
population with the advent of smartphones (Anderson 2015), no major drug discoveries were 
made for the treatment of ovarian cancer; the fifth leading cause of cancer-related death among 
women in the United States (Siegel, Naishadham et al. 2013, Howlader, Noone et al. 2015).  In 
my thesis I detail how this could be attributed to failures in clinical trials for ovarian cancer driven 
in part by culture models that do not accurately represent the most common causes of death in 
clinical disease, resistance to front line chemotherapy.  While many attempts have been made 
to continue to use cytotoxic agents that target many aspects of cell division and have failed 
(Bell, Brady et al. 2006, Bookman, Brady et al. 2009, Pecorelli, Favalli et al. 2009, Mannel, 
Brady et al. 2011), my study provides an alternative method to drug screening that identifies 
drugs that target mechanisms of long term cell survival and stemness.  By identifying a frontline 
drug screening method that targets populations of ovarian cancer cells not represented by 
traditional methods, I have provided a potential pathway for developing new drugs for the 
treatment of ovarian cancer for the first time in almost 30 years. 
 
 In summary, through my thesis studies I developed a 3D cell culture model of ovarian 




associated drug resistance pathways.  This 3D cell culture method provided a drug screening 
platform for identification of unappreciated, anti-inflammatory drugs, with unappreciated anti-
cancer activities which could synergize with paclitaxel.  This thesis research studies provide the 
rationale for further exploration of 3D cell culture for the development of unappreciated drug 
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